XX
PS Example 13; Page 64-65; 115pp; English.
XX
CC The invention relates to a novel nucleic acid molecule expressed in liver
CC or stomach tissue, useful for diagnosing or treating obesity, anorexia
CC etc. The nucleic acid molecule is useful as a diagnostic and therapeutic
CC agent or as a target for agents which act as modulators and/or monitors
CC of physiological processes associated with obesity, anorexia, weight
CC maintenance, impaired muscle development, diabetes and/or metabolic
CC energy levels and/or other physiological conditions. Alkylguanine
CC alkyltransferase (AGT)-117, AGT-110, AGT-199, AGT-107, AGT-114, AGT-116,
CC AGT-115 and/or AGT-108 genes of the invention and the agent that modulate
CC their expression or activity are useful in manufacturing a medicament for
CC treating a condition characterised by obesity, anorexia, diabetes and/or
CC energy imbalance. The invention is useful in gene therapy. The present
CC sequence is human AGT-114 protein
XX
SQ Sequence 395 AA;

Query Match 30.0%; Score 6; DB 6; Length 395;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18
||||||
Db 365 QMLETK 370

RESULT 8
ADJ70703
ID ADJ70703 standard; protein; 395 AA.
XX
AC ADJ70703;
XX
DT 06-MAY-2004 (first entry)
XX
DE Human heat mitochondrial protein as a therapeutic target SeqID2509.
XX
KW mitochondrial; human; screening assay; diabetes mellitus;
KW Huntington's disease; osteoarthritis;
KW Leber's hereditary optic neuropathy; LHON;
KW mitochondrial encephalopathy lactic acidosis and stroke; MELAS;
KW myoclonic epilepsy ragged red fibre syndrome; MERRF; cancer;
KW neuroprotective; nootropic; antidiabetic; anticonvulsant; antiarthritic;
KW osteopathic; ophthalmological; cytostatic.
XX
OS Homo sapiens.
XX
PN WO2003087768-A2.
XX
PD 23-OCT-2003.
XX
PF 04-APR-2003; 2003WO-US010870.
XX
PR 12-APR-2002; 2002US-0372843P.
PR 17-JUN-2002; 2002US-0389987P.
PR 20-SEP-2002; 2002US-0412418P.
XX
PA (MITO-) MITOKOR.
PA (BUCK-) BUCK INST AGE RES.
XX
PI Ghosh SS, Fahy ED, Zhang B, Gibson BW, Taylor SW, Glenn GM;
PI Warnock DE;
XX
DR WPI; 2003-845369/78.
XX
PT Identifying a mitochondrial target for drug screening assays and for
PT treating diseases associated with altered mitochondrial function,
PT comprises detecting a modified polypeptide in a sample and correlating
PT with the disease.
XX
PS Claim 1; SEQ ID NO 2509; 180pp; English.
XX
CC This invention relates to novel mitochondrial targets that can be used
CC for therapeutic intervention in treating a disease associated with
CC altered mitochondrial function. Specifically, it refers to a method for
CC identifying proteins of the human heart mitochondrial proteome that are
CC useful for drug screening assays, as well as therapeutic targets. The
CC present invention describes a method for identifying such proteins that
CC can be used in the treatment of various diseases associated with altered
CC mitochondrial function including diabetes mellitus, Huntington's disease,
CC osteoarthritis, Leber's hereditary optic neuropathy (LHON), mitochondrial
CC encephalopathy lactic acidosis and stroke (MELAS), myoclonic epilepsy
CC ragged red fibre syndrome (MERRF) or cancer. Accordingly, these
CC compositions have neuroprotective, nootropic, antidiabetic,
CC anticonvulsant, antiarthritic, osteopathic, ophthalmological and
CC cytostatic activities. This polypeptide sequence is a human heart
CC mitochondrial protein of the invention.
XX
SQ Sequence 395 AA;

Query Match 30.0%; Score 6; DB 7; Length 395;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18
||||||
Db 365 QMLETK 370

RESULT 9
ABU49025
ID ABU49025 standard; protein; 434 AA.
XX
AC ABU49025;
XX
DT 19-JUN-2003 (first entry)
XX
DE Protein encoded by Prokaryotic essential gene #34552.
XX
KW Antisense; prokaryotic essential gene; cell proliferation; drug design.
XX
OS Vibrio cholerae.
XX
PN WO200277183-A2.
XX
PD 03-OCT-2002.
XX
PF 21-MAR-2002; 2002WO-US009107.
XX
PR 21-MAR-2001; 2001US-00815242.
PR 06-SEP-2001; 2001US-00948993.
PR 25-OCT-2001; 2001US-0342923P.
PR 08-FEB-2002; 2002US-00072851.
PR 06-MAR-2002; 2002US-0362699P.
XX
PA (ELIT-) ELITRA PHARM INC.
XX
PI Wang L, Zamudio C, Malone C, Haselbeck R, Ohlsen KL, Zyskind JW;
PI Wall D, Trawick JD, Carr GJ, Yamamoto R, Forsyth RA, Xu HH;
XX
DR WPI; 2003-029926/02.
DR N-PSDB; ACA52895.
XX
PT New antisense nucleic acids, useful for identifying proteins or screening
PT for homologous nucleic acids required for cellular proliferation to
PT isolate candidate molecules for rational drug discovery programs.
XX
PS Claim 25; SEQ ID NO 76949; 1766pp; English.
XX
CC The invention relates to an isolated nucleic acid comprising any one of
CC the 6213 antisense sequences given in the specification where expression
CC of the nucleic acid inhibits proliferation of a cell. Also included are:
CC (1) a vector comprising a promoter operably linked to the nucleic acid
CC encoding a polypeptide whose expression is inhibited by the antisense
CC nucleic acid; (2) a host cell containing the vector; (3) an isolated

```
CC   polypeptide or its fragment whose expression is inhibited by the
CC   antisense nucleic acid; (4) an antibody capable of specifically binding
CC   the polypeptide;(5) producing the polypeptide; (6) inhibiting cellular
CC   proliferation or the activity of a gene in an operon required for
CC   proliferation; (7) identifying a compound that influences the activity of
CC   the gene product or that has an activity against a biological pathway
CC   required for proliferation, or that inhibits cellular proliferation; (8)
CC   identifying a gene required for cellular proliferation or the biological
CC   pathway in which a proliferation-required gene or its gene product lies
CC   or a gene on which the test compound that inhibits proliferation of an
CC   organism acts; (9) manufacturing an antibiotic; (10) profiling a
CC   compound's activity; (11) a culture comprising strains in which the gene
CC   product is overexpressed or underexpressed; (12) determining the extent
CC   to which each of the strains is present in a culture or collection of
CC   strains; or (13) identifying the target of a compound that inhibits the
CC   proliferation of an organism. The antisense nucleic acids are useful for
CC   identifying proteins or screening for homologous nucleic acids required
CC   for cellular proliferation to isolate candidate molecules for rational
CC   drug discovery programs, or for screening homologous nucleic acids
CC   required for proliferation in cells other than S. aureus, S. typhimurium,
CC   K. pneumoniae or P. aeruginosa. The present sequence is encoded by one of
CC   the target prokaryotic essential genes. Note: The sequence data for this
CC   patent did not form part of the printed specification, but was obtained
CC   in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 434 AA;

  Query Match             30.0%;  Score 6;  DB 6;  Length 434;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          4 APMWLR 9
              ||||||
Db        177 APMWLR 182


RESULT 10
ABB66870
ID   ABB66870 standard; protein; 444 AA.
XX
AC   ABB66870;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Drosophila melanogaster polypeptide SEQ ID NO 27402.
XX
KW   Drosophila; developmental biology; cell signalling; insecticide;
KW   pharmaceutical.
XX
OS   Drosophila melanogaster.
XX
PN   WO200171042-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US009231.
XX
PR   23-MAR-2000; 2000US-0191637P.
PR   11-JUL-2000; 2000US-00614150.
XX
PA   (PEKE ) PE CORP NY.
XX
PI   Venter JC,  Adams M,  Li PWD,  Myers EW;
XX
DR   WPI; 2001-656860/75.
DR   N-PSDB; ABL10973.
XX
PT   New isolated nucleic acid detection reagent for detecting 1000 or more
PT   genes from Drosophila and for elucidating cell signaling and cell-cell
PT   interactions.
XX
PS   Disclosure; SEQ ID NO 27402; 21pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated nucleic acid detection reagent
CC   capable of detecting 1000 or more genes from Drosophila. The invention is
CC   useful in developmental biology and in elucidating cell signalling and
CC   cell-cell interactions in higher eukaryotes for the development of
CC   insecticides, therapeutics and pharmaceutical drugs. The invention
CC   discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC   sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
CC   ABB72072). The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 444 AA;

  Query Match             30.0%;  Score 6;  DB 4;  Length 444;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         15 LETKFL 20
              ||||||
Db        334 LETKFL 339


RESULT 11
ABB61409
ID   ABB61409 standard; protein; 444 AA.
XX
AC   ABB61409;
XX
DT   26-MAR-2002  (first entry)
XX
DE   Drosophila melanogaster polypeptide SEQ ID NO 11019.
XX
KW   Drosophila; developmental biology; cell signalling; insecticide;
KW   pharmaceutical.
XX
OS   Drosophila melanogaster.
XX
PN   WO200171042-A2.
XX
PD   27-SEP-2001.
XX
PF   23-MAR-2001; 2001WO-US009231.
XX
PR   23-MAR-2000; 2000US-0191637P.
PR   11-JUL-2000; 2000US-00614150.
XX
PA   (PEKE ) PE CORP NY.
XX
PI   Venter JC,  Adams M,  Li PWD,  Myers EW;
XX
DR   WPI; 2001-656860/75.
DR   N-PSDB; ABL05512.
XX
PT   New isolated nucleic acid detection reagent for detecting 1000 or more
PT   genes from Drosophila and for elucidating cell signaling and cell-cell
PT   interactions.
XX
PS   Disclosure; SEQ ID NO 11019; 21pp + Sequence Listing; English.
XX
CC   The invention relates to an isolated nucleic acid detection reagent
CC   capable of detecting 1000 or more genes from Drosophila. The invention is
CC   useful in developmental biology and in elucidating cell signalling and
CC   cell-cell interactions in higher eukaryotes for the development of
CC   insecticides, therapeutics and pharmaceutical drugs. The invention
CC   discloses genomic DNA sequences (ABL16176-ABL30511), expressed DNA
CC   sequences (ABL01840-ABL16175) and the encoded proteins (ABB57737-
CC   ABB72072). The sequence data for this patent did not form part of the
CC   printed specification, but was obtained in electronic format directly
CC   from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 444 AA;
```

```
  Query Match             30.0%;  Score 6;  DB 4;  Length 444;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         15 LETKFL 20
              ||||||
Db        334 LETKFL 339


RESULT 12
AAG65822
ID   AAG65822 standard; protein; 501 AA.
XX
AC   AAG65822;
XX
DT   30-JAN-2002  (first entry)
XX
DE   Human GPR38 variant GPR38V polypeptide.
XX
KW   GPR38V; variant; antibacterial; cytostatic; analgesic; antiasthmatic;
KW   anti-Parkinsonian; hypertensive; hypotensive; antidiabetic; osteopathic;
KW   antiallergic; antimigraine; neuroleptic; nootropic; anticonvulsant;
KW   antiulcer; antiemetic; cardiant; vaccine; human.
XX
OS   Homo sapiens.
XX
PN   WO200164836-A2.
XX
PD   07-SEP-2001.
XX
PF   28-FEB-2001; 2001WO-US006277.
XX
PR   01-MAR-2000; 2000US-00516315.
XX
PA   (SMIK ) SMITHKLINE BEECHAM CORP.
XX
PI   Elshourbagy N,  Shabon U;
XX
DR   WPI; 2001-638956/73.
DR   N-PSDB; AAI66989.
XX
PT   New human GPR38V polypeptide and polynucleotide, useful for treating e.g.
PT   bacterial, fungal, protozoal and viral infections, cancers or allergies,
PT   as vaccines, and for identifying agonists and antagonists potentially
PT   useful in therapy.
XX
PS   Claim 1; Page 26; 32pp; English.
XX
CC   This represents a human GPR38 variant (GPR38V) polypeptide. GPR38V can be
CC   expressed by standard recombinant methodology. The polynucleotides and
CC   polypeptides are used in the treatment of bacterial, fungal, protozoal
CC   and viral infections, infections caused by HIV-1 or HIV-2, pain, cancers,
CC   diabetes, obesity, anorexia, asthma, Parkinson's disease, acute heart
CC   failure, hypertension, urinary retentions, osteoporosis, allergies,
CC   ulcers, migraine, psychotic and neurological disorders, or dyskinesias.
CC   They are also useful for identifying agonists and antagonists that are
CC   potentially useful in therapy, as vaccines to induce immunological
CC   response in a mammal. The polypeptides may also be used as immunogens to
CC   produce antibodies immunospecific for the polypeptides, and to identify
CC   membrane bound or soluble receptors
XX
SQ   Sequence 501 AA;

  Query Match             30.0%;  Score 6;  DB 4;  Length 501;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAPM 6
              ||||||
Db         85 PRGAPM 90


RESULT 13
```

```
ABR58452
ID   ABR58452 standard; protein; 571 AA.
XX
AC   ABR58452;
XX
DT   07-JUL-2003  (first entry)
XX
DE   Human NOV47c.
XX
KW   Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
KW   immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
KW   antiparkinsonian; antilipaemic; gene therapy; metabolic disorder;
KW   diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
KW   neurodegenerative disorder; Alzheimer's disease; immune disorder;
KW   haematopoietic disorder.
XX
OS   Homo sapiens.
XX
PN   WO2003029423-A2.
XX
PD   10-APR-2003.
XX
PF   02-OCT-2002; 2002WO-US031358.
XX
PR   02-OCT-2001; 2001US-0326483P.
PR   05-OCT-2001; 2001US-0327342P.
PR   09-OCT-2001; 2001US-0327917P.
PR   09-OCT-2001; 2001US-0328029P.
PR   09-OCT-2001; 2001US-0328044P.
PR   09-OCT-2001; 2001US-0328056P.
PR   12-OCT-2001; 2001US-0328849P.
PR   15-OCT-2001; 2001US-0329414P.
PR   17-OCT-2001; 2001US-0330142P.
PR   22-OCT-2001; 2001US-0341058P.
PR   24-OCT-2001; 2001US-0339266P.
PR   24-OCT-2001; 2001US-0343629P.
PR   29-OCT-2001; 2001US-0349575P.
PR   01-NOV-2001; 2001US-0346357P.
PR   12-APR-2002; 2002US-0371972P.
PR   12-APR-2002; 2002US-0371980P.
PR   17-APR-2002; 2002US-0373261P.
PR   19-APR-2002; 2002US-0373805P.
PR   23-APR-2002; 2002US-0374738P.
PR   16-MAY-2002; 2002US-0381101P.
PR   17-MAY-2002; 2002US-0381635P.
PR   29-MAY-2002; 2002US-0383830P.
PR   01-OCT-2002; 2002US-00262839.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Alsobrook JP,  Anderson DW,  Boldog FL,  Burgess CE,  Catterton E;
PI   Edinger SR,  Ellerman K,  Gerlach VL,  Gorman L,  Guo X,  Ji W;
PI   Kekuda R,  Leach MD,  Li L,  Miller CE,  Patturajan M,  Rieger DK;
PI   Rothenberg ME,  Shimkets RA,  Smithson G,  Spytek KA,  Taupier RJ;
PI   Vernet CAM,  Voss EZ,  Zerhusen BD,  Zhong M;
XX
DR   WPI; 2003-381625/36.
DR   N-PSDB; ACC72164.
XX
PT   NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
PT   treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
PT   dyslipidemia, and in chromosome mapping, tissue typing or
PT   pharmacogenomics.
XX
PS   Claim 1; Page 256; 487pp; English.
XX
CC   The present invention relates to novel human NOV proteins and their
CC   coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
CC   proteins are useful in manufacturing a medicament for treating a syndrome
CC   associated with a human disease. The NOV proteins and coding sequences
CC   may be used to diagnose, treat or prevent metabolic disorders such as
CC   diabetes or obesity, infections, cachexia, cancer, neurodegenerative
CC   disorders such as Alzheimer's disease or Parkinson's disease, immune
```

```
CC   disorders, haematopoietic disorders and various dyslipidaemias
XX
SQ   Sequence 571 AA;

  Query Match             30.0%;  Score 6;  DB 6;  Length 571;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db        545 QMLETK 550


RESULT 14
ABR58460
ID   ABR58460 standard; protein; 577 AA.
XX
AC   ABR58460;
XX
DT   07-JUL-2003  (first entry)
XX
DE   Human NOV47k.
XX
KW   Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
KW   immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
KW   antiparkinsonian; antilipaemic; gene therapy; metabolic disorder;
KW   diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
KW   neurodegenerative disorder; Alzheimer's disease; immune disorder;
KW   haematopoietic disorder.
XX
OS   Homo sapiens.
XX
PN   WO2003029423-A2.
XX
PD   10-APR-2003.
XX
PF   02-OCT-2002; 2002WO-US031358.
XX
PR   02-OCT-2001; 2001US-0326483P.
PR   05-OCT-2001; 2001US-0327342P.
PR   09-OCT-2001; 2001US-0327917P.
PR   09-OCT-2001; 2001US-0328029P.
PR   09-OCT-2001; 2001US-0328044P.
PR   09-OCT-2001; 2001US-0328056P.
PR   12-OCT-2001; 2001US-0328849P.
PR   15-OCT-2001; 2001US-0329414P.
PR   17-OCT-2001; 2001US-0330142P.
PR   22-OCT-2001; 2001US-0341058P.
PR   24-OCT-2001; 2001US-0339266P.
PR   24-OCT-2001; 2001US-0343629P.
PR   29-OCT-2001; 2001US-0349575P.
PR   01-NOV-2001; 2001US-0346357P.
PR   12-APR-2002; 2002US-0371972P.
PR   12-APR-2002; 2002US-0371980P.
PR   17-APR-2002; 2002US-0373261P.
PR   19-APR-2002; 2002US-0373805P.
PR   23-APR-2002; 2002US-0374738P.
PR   16-MAY-2002; 2002US-0381101P.
PR   17-MAY-2002; 2002US-0381635P.
PR   29-MAY-2002; 2002US-0383830P.
PR   01-OCT-2002; 2002US-00262839.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Alsobrook JP,  Anderson DW,  Boldog FL,  Burgess CE,  Catterton E;
PI   Edinger SR,  Ellerman K,  Gerlach VL,  Gorman L,  Guo X,  Ji W;
PI   Kekuda R,  Leach MD,  Li L,  Miller CE,  Patturajan M,  Rieger DK;
PI   Rothenberg ME,  Shimkets RA,  Smithson G,  Spytek KA,  Taupier RJ;
PI   Vernet CAM,  Voss EZ,  Zerhusen BD,  Zhong M;
XX
DR   WPI; 2003-381625/36.
DR   N-PSDB; ACC72172.
XX
PT   NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
PT   treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
PT   dyslipidemia, and in chromosome mapping, tissue typing or
PT   pharmacogenomics.
XX
PS   Claim 1; Page 265; 487pp; English.
XX
CC   The present invention relates to novel human NOV proteins and their
CC   coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
CC   proteins are useful in manufacturing a medicament for treating a syndrome
CC   associated with a human disease. The NOV proteins and coding sequences
CC   may be used to diagnose, treat or prevent metabolic disorders such as
CC   diabetes or obesity, infections, cachexia, cancer, neurodegenerative
CC   disorders such as Alzheimer's disease or Parkinson's disease, immune
CC   disorders, haematopoietic disorders and various dyslipidaemias
XX
SQ   Sequence 577 AA;

  Query Match             30.0%;  Score 6;  DB 6;  Length 577;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db        546 QMLETK 551


RESULT 15
ADJ71063
ID   ADJ71063 standard; protein; 731 AA.
XX
AC   ADJ71063;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human heat mitochondrial protein as a therapeutic target SeqID2869.
XX
KW   mitochondrial; human; screening assay; diabetes mellitus;
KW   Huntington's disease; osteoarthritis;
KW   Leber's hereditary optic neuropathy; LHON;
KW   mitochondrial encephalopathy lactic acidosis and stroke; MELAS;
KW   myoclonic epilepsy ragged red fibre syndrome; MERRF; cancer;
KW   neuroprotective; nootropic; antidiabetic; anticonvulsant; antiarthritic;
KW   osteopathic; ophthalmological; cytostatic.
XX
OS   Homo sapiens.
XX
PN   WO2003087768-A2.
XX
PD   23-OCT-2003.
XX
PF   04-APR-2003; 2003WO-US010870.
XX
PR   12-APR-2002; 2002US-0372843P.
PR   17-JUN-2002; 2002US-0389987P.
PR   20-SEP-2002; 2002US-0412418P.
XX
PA   (MITO-) MITOKOR.
PA   (BUCK-) BUCK INST AGE RES.
XX
PI   Ghosh SS,  Fahy ED,  Zhang B,  Gibson BW,  Taylor SW,  Glenn GM;
PI   Warnock DE;
XX
DR   WPI; 2003-845369/78.
XX
PT   Identifying a mitochondrial target for drug screening assays and for
PT   treating diseases associated with altered mitochondrial function,
PT   comprises detecting a modified polypeptide in a sample and correlating
PT   with the disease.
XX
PS   Claim 1; SEQ ID NO 2869; 180pp; English.
XX
CC   This invention relates to novel mitochondrial targets that can be used
```

CC for therapeutic intervention in treating a disease associated with
CC altered mitochondrial function. Specifically, it refers to a method for
CC identifying proteins of the human heart mitochondrial proteome that are
CC useful for drug screening assays, as well as therapeutic targets. The
CC present invention describes a method for identifying such proteins that
CC can be used in the treatment of various diseases associated with altered
CC mitochondrial function including diabetes mellitus, Huntington's disease,
CC osteoarthritis, Leber's hereditary optic neuropathy (LHON), mitochondrial
CC encephalopathy lactic acidosis and stroke (MELAS), myoclonic epilepsy
CC ragged red fibre syndrome (MERRF) or cancer. Accordingly, these
CC compositions have neuroprotective, nootropic, antidiabetic,
CC anticonvulsant, antiarthritic, osteopathic, ophthalmological and
CC cytostatic activities. This polypeptide sequence is a human heart
CC mitochondrial protein of the invention.
XX
SQ Sequence 731 AA;

Query Match 30.0%; Score 6; DB 7; Length 731;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAPM 6
||||||
Db 542 PRGAPM 547

RESULT 16
ADN99559
ID ADN99559 standard; protein; 847 AA.
XX
AC ADN99559;
XX
DT 29-JUL-2004 (first entry)
XX
DE Novel human protein sequence #375.
XX
KW anti-inflammatory; dermatological; neuroprotective; immunomodulator;
KW antibacterial; virucide; antipsoriatic; cytostatic; gene therapy;
KW vaccine; inflammatory; CNS; immune disorder; cancer; psoriasis; diabetes;
KW early aging; hormonal imbalance; ischemic heart disease;
KW ulcerative colitis.
XX
OS Homo sapiens.
XX
PN WO2004038003-A2.
XX
PD 06-MAY-2004.
XX
PF 24-OCT-2003; 2003WO-US033947.
XX
PR 25-OCT-2002; 2002US-0421061P.
PR 25-OCT-2002; 2002US-0421080P.
PR 25-OCT-2002; 2002US-0421552P.
PR 25-OCT-2002; 2002US-0421614P.
PR 30-OCT-2002; 2002US-0422177P.
PR 30-OCT-2002; 2002US-0422178P.
PR 15-NOV-2002; 2002US-0426355P.
PR 15-NOV-2002; 2002US-0426384P.
PR 15-NOV-2002; 2002US-0426394P.
PR 15-NOV-2002; 2002US-0426430P.
PR 15-NOV-2002; 2002US-0426916P.
PR 27-NOV-2002; 2002US-0429224P.
PR 27-NOV-2002; 2002US-0429275P.
PR 27-NOV-2002; 2002US-0429302P.
PR 27-NOV-2002; 2002US-0429326P.
PR 27-NOV-2002; 2002US-0429651P.
PR 04-DEC-2002; 2002US-0430645P.
PR 04-DEC-2002; 2002US-0430651P.
PR 04-DEC-2002; 2002US-0430657P.
PR 04-DEC-2002; 2002US-0430663P.
PR 04-DEC-2002; 2002US-0430668P.
PR 04-DEC-2002; 2002US-0430684P.
PR 05-DEC-2002; 2002US-0430937P.
PR 05-DEC-2002; 2002US-0430965P.
PR 05-DEC-2002; 2002US-0431458P.
PR 12-DEC-2002; 2002US-0433251P.
PR 12-DEC-2002; 2002US-0433500P.
PR 13-DEC-2002; 2002US-0433316P.
PR 13-DEC-2002; 2002US-0433318P.
PR 23-DEC-2002; 2002US-0436236P.
PR 03-JAN-2003; 2003US-0437914P.
PR 17-JAN-2003; 2003US-0440820P.
PR 17-JAN-2003; 2003US-0440821P.
PR 18-APR-2003; 2003US-0463700P.
PR 18-APR-2003; 2003US-0463708P.
PR 18-APR-2003; 2003US-0463716P.
PR 18-APR-2003; 2003US-0463732P.
PR 02-MAY-2003; 2003US-0467199P.
PR 02-MAY-2003; 2003US-0467201P.
PR 02-MAY-2003; 2003US-0467203P.
PR 02-MAY-2003; 2003US-0467230P.
PR 19-MAY-2003; 2003US-0471306P.
PR 19-MAY-2003; 2003US-0471336P.
PR 22-MAY-2003; 2003US-0472420P.
PR 22-MAY-2003; 2003US-0472430P.
PR 09-JUN-2003; 2003US-0476609P.
PR 09-JUN-2003; 2003US-0476621P.
PR 09-JUN-2003; 2003US-0476632P.
PR 09-JUN-2003; 2003US-0476641P.
PR 08-JUL-2003; 2003US-0485217P.
PR 08-JUL-2003; 2003US-0485218P.
PR 08-JUL-2003; 2003US-0485223P.
PR 08-JUL-2003; 2003US-0485224P.
PR 08-JUL-2003; 2003US-0485325P.
PR 08-JUL-2003; 2003US-0485359P.
PR 14-JUL-2003; 2003US-0486446P.
PR 14-JUL-2003; 2003US-0486480P.
PR 15-JUL-2003; 2003US-0486891P.
PR 15-JUL-2003; 2003US-0486960P.
PR 08-AUG-2003; 2003US-0493341P.
PR 08-AUG-2003; 2003US-0493370P.
PR 08-AUG-2003; 2003US-0493573P.
PR 08-AUG-2003; 2003US-0493577P.
XX
PA (FIVE-) FIVE PRIME THERAPEUTICS INC.
XX
PI Williams LT, Chu K, Lee E, Hestir K, Beaurang PA, Behrens D;
PI Halenbeck RF, Kothakota S, Lin H, Linnemann T, Pierce K, Wang Y;
PI Wong JGP, Wu G, Zhang H, Zeng C;
XX
DR WPI; 2004-365511/34.
DR N-PSDB; ADN98775.
XX
PT New nucleic acid molecules, useful in preparing a composition for
PT treating or preventing e.g. inflammatory, CNS, bacterial or viral
PT disorders, cancer, psoriasis, diabetes, ischemic heart disease or
PT ulcerative colitis.
XX
PS Claim 14; SEQ ID NO 1159; 532pp; English.
XX
CC The invention relates to a nucleic acid molecule comprising a
CC polynucleotide sequence or its complement that encodes a polypeptide. The
CC nucleic acid is useful in preparing a composition for treating or
CC preventing inflammatory, CNS, immune, bacterial or viral disorder,
CC cancer, psoriasis, diabetes, early aging, hormonal imbalance, ischemic
CC heart disease or ulcerative colitis. This sequence corresponds to a
CC protein of the invention.
XX
SQ Sequence 847 AA;

Query Match 30.0%; Score 6; DB 8; Length 847;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 15 LETKFL 20
||||||

```
Db        385 LETKFL 390


RESULT 17
ADL15079
ID   ADL15079 standard; protein; 1290 AA.
XX
AC   ADL15079;
XX
DT   06-MAY-2004  (first entry)
XX
DE   Human adult male brain KIAAA0960 protein for cancer treatment.
XX
KW   cytostatic; gene therapy; binding moiety; medicine; imaging; diagnosis;
KW   prognosis; mantle cell lymphoma; cancer.
XX
OS   Homo sapiens.
XX
PN   WO2003068268-A2.
XX
PD   21-AUG-2003.
XX
PF   13-FEB-2003; 2003WO-EP001461.
XX
PR   14-FEB-2002; 2002GB-00003480.
PR   29-JUN-2002; 2002GB-00015095.
XX
PA   (BIOI-) BIOINVENT INT AB.
XX
PI   Ek S,  Borrebaeck CAK,  Ehinger M;
XX
DR   WPI; 2003-697496/66.
DR   N-PSDB; ADL15080.
XX
PT   New compound for treating, imaging, diagnosing or prognosing mantle cell
PT   lymphoma, comprises a binding moiety (e.g. antibody) that binds to a
PT   protein (e.g. human autotaxin polypeptide), and a further moiety (e.g.
PT   nucleic acid).
XX
PS   Disclosure; SEQ ID NO 91; 342pp; English.
XX
CC   The invention relates to a compound comprising a binding moiety which
CC   selectively binds to a protein or polypeptide listed in the specification
CC   (e.g. human autotaxin polypeptide or human CD24 signal transducer
CC   polypeptide), and a further moiety. The compound is useful in medicine or
CC   in the treatment, imaging, diagnosis or prognosis of mantle cell
CC   lymphomas (MCL). It is used in preparing a medicament for treating MCL, a
CC   diagnostic or prognostic agent for MCL, or an agent for imaging MCL cells
CC   in the body of an individual. This sequence corresponds to one of the
CC   polypeptides of the invention.
XX
SQ   Sequence 1290 AA;

  Query Match             30.0%;  Score 6;  DB 7;  Length 1290;
  Best Local Similarity   100.0%;  Pred. No. 5.2e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db       1095 QMLETK 1100


RESULT 18
ABR58454
ID   ABR58454 standard; protein; 1490 AA.
XX
AC   ABR58454;
XX
DT   07-JUL-2003  (first entry)
XX
DE   Human NOV47e.
XX
KW   Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
KW   immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
KW   antiparkinsonian; antilipaemic; gene therapy; metabolic disorder;
KW   diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
KW   neurodegenerative disorder; Alzheimer's disease; immune disorder;
KW   haematopoietic disorder.
XX
OS   Homo sapiens.
XX
PN   WO2003029423-A2.
XX
PD   10-APR-2003.
XX
PF   02-OCT-2002; 2002WO-US031358.
XX
PR   02-OCT-2001; 2001US-0326483P.
PR   05-OCT-2001; 2001US-0327342P.
PR   09-OCT-2001; 2001US-0327917P.
PR   09-OCT-2001; 2001US-0328029P.
PR   09-OCT-2001; 2001US-0328044P.
PR   09-OCT-2001; 2001US-0328056P.
PR   12-OCT-2001; 2001US-0328849P.
PR   15-OCT-2001; 2001US-0329414P.
PR   17-OCT-2001; 2001US-0330142P.
PR   22-OCT-2001; 2001US-0341058P.
PR   24-OCT-2001; 2001US-0339266P.
PR   24-OCT-2001; 2001US-0343629P.
PR   29-OCT-2001; 2001US-0349575P.
PR   01-NOV-2001; 2001US-0346357P.
PR   12-APR-2002; 2002US-0371972P.
PR   12-APR-2002; 2002US-0371980P.
PR   17-APR-2002; 2002US-0373261P.
PR   19-APR-2002; 2002US-0373805P.
PR   23-APR-2002; 2002US-0374738P.
PR   16-MAY-2002; 2002US-0381101P.
PR   17-MAY-2002; 2002US-0381635P.
PR   29-MAY-2002; 2002US-0383830P.
PR   01-OCT-2002; 2002US-00262839.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Alsobrook JP,  Anderson DW,  Boldog FL,  Burgess CE,  Catterton E;
PI   Edinger SR,  Ellerman K,  Gerlach VL,  Gorman L,  Guo X,  Ji W;
PI   Kekuda R,  Leach MD,  Li L,  Miller CE,  Patturajan M,  Rieger DK;
PI   Rothenberg ME,  Shimkets RA,  Smithson G,  Spytek KA,  Taupier RJ;
PI   Vernet CAM,  Voss EZ,  Zerhusen BD,  Zhong M;
XX
DR   WPI; 2003-381625/36.
DR   N-PSDB; ACC72166.
XX
PT   NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
PT   treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
PT   dyslipidemia, and in chromosome mapping, tissue typing or
PT   pharmacogenomics.
XX
PS   Claim 1; Page 258-259; 487pp; English.
XX
CC   The present invention relates to novel human NOV proteins and their
CC   coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
CC   proteins are useful in manufacturing a medicament for treating a syndrome
CC   associated with a human disease. The NOV proteins and coding sequences
CC   may be used to diagnose, treat or prevent metabolic disorders such as
CC   diabetes or obesity, infections, cachexia, cancer, neurodegenerative
CC   disorders such as Alzheimer's disease or Parkinson's disease, immune
CC   disorders, haematopoietic disorders and various dyslipidaemias
XX
SQ   Sequence 1490 AA;

  Query Match             30.0%;  Score 6;  DB 6;  Length 1490;
  Best Local Similarity   100.0%;  Pred. No. 5.8e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
```

```
Db       1393 QMLETK 1398


RESULT 19
ABR58453
ID   ABR58453 standard; protein; 1545 AA.
XX
AC   ABR58453;
XX
DT   07-JUL-2003  (first entry)
XX
DE   Human NOV47d.
XX
KW   Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
KW   immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
KW   antiparkinsonian; antilipaemic; gene therapy; metabolic disorder;
KW   diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
KW   neurodegenerative disorder; Alzheimer's disease; immune disorder;
KW   haematopoietic disorder.
XX
OS   Homo sapiens.
XX
PN   WO2003029423-A2.
XX
PD   10-APR-2003.
XX
PF   02-OCT-2002; 2002WO-US031358.
XX
PR   02-OCT-2001; 2001US-0326483P.
PR   05-OCT-2001; 2001US-0327342P.
PR   09-OCT-2001; 2001US-0327917P.
PR   09-OCT-2001; 2001US-0328029P.
PR   09-OCT-2001; 2001US-0328044P.
PR   09-OCT-2001; 2001US-0328056P.
PR   12-OCT-2001; 2001US-0328849P.
PR   15-OCT-2001; 2001US-0329414P.
PR   17-OCT-2001; 2001US-0330142P.
PR   22-OCT-2001; 2001US-0341058P.
PR   24-OCT-2001; 2001US-0339266P.
PR   24-OCT-2001; 2001US-0343629P.
PR   29-OCT-2001; 2001US-0349575P.
PR   01-NOV-2001; 2001US-0346357P.
PR   12-APR-2002; 2002US-0371972P.
PR   12-APR-2002; 2002US-0371980P.
PR   17-APR-2002; 2002US-0373261P.
PR   19-APR-2002; 2002US-0373805P.
PR   23-APR-2002; 2002US-0374738P.
PR   16-MAY-2002; 2002US-0381101P.
PR   17-MAY-2002; 2002US-0381635P.
PR   29-MAY-2002; 2002US-0383830P.
PR   01-OCT-2002; 2002US-00262839.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Alsobrook JP,  Anderson DW,  Boldog FL,  Burgess CE,  Catterton E;
PI   Edinger SR,  Ellerman K,  Gerlach VL,  Gorman L,  Guo X,  Ji W;
PI   Kekuda R,  Leach MD,  Li L,  Miller CE,  Patturajan M,  Rieger DK;
PI   Rothenberg ME,  Shimkets RA,  Smithson G,  Spytek KA,  Taupier RJ;
PI   Vernet CAM,  Voss EZ,  Zerhusen BD,  Zhong M;
XX
DR   WPI; 2003-381625/36.
DR   N-PSDB; ACC72165.
XX
PT   NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
PT   treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
PT   dyslipidemia, and in chromosome mapping, tissue typing or
PT   pharmacogenomics.
XX
PS   Claim 1; Page 257; 487pp; English.
XX
CC   The present invention relates to novel human NOV proteins and their
CC   coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
CC   proteins are useful in manufacturing a medicament for treating a syndrome
CC   associated with a human disease. The NOV proteins and coding sequences
CC   may be used to diagnose, treat or prevent metabolic disorders such as
CC   diabetes or obesity, infections, cachexia, cancer, neurodegenerative
CC   disorders such as Alzheimer's disease or Parkinson's disease, immune
CC   disorders, haematopoietic disorders and various dyslipidaemias
XX
SQ   Sequence 1545 AA;

  Query Match             30.0%;  Score 6;  DB 6;  Length 1545;
  Best Local Similarity   100.0%;  Pred. No. 5.9e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db       1393 QMLETK 1398


RESULT 20
ABR58455
ID   ABR58455 standard; protein; 1549 AA.
XX
AC   ABR58455;
XX
DT   07-JUL-2003  (first entry)
XX
DE   Human NOV47f.
XX
KW   Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
KW   immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
KW   antiparkinsonian; antilipaemic; gene therapy; metabolic disorder;
KW   diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
KW   neurodegenerative disorder; Alzheimer's disease; immune disorder;
KW   haematopoietic disorder.
XX
OS   Homo sapiens.
XX
PN   WO2003029423-A2.
XX
PD   10-APR-2003.
XX
PF   02-OCT-2002; 2002WO-US031358.
XX
PR   02-OCT-2001; 2001US-0326483P.
PR   05-OCT-2001; 2001US-0327342P.
PR   09-OCT-2001; 2001US-0327917P.
PR   09-OCT-2001; 2001US-0328029P.
PR   09-OCT-2001; 2001US-0328044P.
PR   09-OCT-2001; 2001US-0328056P.
PR   12-OCT-2001; 2001US-0328849P.
PR   15-OCT-2001; 2001US-0329414P.
PR   17-OCT-2001; 2001US-0330142P.
PR   22-OCT-2001; 2001US-0341058P.
PR   24-OCT-2001; 2001US-0339266P.
PR   24-OCT-2001; 2001US-0343629P.
PR   29-OCT-2001; 2001US-0349575P.
PR   01-NOV-2001; 2001US-0346357P.
PR   12-APR-2002; 2002US-0371972P.
PR   12-APR-2002; 2002US-0371980P.
PR   17-APR-2002; 2002US-0373261P.
PR   19-APR-2002; 2002US-0373805P.
PR   23-APR-2002; 2002US-0374738P.
PR   16-MAY-2002; 2002US-0381101P.
PR   17-MAY-2002; 2002US-0381635P.
PR   29-MAY-2002; 2002US-0383830P.
PR   01-OCT-2002; 2002US-00262839.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Alsobrook JP,  Anderson DW,  Boldog FL,  Burgess CE,  Catterton E;
PI   Edinger SR,  Ellerman K,  Gerlach VL,  Gorman L,  Guo X,  Ji W;
PI   Kekuda R,  Leach MD,  Li L,  Miller CE,  Patturajan M,  Rieger DK;
PI   Rothenberg ME,  Shimkets RA,  Smithson G,  Spytek KA,  Taupier RJ;
PI   Vernet CAM,  Voss EZ,  Zerhusen BD,  Zhong M;
```

XX
DR WPI; 2003-381625/36.
DR N-PSDB; ACC72167.
XX
PT NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
PT treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
PT dyslipidemia, and in chromosome mapping, tissue typing or
PT pharmacogenomics.
XX
PS Claim 1; Page 260; 487pp; English.
XX
CC The present invention relates to novel human NOV proteins and their
CC coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
CC proteins are useful in manufacturing a medicament for treating a syndrome
CC associated with a human disease. The NOV proteins and coding sequences
CC may be used to diagnose, treat or prevent metabolic disorders such as
CC diabetes or obesity, infections, cachexia, cancer, neurodegenerative
CC disorders such as Alzheimer's disease or Parkinson's disease, immune
CC disorders, haematopoietic disorders and various dyslipidaemias
XX
SQ Sequence 1549 AA;

Query Match 30.0%; Score 6; DB 6; Length 1549;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18
||||||
Db 1395 QMLETK 1400

RESULT 21
AAM41081
ID AAM41081 standard; protein; 1551 AA.
XX
AC AAM41081;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 6012.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US034263.
XX
PR 23-DEC-1999; 99US-00471275.
PR 21-JAN-2000; 2000US-00488725.
PR 25-APR-2000; 2000US-00552317.
PR 20-JUN-2000; 2000US-00598042.
PR 19-JUL-2000; 2000US-00620312.
PR 03-AUG-2000; 2000US-00653450.
PR 14-SEP-2000; 2000US-00662191.
PR 19-OCT-2000; 2000US-00693036.
PR 29-NOV-2000; 2000US-00727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J, Zhao QA;
PI Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR N-PSDB; AAI60237.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders such
PT as central nervous system injuries.
XX
PS Example 2; SEQ ID NO 6012; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and the
CC encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders. Note: The sequence data for this patent did not form
CC part of the printed specification
XX
SQ Sequence 1551 AA;

Query Match 30.0%; Score 6; DB 4; Length 1551;
Best Local Similarity 100.0%; Pred. No. 5.9e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18
||||||
Db 1356 QMLETK 1361

RESULT 22
ADO00979
ID ADO00979 standard; protein; 1568 AA.
XX
AC ADO00979;
XX
DT 01-JUL-2004 (first entry)
XX
DE Mouse homologue of Fruit fly AD-related protein CG15671.
XX
KW Mouse; Alzheimer's disease; Gamma secretase; Psn gene; P-element; EP;
KW APPL-SV; Amyloid precursor-like protein; APP;
KW suppressor of hairless transcription factor; Su(H);
KW VP16 activation domain; dementia; memory loss; language deterioration;
KW impaired visuospatial skill.
XX
OS Mus sp.
XX
PN US2004067535-A1.
XX
PD 08-APR-2004.
XX
PF 03-OCT-2002; 2002US-00263929.
XX
PR 03-OCT-2002; 2002US-00263929.
XX
PA (LIFE-) LIFE SCI DEV CORP.
XX
PI Kim J, Galant R;
XX
DR WPI; 2004-355296/33.
DR N-PSDB; ADO00877.
XX
PT Identifying compound by exposing cell that expresses gene having
PT enhancing or suppression effect on APPL-SV phenotype to agent,
PT identifying modulation of Alzheimer's disease (AD), regulation of gene or
PT protein expression with AD.
XX
PS Claim 18; SEQ ID NO 117; 185pp; English.

XX
CC The invention relates to identifying a compound comprising exposing cell
CC expressing gene 1 having enhancing or suppression effect on an APPL-SV
CC phenotype (a transgenic fruit fly expressing the Amyloid precursor-like
CC protein, APP, as a fusion protein with the suppressor of hairless
CC transcription factor , Su(H) and VP16 activation domain. The fusion
CC protein is cleaved by gamma secretase (encoded by the Psn gene) to
CC release the Su(H-VP16, which affects wing vein development. Genes
CC affecting Psn expression/activity were screened by crossing the APP-SV
CC line with an EP P-element insertion library, and the DNA recovered from
CC the appropriate EP strain and sequenced) chosen from ADO00863-ADO00964,
CC being the identified fruit fly genes affecting APP processing and their
CC mammalian homologues, identifying modulation of Alzheimer's disease (AD)
CC symptom, regulation of biological pathway, gene expression or protein
CC function associated with AD relative to cell in absence of agent. Also
CC included are regulating AD (involves providing a subject with AD or
CC symptoms of AD and an agent that changes the expression of a gene
CC detailed above or changes the activity of a polypeptide having a sequence
CC chosen from ADO00965-ADO01066, and treating the subject with the agent)
CC and a composition (comprising a nucleic acid encoding a polypeptide
CC detailed above or an expression vector comprising the nucleic acid or a
CC host cell comprising the expression vector or an antisense
CC oligonucleotide that hybridises under stringent conditions to the nucleic
CC acid or polypeptide or an antibody that specifically binds to the
CC polypeptide). The method is useful for identifying compounds modulating
CC symptom of Alzheimer's disease (AD), regulation of biological pathway
CC associated with AD, or regulation of gene expression or protein function
CC of gene or protein associated with AD. The nucleic acids and proteins are
CC useful in drug screening and useful in screening and treating the subject
CC having increased susceptibility to AD or symptoms of AD such as dementia,
CC memory loss, language deterioration and impaired visuospatial skills. The
CC present sequence is a mouse homologue of a fruit fly protein from a gene
CC identified as having an effect on the APP-SV phenotype.
XX
SQ Sequence 1568 AA;

Query Match 30.0%; Score 6; DB 8; Length 1568;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVCQ 13
||||||
Db 394 LRCVCQ 399

RESULT 23
AAB20155
ID AAB20155 standard; protein; 1588 AA.
XX
AC AAB20155;
XX
DT 30-APR-2001 (first entry)
XX
DE Secreted protein SECP1.
XX
KW SECP1; secreted protein; human; diagnosis; therapy; lung cancer.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT Peptide 1. .23
FT /label= Signal_peptide
FT Protein 24. .1588
FT /label= Mature_protein
FT /note= "mature SECP1 is also specifically claimed in
FT Claim 1"
XX
PN WO200105971-A2.
XX
PD 25-JAN-2001.
XX
PF 20-JUL-2000; 2000WO-US019890.
XX
PR 20-JUL-1999; 99US-0144722P.
PR 29-NOV-1999; 99US-0167785P.
PR 19-JUL-2000; 2000US-00619252.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Shimkets RA, Fernandes E;
XX
DR WPI; 2001-091973/10.
DR N-PSDB; AAF30188.
XX
PT New polypeptide designated SECP, its encoding nucleic acid and its
PT immunospecific antibody, useful for diagnosing, preventing and treating
PT SECP-associated disorders such as cancer.
XX
PS Claim 1; Fig 1; 124pp; English.
XX
CC The present sequence is that of novel secreted protein SECP1, which is
CC predicted to localise in the plasma membrane. The protein shows homology
CC to human KIAA0960 protein. RNA species with homology to the SECP1 cDNA
CC were detected in endothelial cells, pancreas, adipose, adrenal gland,
CC thyroid, mammary gland, myometrium, uterus, placenta, prostate, testis,
CC and in neoplastic cells derived from ovarian carcinoma, breast carcinoma,
CC prostate carcinoma (bone metastases) and melanoma. SECP1 was also highly
CC expressed in a small cell lung cancer, a large cell lung cancer, and a
CC non-small cell lung cancer, and may be useful as a target for the
CC treatment of such cancers. The predicted SECP1 protein showed homology to
CC human KIAA0960. The invention provides 9 novel SECP secreted proteins
CC (see AAB20155-63), nucleic acids encoding them (see AAF30188-96),
CC antibodies, mutants or fragments. These can be used to detect, treat or
CC prevent an SECP-associated disorder, to screen for predisposition to such
CC a disorder, and to identify agents that modulate the expression or
CC activity of SECP
XX
SQ Sequence 1588 AA;

Query Match 30.0%; Score 6; DB 4; Length 1588;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18
||||||
Db 1393 QMLETK 1398

RESULT 24
AAM39295
ID AAM39295 standard; protein; 1588 AA.
XX
AC AAM39295;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 2440.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US034263.
XX
PR 23-DEC-1999; 99US-00471275.
PR 21-JAN-2000; 2000US-00488725.
PR 25-APR-2000; 2000US-00552317.

```
PR   20-JUN-2000; 2000US-00598042.
PR   19-JUL-2000; 2000US-00620312.
PR   03-AUG-2000; 2000US-00653450.
PR   14-SEP-2000; 2000US-00662191.
PR   19-OCT-2000; 2000US-00693036.
PR   29-NOV-2000; 2000US-00727344.
XX
PA   (HYSE-) HYSEQ INC.
XX
PI   Tang YT,  Liu C,  Asundi V,  Chen R,  Ma Y,  Qian XB,  Ren F,  Wang D;
PI   Wang J,  Wang Z,  Wehrman T,  Xu C,  Xue AJ,  Yang Y,  Zhang J,  Zhao QA;
PI   Zhou P,  Goodrich R,  Drmanac RT;
XX
DR   WPI; 2001-442253/47.
DR   N-PSDB; AAI58451.
XX
PT   Novel nucleic acids and polypeptides, useful for treating disorders such
PT   as central nervous system injuries.
XX
PS   Example 4; SEQ ID NO 2440; 10078pp; English.
XX
CC   The invention relates to human nucleic acids (AAI57798-AAI61369) and the
CC   encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC   immunosuppressant and cytostatic activity. The polynucleotides are useful
CC   in gene therapy. A composition containing a polypeptide or polynucleotide
CC   of the invention may be used to treat diseases of the peripheral nervous
CC   system, such as peripheral nervous injuries, peripheral neuropathy and
CC   localised neuropathies and central nervous system diseases, such as
CC   Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC   lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC   utilisation of the activities such as: Immune system suppression,
CC   Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC   and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC   assays for receptor activity, arthritis and inflammation, leukaemias and
CC   C.N.S disorders. Note: The sequence data for this patent did not form
CC   part of the printed specification
XX
SQ   Sequence 1588 AA;

  Query Match             30.0%;  Score 6;  DB 4;  Length 1588;
  Best Local Similarity   100.0%;  Pred. No. 6e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db       1393 QMLETK 1398


RESULT 25
ABR58450
ID   ABR58450 standard; protein; 1588 AA.
XX
AC   ABR58450;
XX
DT   07-JUL-2003  (first entry)
XX
DE   Human NOV47a.
XX
KW   Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
KW   immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
KW   antiparkinsonian; antilipaemic; gene therapy; metabolic disorder;
KW   diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
KW   neurodegenerative disorder; Alzheimer's disease; immune disorder;
KW   haematopoietic disorder.
XX
OS   Homo sapiens.
XX
PN   WO2003029423-A2.
XX
PD   10-APR-2003.
XX
PF   02-OCT-2002; 2002WO-US031358.
XX
PR   02-OCT-2001; 2001US-0326483P.
PR   05-OCT-2001; 2001US-0327342P.
PR   09-OCT-2001; 2001US-0327917P.
PR   09-OCT-2001; 2001US-0328029P.
PR   09-OCT-2001; 2001US-0328044P.
PR   09-OCT-2001; 2001US-0328056P.
PR   12-OCT-2001; 2001US-0328849P.
PR   15-OCT-2001; 2001US-0329414P.
PR   17-OCT-2001; 2001US-0330142P.
PR   22-OCT-2001; 2001US-0341058P.
PR   24-OCT-2001; 2001US-0339266P.
PR   24-OCT-2001; 2001US-0343629P.
PR   29-OCT-2001; 2001US-0349575P.
PR   01-NOV-2001; 2001US-0346357P.
PR   12-APR-2002; 2002US-0371972P.
PR   12-APR-2002; 2002US-0371980P.
PR   17-APR-2002; 2002US-0373261P.
PR   19-APR-2002; 2002US-0373805P.
PR   23-APR-2002; 2002US-0374738P.
PR   16-MAY-2002; 2002US-0381101P.
PR   17-MAY-2002; 2002US-0381635P.
PR   29-MAY-2002; 2002US-0383830P.
PR   01-OCT-2002; 2002US-00262839.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Alsobrook JP,  Anderson DW,  Boldog FL,  Burgess CE,  Catterton E;
PI   Edinger SR,  Ellerman K,  Gerlach VL,  Gorman L,  Guo X,  Ji W;
PI   Kekuda R,  Leach MD,  Li L,  Miller CE,  Patturajan M,  Rieger DK;
PI   Rothenberg ME,  Shimkets RA,  Smithson G,  Spytek KA,  Taupier RJ;
PI   Vernet CAM,  Voss EZ,  Zerhusen BD,  Zhong M;
XX
DR   WPI; 2003-381625/36.
DR   N-PSDB; ACC72162.
XX
PT   NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
PT   treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
PT   dyslipidemia, and in chromosome mapping, tissue typing or
PT   pharmacogenomics.
XX
PS   Claim 1; Page 254-255; 487pp; English.
XX
CC   The present invention relates to novel human NOV proteins and their
CC   coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
CC   proteins are useful in manufacturing a medicament for treating a syndrome
CC   associated with a human disease. The NOV proteins and coding sequences
CC   may be used to diagnose, treat or prevent metabolic disorders such as
CC   diabetes or obesity, infections, cachexia, cancer, neurodegenerative
CC   disorders such as Alzheimer's disease or Parkinson's disease, immune
CC   disorders, haematopoietic disorders and various dyslipidaemias
XX
SQ   Sequence 1588 AA;

  Query Match             30.0%;  Score 6;  DB 6;  Length 1588;
  Best Local Similarity   100.0%;  Pred. No. 6e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db       1393 QMLETK 1398


RESULT 26
ABR58456
ID   ABR58456 standard; protein; 1588 AA.
XX
AC   ABR58456;
XX
DT   07-JUL-2003  (first entry)
XX
DE   Human NOV47g.
XX
KW   Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
```

KW immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
KW antiparkinsonian; antilipaemic; gene therapy; metabolic disorder;
KW diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
KW neurodegenerative disorder; Alzheimer's disease; immune disorder;
KW haematopoietic disorder.
XX
OS Homo sapiens.
XX
PN WO2003029423-A2.
XX
PD 10-APR-2003.
XX
PF 02-OCT-2002; 2002WO-US031358.
XX
PR 02-OCT-2001; 2001US-0326483P.
PR 05-OCT-2001; 2001US-0327342P.
PR 09-OCT-2001; 2001US-0327917P.
PR 09-OCT-2001; 2001US-0328029P.
PR 09-OCT-2001; 2001US-0328044P.
PR 09-OCT-2001; 2001US-0328056P.
PR 12-OCT-2001; 2001US-0328849P.
PR 15-OCT-2001; 2001US-0329414P.
PR 17-OCT-2001; 2001US-0330142P.
PR 22-OCT-2001; 2001US-0341058P.
PR 24-OCT-2001; 2001US-0339266P.
PR 24-OCT-2001; 2001US-0343629P.
PR 29-OCT-2001; 2001US-0349575P.
PR 01-NOV-2001; 2001US-0346357P.
PR 12-APR-2002; 2002US-0371972P.
PR 12-APR-2002; 2002US-0371980P.
PR 17-APR-2002; 2002US-0373261P.
PR 19-APR-2002; 2002US-0373805P.
PR 23-APR-2002; 2002US-0374738P.
PR 16-MAY-2002; 2002US-0381101P.
PR 17-MAY-2002; 2002US-0381635P.
PR 29-MAY-2002; 2002US-0383830P.
PR 01-OCT-2002; 2002US-00262839.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Alsobrook JP, Anderson DW, Boldog FL, Burgess CE, Catterton E;
PI Edinger SR, Ellerman K, Gerlach VL, Gorman L, Guo X, Ji W;
PI Kekuda R, Leach MD, Li L, Miller CE, Patturajan M, Rieger DK;
PI Rothenberg ME, Shimkets RA, Smithson G, Spytek KA, Taupier RJ;
PI Vernet CAM, Voss EZ, Zerhusen BD, Zhong M;
XX
DR WPI; 2003-381625/36.
DR N-PSDB; ACC72168.
XX
PT NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
PT treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
PT dyslipidemia, and in chromosome mapping, tissue typing or
PT pharmacogenomics.
XX
PS Claim 1; Page 262; 487pp; English.
XX
CC The present invention relates to novel human NOV proteins and their
CC coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
CC proteins are useful in manufacturing a medicament for treating a syndrome
CC associated with a human disease. The NOV proteins and coding sequences
CC may be used to diagnose, treat or prevent metabolic disorders such as
CC diabetes or obesity, infections, cachexia, cancer, neurodegenerative
CC disorders such as Alzheimer's disease or Parkinson's disease, immune
CC disorders, haematopoietic disorders and various dyslipidaemias
XX
SQ Sequence 1588 AA;

Query Match 30.0%; Score 6; DB 6; Length 1588;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18
||||||

Db 1393 QMLETK 1398

RESULT 27
ABR58459
ID ABR58459 standard; protein; 1588 AA.
XX
AC ABR58459;
XX
DT 07-JUL-2003 (first entry)
XX
DE Human NOV47j.
XX
KW Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
KW immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
KW antiparkinsonian; antilipaemic; gene therapy; metabolic disorder;
KW diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
KW neurodegenerative disorder; Alzheimer's disease; immune disorder;
KW haematopoietic disorder.
XX
OS Homo sapiens.
XX
PN WO2003029423-A2.
XX
PD 10-APR-2003.
XX
PF 02-OCT-2002; 2002WO-US031358.
XX
PR 02-OCT-2001; 2001US-0326483P.
PR 05-OCT-2001; 2001US-0327342P.
PR 09-OCT-2001; 2001US-0327917P.
PR 09-OCT-2001; 2001US-0328029P.
PR 09-OCT-2001; 2001US-0328044P.
PR 09-OCT-2001; 2001US-0328056P.
PR 12-OCT-2001; 2001US-0328849P.
PR 15-OCT-2001; 2001US-0329414P.
PR 17-OCT-2001; 2001US-0330142P.
PR 22-OCT-2001; 2001US-0341058P.
PR 24-OCT-2001; 2001US-0339266P.
PR 24-OCT-2001; 2001US-0343629P.
PR 29-OCT-2001; 2001US-0349575P.
PR 01-NOV-2001; 2001US-0346357P.
PR 12-APR-2002; 2002US-0371972P.
PR 12-APR-2002; 2002US-0371980P.
PR 17-APR-2002; 2002US-0373261P.
PR 19-APR-2002; 2002US-0373805P.
PR 23-APR-2002; 2002US-0374738P.
PR 16-MAY-2002; 2002US-0381101P.
PR 17-MAY-2002; 2002US-0381635P.
PR 29-MAY-2002; 2002US-0383830P.
PR 01-OCT-2002; 2002US-00262839.
XX
PA (CURA-) CURAGEN CORP.
XX
PI Alsobrook JP, Anderson DW, Boldog FL, Burgess CE, Catterton E;
PI Edinger SR, Ellerman K, Gerlach VL, Gorman L, Guo X, Ji W;
PI Kekuda R, Leach MD, Li L, Miller CE, Patturajan M, Rieger DK;
PI Rothenberg ME, Shimkets RA, Smithson G, Spytek KA, Taupier RJ;
PI Vernet CAM, Voss EZ, Zerhusen BD, Zhong M;
XX
DR WPI; 2003-381625/36.
DR N-PSDB; ACC72171.
XX
PT NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
PT treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
PT dyslipidemia, and in chromosome mapping, tissue typing or
PT pharmacogenomics.
XX
PS Claim 1; Page 264-265; 487pp; English.
XX
CC The present invention relates to novel human NOV proteins and their
CC coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
CC proteins are useful in manufacturing a medicament for treating a syndrome

```
CC   associated with a human disease. The NOV proteins and coding sequences
CC   may be used to diagnose, treat or prevent metabolic disorders such as
CC   diabetes or obesity, infections, cachexia, cancer, neurodegenerative
CC   disorders such as Alzheimer's disease or Parkinson's disease, immune
CC   disorders, haematopoietic disorders and various dyslipidaemias
XX
SQ   Sequence 1588 AA;

  Query Match             30.0%;  Score 6;  DB 6;  Length 1588;
  Best Local Similarity   100.0%;  Pred. No. 6e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db       1393 QMLETK 1398


RESULT 28
ABR58462
ID   ABR58462 standard; protein; 1588 AA.
XX
AC   ABR58462;
XX
DT   07-JUL-2003  (first entry)
XX
DE   Human NOV47m.
XX
KW   Human; NOV; antidiabetic; anorectic; antibacterial; virucide;
KW   immunomodulator; cytostatic; nootropic; neuroprotective; dyslipidaemia;
KW   antiparkinsonian; antilipaemic; gene therapy; metabolic disorder;
KW   diabetes; obesity; infection; cachexia; cancer; Parkinson's disease;
KW   neurodegenerative disorder; Alzheimer's disease; immune disorder;
KW   haematopoietic disorder.
XX
OS   Homo sapiens.
XX
PN   WO2003029423-A2.
XX
PD   10-APR-2003.
XX
PF   02-OCT-2002; 2002WO-US031358.
XX
PR   02-OCT-2001; 2001US-0326483P.
PR   05-OCT-2001; 2001US-0327342P.
PR   09-OCT-2001; 2001US-0327917P.
PR   09-OCT-2001; 2001US-0328029P.
PR   09-OCT-2001; 2001US-0328044P.
PR   09-OCT-2001; 2001US-0328056P.
PR   12-OCT-2001; 2001US-0328849P.
PR   15-OCT-2001; 2001US-0329414P.
PR   17-OCT-2001; 2001US-0330142P.
PR   22-OCT-2001; 2001US-0341058P.
PR   24-OCT-2001; 2001US-0339266P.
PR   24-OCT-2001; 2001US-0343629P.
PR   29-OCT-2001; 2001US-0349575P.
PR   01-NOV-2001; 2001US-0346357P.
PR   12-APR-2002; 2002US-0371972P.
PR   12-APR-2002; 2002US-0371980P.
PR   17-APR-2002; 2002US-0373261P.
PR   19-APR-2002; 2002US-0373805P.
PR   23-APR-2002; 2002US-0374738P.
PR   16-MAY-2002; 2002US-0381101P.
PR   17-MAY-2002; 2002US-0381635P.
PR   29-MAY-2002; 2002US-0383830P.
PR   01-OCT-2002; 2002US-00262839.
XX
PA   (CURA-) CURAGEN CORP.
XX
PI   Alsobrook JP,  Anderson DW,  Boldog FL,  Burgess CE,  Catterton E;
PI   Edinger SR,  Ellerman K,  Gerlach VL,  Gorman L,  Guo X,  Ji W;
PI   Kekuda R,  Leach MD,  Li L,  Miller CE,  Patturajan M,  Rieger DK;
PI   Rothenberg ME,  Shimkets RA,  Smithson G,  Spytek KA,  Taupier RJ;
PI   Vernet CAM,  Voss EZ,  Zerhusen BD,  Zhong M;
XX
DR   WPI; 2003-381625/36.
DR   N-PSDB; ACC72174.
XX
PT   NOVX polypeptides and nucleic acids useful for diagnosing, preventing or
PT   treating NOVX-associated disorders, e.g. diabetes, obesity, cancer or
PT   dyslipidemia, and in chromosome mapping, tissue typing or
PT   pharmacogenomics.
XX
PS   Claim 1; Page 267; 487pp; English.
XX
CC   The present invention relates to novel human NOV proteins and their
CC   coding sequences (ACC72075-ACC72181 and ABR58363-ABR58469). The NOV
CC   proteins are useful in manufacturing a medicament for treating a syndrome
CC   associated with a human disease. The NOV proteins and coding sequences
CC   may be used to diagnose, treat or prevent metabolic disorders such as
CC   diabetes or obesity, infections, cachexia, cancer, neurodegenerative
CC   disorders such as Alzheimer's disease or Parkinson's disease, immune
CC   disorders, haematopoietic disorders and various dyslipidaemias
XX
SQ   Sequence 1588 AA;

  Query Match             30.0%;  Score 6;  DB 6;  Length 1588;
  Best Local Similarity   100.0%;  Pred. No. 6e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db       1393 QMLETK 1398


RESULT 29
ADG38871
ID   ADG38871 standard; protein; 1588 AA.
XX
AC   ADG38871;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human SECP10.
XX
KW   SECP; SECP-associated disorder; cancer; wound; AIDS; hepatitis;
KW   arteriosclerosis; psoriasis; autoimmune disease; Crohn's disease;
KW   inflammatory disorder; anaemia; allergy; asthma; Grave's disease;
KW   multiple sclerosis; scleroderma; infection; diabetes; metabolic disorder;
KW   Addison's disease; cystic fibrosis; glycogen storage disease;
KW   Alzheimer's disease; Parkinson's disease; addiction; cardiomyopathy;
KW   obesity; tissue typing; vaccine; human.
XX
OS   Homo sapiens.
XX
PN   US2003207348-A1.
XX
PD   06-NOV-2003.
XX
PF   13-FEB-2002; 2002US-00074566.
XX
PR   20-JUL-1999;   99US-0144722P.
PR   29-NOV-1999;   99US-0167785P.
PR   19-JUL-2000; 2000US-00619252.
PR   19-MAR-2001; 2001US-0276994P.
PR   02-APR-2001; 2001US-0280898P.
PR   02-MAY-2001; 2001US-0288062P.
PR   17-MAY-2001; 2001US-0291766P.
PR   21-AUG-2001; 2001US-0314007P.
PR   14-NOV-2001; 2001US-0332241P.
XX
PA   (SHIM/) SHIMKETS R A.
PA   (FERN/) FERNANDES E R.
PA   (LILL/) LI L.
PA   (GORM/) GORMAN L.
PA   (GUSE/) GUSEV V Y.
PA   (PADI/) PADIGARU M.
```

PA (PATT/) PATTURAJAN M.
PA (SHEN/) SHENOY S G.
PA (SPYT/) SPYTEK K A.
XX
PI Shimkets RA, Fernandes ER, Li L, Gorman L, Gusev VY, Padigaru M;
PI Patturajan M, Shenoy SG, Spytek KA;
XX
DR WPI; 2003-901057/82.
DR N-PSDB; ADG38870.
XX
PT New SECP polypeptides and nucleic acids, useful for preventing or
PT treating SECP-associated disorders, e.g. cancer, diabetes, asthma, AIDS
PT or autoimmune diseases, and in chromosome mapping, tissue typing or
PT pharmacogenomics.
XX
PS Claim 1; SEQ ID NO 41; 278pp; English.
XX
CC The invention relates to a new isolated SECP polypeptide. The SECP
CC polypeptide, nucleic acid molecule or antibody is useful in the
CC manufacture of a medicament for treating a syndrome associated with a
CC human disease, the disease being selected from SECP-associated disorders.
CC These are used in diagnosing, treating or preventing the SECP-associated
CC disorders such as cancer, wounds, AIDS, hepatitis, arteriosclerosis,
CC psoriasis, autoimmune diseases, Crohn's disease, inflammatory disorder,
CC anaemia, allergy, asthma, Grave's disease, multiple sclerosis,
CC scleroderma, infection, diabetes, metabolic disorder, Addison's disease,
CC cystic fibrosis, glycogen storage disease, Alzheimer's disease,
CC Parkinson's disease, addiction, cardiomyopathy or obesity. The nucleic
CC acids are further used as hybridisation probes, in chromosome mapping,
CC tissue typing, preventive medicine, and pharmacogenomics. The
CC polypeptides are also useful as vaccines. The present sequence is used in
CC the exemplification of the present invention.
XX
SQ Sequence 1588 AA;

Query Match 30.0%; Score 6; DB 7; Length 1588;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18
||||||
Db 1393 QMLETK 1398

RESULT 30
ADG38832
ID ADG38832 standard; protein; 1588 AA.
XX
AC ADG38832;
XX
DT 26-FEB-2004 (first entry)
XX
DE Human SECP1.
XX
KW SECP; SECP-associated disorder; cancer; wound; AIDS; hepatitis;
KW arteriosclerosis; psoriasis; autoimmune disease; Crohn's disease;
KW inflammatory disorder; anaemia; allergy; asthma; Grave's disease;
KW multiple sclerosis; scleroderma; infection; diabetes; metabolic disorder;
KW Addison's disease; cystic fibrosis; glycogen storage disease;
KW Alzheimer's disease; Parkinson's disease; addiction; cardiomyopathy;
KW obesity; tissue typing; vaccine; human.
XX
OS Homo sapiens.
XX
PN US2003207348-A1.
XX
PD 06-NOV-2003.
XX
PF 13-FEB-2002; 2002US-00074566.
XX
PR 20-JUL-1999; 99US-0144722P.
PR 29-NOV-1999; 99US-0167785P.
PR 19-JUL-2000; 2000US-00619252.
PR 19-MAR-2001; 2001US-0276994P.
PR 02-APR-2001; 2001US-0280898P.
PR 02-MAY-2001; 2001US-0288062P.
PR 17-MAY-2001; 2001US-0291766P.
PR 21-AUG-2001; 2001US-0314007P.
PR 14-NOV-2001; 2001US-0332241P.
XX
PA (SHIM/) SHIMKETS R A.
PA (FERN/) FERNANDES E R.
PA (LILL/) LI L.
PA (GORM/) GORMAN L.
PA (GUSE/) GUSEV V Y.
PA (PADI/) PADIGARU M.
PA (PATT/) PATTURAJAN M.
PA (SHEN/) SHENOY S G.
PA (SPYT/) SPYTEK K A.
XX
PI Shimkets RA, Fernandes ER, Li L, Gorman L, Gusev VY, Padigaru M;
PI Patturajan M, Shenoy SG, Spytek KA;
XX
DR WPI; 2003-901057/82.
DR N-PSDB; ADG38831.
XX
PT New SECP polypeptides and nucleic acids, useful for preventing or
PT treating SECP-associated disorders, e.g. cancer, diabetes, asthma, AIDS
PT or autoimmune diseases, and in chromosome mapping, tissue typing or
PT pharmacogenomics.
XX
PS Claim 1; SEQ ID NO 2; 278pp; English.
XX
CC The invention relates to a new isolated SECP polypeptide. The SECP
CC polypeptide, nucleic acid molecule or antibody is useful in the
CC manufacture of a medicament for treating a syndrome associated with a
CC human disease, the disease being selected from SECP-associated disorders.
CC These are used in diagnosing, treating or preventing the SECP-associated
CC disorders such as cancer, wounds, AIDS, hepatitis, arteriosclerosis,
CC psoriasis, autoimmune diseases, Crohn's disease, inflammatory disorder,
CC anaemia, allergy, asthma, Grave's disease, multiple sclerosis,
CC scleroderma, infection, diabetes, metabolic disorder, Addison's disease,
CC cystic fibrosis, glycogen storage disease, Alzheimer's disease,
CC Parkinson's disease, addiction, cardiomyopathy or obesity. The nucleic
CC acids are further used as hybridisation probes, in chromosome mapping,
CC tissue typing, preventive medicine, and pharmacogenomics. The
CC polypeptides are also useful as vaccines. The present sequence is used in
CC the exemplification of the present invention.
XX
SQ Sequence 1588 AA;

Query Match 30.0%; Score 6; DB 7; Length 1588;
Best Local Similarity 100.0%; Pred. No. 6e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18
||||||
Db 1393 QMLETK 1398

RESULT 31
AAE23979
ID AAE23979 standard; protein; 1624 AA.
XX
AC AAE23979;
XX
DT 23-SEP-2002 (first entry)
XX
DE Human LP217 secreted protein.
XX
KW Human; secreted protein; atherosclerosis; Alzheimer's disease; LP217;
KW diabetic retinopathy; severe combined immunodeficiency; pancreatitis;
KW rheumatoid arthritis; colorectal adenoma; haemolytic anaemia; cancer;
KW reperfusion injury; arteriosclerosis; wound healing; transgenic animal;
KW gene therapy; neoplasm; transgenic; psoriasis; ischaemia; carcinoma;
KW chromosome 7p21-p22.

```
XX
OS   Homo sapiens.
XX
FH   Key             Location/Qualifiers
FT   Peptide         1. .15
FT                   /label= Signal_peptide
FT   Protein         16. .1624
FT                   /note= "Mature human LP217 secreted protein"
XX
PN   WO200226801-A2.
XX
PD   04-APR-2002.
XX
PF   14-SEP-2001; 2001WO-US026026.
XX
PR   28-SEP-2000; 2000US-0236088P.
XX
PA   (ELIL ) LILLY & CO ELI.
XX
PI   Su EW,  Wang H;
XX
DR   WPI; 2002-471259/50.
DR   N-PSDB; AAD38694.
XX
PT   Novel proteins and polynucleotides of secreted proteins useful for
PT   treating various diseases e.g. rheumatoid arthritis, cancer, psoriasis,
PT   diabetic retinopathy, arteriosclerosis, ischemia or reperfusion injury.
XX
PS   Claim 8; Page 117-123; 145pp; English.
XX
CC   The invention relates to human secreted polypeptides designated LP095,
CC   LP191, LP217, LP220, LP221, LP222, LP229, LP237 or LP238 and nucleic acid
CC   molecules encoding such polypeptides. Novel secreted proteins of the
CC   invention are used for treating diseases such as atherosclerosis,
CC   Alzheimer's disease, diabetic retinopathy, psoriasis, pancreatitis,
CC   arteriosclerosis, rheumatoid arthritis, colorectal adenomas, severe
CC   combined immunodeficiency, ischaemia, carcinomas, haemolytic anaemia,
CC   reperfusion injury, neoplasms and cancer especially liver cancer. They
CC   are also used for wound healing. Polynucleotides of the invention can be
CC   used to generate transgenic animals or knock out animals, which in turn,
CC   are useful in the development and screening of therapeutically useful
CC   reagents for use in the treatment of diseases associated with LP
CC   polypeptide associated activity. They are also used in gene therapy. The
CC   present sequence is human LP217 secreted protein. LP217 gene is located
CC   on chromosome 7p21-p22
XX
SQ   Sequence 1624 AA;

  Query Match             30.0%;  Score 6;  DB 5;  Length 1624;
  Best Local Similarity   100.0%;  Pred. No. 6.1e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db       1429 QMLETK 1434


RESULT 32
AAR37732
ID   AAR37732 standard; peptide; 9 AA.
XX
AC   AAR37732;
XX
DT   25-MAR-2003  (revised)
DT   07-SEP-1993  (first entry)
XX
DE   Collagen-like polymer #15.
XX
KW   Recombinant; collagen-like polymer; CLP; tripeptide; helix; membrane;
KW   fibre; film; coating; triad sequence; collagen; mammalian; moulding;
KW   hydrogel; interchain linkage; colloid suspension.
XX
OS   Synthetic.
XX
PN   WO9310154-A1.
XX
PD   27-MAY-1993.
XX
PF   04-NOV-1992;   92WO-US009485.
XX
PR   12-NOV-1991;   91US-00791960.
XX
PA   (PROT-) PROTEIN POLYMER TECHNOLOGIES INC.
XX
PI   Cappello J,  Ferrari FA;
XX
DR   WPI; 1993-182496/22.
XX
PT   High mol. wt. collagen-like protein polymers - capable of being produced
PT   in unicellular microorganisms.
XX
PS   Disclosure; Page 12; 82pp; English.
XX
CC   The sequences given in AAR37718-32 are examples of recombinantly produced
CC   collagen-like polymers (CLPs) which consist of repeated tripeptide
CC   sequences selected from a wide range of GXY sequences, where X and Y can
CC   be any amino acid. These polymers have molecular weights of >30 kD and
CC   are able to form helices due to interchain linkages. These polymers pref.
CC   contain a proportion of tripeptide triad sequences found in natural
CC   collagens, pref. mammalian collagens. The CLPs impart unique
CC   characteristics to materials such as fibres, membranes, films, coatings,
CC   hydrogels, colloid suspensions and moulded articles. (Updated on 25-MAR-
CC   2003 to correct PN field.)
XX
SQ   Sequence 9 AA;

  Query Match             25.0%;  Score 5;  DB 2;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db          5 PRGAP 9


RESULT 33
AAR93239
ID   AAR93239 standard; peptide; 9 AA.
XX
AC   AAR93239;
XX
DT   25-MAR-2003  (revised)
DT   24-FEB-1996  (first entry)
XX
DE   Collagen-like GUB sequence motif 5.
XX
KW   collagen; repetitive triad motif; recombinant production; photographic;
KW   medical; structural; fibre.
XX
OS   Synthetic.
XX
PN   US5496712-A.
XX
PD   05-MAR-1996.
XX
PF   05-NOV-1992;   92US-00972032.
XX
PR   06-NOV-1990;   90US-00609716.
PR   12-NOV-1991;   91US-00791960.
XX
PA   (PROT-) PROTEIN POLYMER TECHNOLOGIES INC.
XX
PI   Cappello J,  Ferrari FA;
XX
DR   WPI; 1996-150728/15.
XX
```

PT Collagen-like polymers comprising repetitive triads - produced in
PT unicellular organisms with improved characteristics, useful in, e.g.
PT photographic and medical fibres.
XX
PS Disclosure; Col 6; 43pp; English.
XX
CC The invention concerns collagen-like polymers having repetitive triads
CC with reduced proline content, and where glycine is the initial amino acid
CC and the subsequent amino acids are varied. The choice of triads utilised
CC in a recombinant collagen-like polymer are chosen in order to affect
CC properties such as helix stability, hydration, solubility, gel point,
CC biodegradation and immunogenicity. Also considered is the level of
CC guanidine and cytosine nucleotides (due to levels of glycine and proline)
CC present in the genes encoding the polymers. As the gene is synthesised
CC there is opportunity for strands to loop out, single- stranded DNA to be
CC excised, recombination events to occur which can result in loss of
CC segments of the gene, and inefficient transcription and/or translation
CC (due to the presence of self-complementary sequences), hence genes of the
CC invention are designed to provide the advantageous properties of
CC collagen, while at the same time allowing for stable expression of high
CC mol. wt. collagen-like proteins. Triads of particular interest include
CC GAP, GPA, GPP, GAS, GPG, GPS, GAQ, GSP, GLQ, GPR, GPK, GAK, GAR, GER,
CC GDR, GEP, GDA, GAH and GEA. The collagen-like polymers may impart new
CC characteristics, finding wide used in photographic, medical, structural
CC and fibre applications, and are capable of being produced in unicellular
CC microorganisms at high mol. wts. and in high efficiency. AAR93235-39 are
CC peptides defining GUB (sic) sequences. The peptides are useful as
CC haptens, to produce antisera or monoclonal antibodies specific to the
CC sequences which are then used for affinity purification, identification
CC of the polymers, etc. . (Updated on 25-MAR-2003 to correct PF field.)
CC (Updated on 25-MAR-2003 to correct PA field.)
XX
SQ Sequence 9 AA;

Query Match 25.0%; Score 5; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
|||||
Db 5 PRGAP 9

RESULT 34
AAW57686
ID AAW57686 standard; peptide; 9 AA.
XX
AC AAW57686;
XX
DT 27-AUG-1998 (first entry)
XX
DE Collagen-like polymer fragment.
XX
KW Collagen-like polymer; synthetic polymer; fibre coating;
KW prosthetic device; catalytic substance.
XX
OS Synthetic.
XX
PN US5773249-A.
XX
PD 30-JUN-1998.
XX
PF 02-MAY-1996; 96US-00642255.
XX
PR 04-NOV-1986; 86US-00927258.
PR 29-OCT-1987; 87US-00114618.
PR 09-NOV-1988; 88US-00269429.
PR 06-NOV-1990; 90US-00609716.
PR 12-NOV-1991; 91US-00791960.
PR 05-NOV-1992; 92US-00972032.
PR 22-DEC-1995; 95US-00577046.
XX
PA (PROT-) PROTEIN POLYMER TECHNOLOGIES INC.
XX
PI Ferrari FA, Cappello J;
XX
DR WPI; 1998-387004/33.
XX
PT Recombinant collagen-like polymers - useful for making gels, films,
PT fibres, etc.
XX
PS Disclosure; Col 6; 93pp; English.
XX
CC This sequence represents a fragment of a unnatural collagen-like polymer
CC of the invention. The products may be used as films, fibres, moulded
CC objects and admixed with other natural or synthetic polymers or coatings
CC on fibres, films, labware or other surfaces, e.g. prosthetic devices. The
CC polymers may be used for binding a wide variety of specific binding
CC materials, as catalytic substances (where the amino acid sequence may
CC specifically chelate a wide variety of elements), as purification media,
CC composites, laminates or adhesives. They may also be combined with
CC inorganic or organic materials such as carbon fibres, nylon fibres,
CC nitrocellulose, etc., as flask coatings or in synthetic matrices for the
CC growth and study of cells, as affinity columns or as supports for
CC biological materials. The polymers have collagen-like properties, but may
CC be easily expressed in micro-organisms in high efficiency. The new
CC sequences can be tailored to give the desired properties
XX
SQ Sequence 9 AA;

Query Match 25.0%; Score 5; DB 2; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
|||||
Db 5 PRGAP 9

RESULT 35
AAU71713
ID AAU71713 standard; peptide; 9 AA.
XX
AC AAU71713;
XX
DT 26-FEB-2002 (first entry)
XX
DE Human MHC molecule HLA-B35 binding 103P3E8 peptide #20.
XX
KW 103P3E8; prostate; bladder; kidney; colon; lung; breast; rectum; stomach;
KW tumour; cancer; cytostatic; gene therapy; antibody therapy; ribozyme;
KW single chain monoclonal antibody; serum; blood; urine; tissue; human;
KW chromosome 9q13-q21.
XX
OS Homo sapiens.
XX
PN WO200179557-A2.
XX
PD 25-OCT-2001.
XX
PF 12-APR-2001; 2001WO-US012181.
XX
PR 12-APR-2000; 2000US-0196647P.
XX
PA (UROG-) UROGENESYS INC.
XX
PI Faris M, Challita-Eid PM, Raitano AB, Mitchell SC, Afar DEH;
PI Jakobovits A;
XX
DR WPI; 2002-061976/08.
XX
PT Monitoring 103P3E8 gene products in sample from patient (suspected of)
PT having cancer, useful for diagnosing, managing or treating cancers, e.g.
PT prostate cancer, comprises determining presence of aberrant 103P3E8 gene
PT products.
XX

PS Disclosure; Page 98; 128pp; English.
XX
CC Sequences AAU71093-AAU71796 represent the 103P3E8-related protein and
CC peptide fragments of the protein. 103P3E8 exhibits tissue specific
CC expression in normal adult tissue, but it is also aberrantly expressed in
CC many cancers including tumours of the prostate, bladder, kidney, colon,
CC lung, breast, rectum and stomach. The 103P3E8 polynucleotide, its related
CC protein and peptide fragments and specific PCR primers are therefore
CC useful for diagnosing and treating cancer. A vector comprising a
CC polynucleotide which encodes a single chain monoclonal antibody, that
CC immunospecifically binds to an 103P3E8-related protein, and a ribozyme
CC capable of cleaving a polynucleotide having the 103P3E8 coding sequence,
CC are both useful in the preparation of a composition for treating a
CC patient with a cancer that expresses 103P3E8. The sequences can be used
CC in diagnostic methods to monitor the level of 103P3E8 gene products in
CC serum, blood, urine and tissue and to thereby detect the presence of
CC cancerous cells
XX
SQ Sequence 9 AA;

Query Match 25.0%; Score 5; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
|||||
Db 2 PRGAP 6

RESULT 36
AAU71607
ID AAU71607 standard; peptide; 9 AA.
XX
AC AAU71607;
XX
DT 26-FEB-2002 (first entry)
XX
DE Human MHC class I molecule HLA-B7 binding 103P3E8 peptide #14.
XX
KW 103P3E8; prostate; bladder; kidney; colon; lung; breast; rectum; stomach;
KW tumour; cancer; cytostatic; gene therapy; antibody therapy; ribozyme;
KW single chain monoclonal antibody; serum; blood; urine; tissue; human;
KW chromosome 9q13-q21.
XX
OS Homo sapiens.
XX
PN WO200179557-A2.
XX
PD 25-OCT-2001.
XX
PF 12-APR-2001; 2001WO-US012181.
XX
PR 12-APR-2000; 2000US-0196647P.
XX
PA (UROG-) UROGENESYS INC.
XX
PI Faris M, Challita-Eid PM, Raitano AB, Mitchell SC, Afar DEH;
PI Jakobovits A;
XX
DR WPI; 2002-061976/08.
XX
PT Monitoring 103P3E8 gene products in sample from patient (suspected of)
PT having cancer, useful for diagnosing, managing or treating cancers, e.g.
PT prostate cancer, comprises determining presence of aberrant 103P3E8 gene
PT products.
XX
PS Disclosure; Page 95; 128pp; English.
XX
CC Sequences AAU71093-AAU71796 represent the 103P3E8-related protein and
CC peptide fragments of the protein. 103P3E8 exhibits tissue specific
CC expression in normal adult tissue, but it is also aberrantly expressed in
CC many cancers including tumours of the prostate, bladder, kidney, colon,
CC lung, breast, rectum and stomach. The 103P3E8 polynucleotide, its related
CC protein and peptide fragments and specific PCR primers are therefore
CC useful for diagnosing and treating cancer. A vector comprising a
CC polynucleotide which encodes a single chain monoclonal antibody, that
CC immunospecifically binds to an 103P3E8-related protein, and a ribozyme
CC capable of cleaving a polynucleotide having the 103P3E8 coding sequence,
CC are both useful in the preparation of a composition for treating a
CC patient with a cancer that expresses 103P3E8. The sequences can be used
CC in diagnostic methods to monitor the level of 103P3E8 gene products in
CC serum, blood, urine and tissue and to thereby detect the presence of
CC cancerous cells
XX
SQ Sequence 9 AA;

Query Match 25.0%; Score 5; DB 5; Length 9;
Best Local Similarity 100.0%; Pred. No. 1.7e+06;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
|||||
Db 2 PRGAP 6

RESULT 37
AAU71662
ID AAU71662 standard; peptide; 10 AA.
XX
AC AAU71662;
XX
DT 26-FEB-2002 (first entry)
XX
DE Human MHC class I molecule HLA-B7 binding 103P3E8 peptide #69.
XX
KW 103P3E8; prostate; bladder; kidney; colon; lung; breast; rectum; stomach;
KW tumour; cancer; cytostatic; gene therapy; antibody therapy; ribozyme;
KW single chain monoclonal antibody; serum; blood; urine; tissue; human;
KW chromosome 9q13-q21.
XX
OS Homo sapiens.
XX
PN WO200179557-A2.
XX
PD 25-OCT-2001.
XX
PF 12-APR-2001; 2001WO-US012181.
XX
PR 12-APR-2000; 2000US-0196647P.
XX
PA (UROG-) UROGENESYS INC.
XX
PI Faris M, Challita-Eid PM, Raitano AB, Mitchell SC, Afar DEH;
PI Jakobovits A;
XX
DR WPI; 2002-061976/08.
XX
PT Monitoring 103P3E8 gene products in sample from patient (suspected of)
PT having cancer, useful for diagnosing, managing or treating cancers, e.g.
PT prostate cancer, comprises determining presence of aberrant 103P3E8 gene
PT products.
XX
PS Disclosure; Page 96; 128pp; English.
XX
CC Sequences AAU71093-AAU71796 represent the 103P3E8-related protein and
CC peptide fragments of the protein. 103P3E8 exhibits tissue specific
CC expression in normal adult tissue, but it is also aberrantly expressed in
CC many cancers including tumours of the prostate, bladder, kidney, colon,
CC lung, breast, rectum and stomach. The 103P3E8 polynucleotide, its related
CC protein and peptide fragments and specific PCR primers are therefore
CC useful for diagnosing and treating cancer. A vector comprising a
CC polynucleotide which encodes a single chain monoclonal antibody, that
CC immunospecifically binds to an 103P3E8-related protein, and a ribozyme
CC capable of cleaving a polynucleotide having the 103P3E8 coding sequence,
CC are both useful in the preparation of a composition for treating a
CC patient with a cancer that expresses 103P3E8. The sequences can be used

```
CC   in diagnostic methods to monitor the level of 103P3E8 gene products in
CC   serum, blood, urine and tissue and to thereby detect the presence of
CC   cancerous cells
XX
SQ   Sequence 10 AA;

  Query Match             25.0%;  Score 5;  DB 5;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db          2 PRGAP 6


RESULT 38
ABP72812
ID   ABP72812 standard; peptide; 12 AA.
XX
AC   ABP72812;
XX
DT   17-JUN-2003  (first entry)
XX
DE   Human cancer antigen cytokeratin 8 peptide fragment.
XX
KW   Human; cytokeratin 8; cancer; antigen; immunotherapy; therapy; diagnosis.
XX
OS   Homo sapiens.
XX
PN   WO2003024191-A2.
XX
PD   27-MAR-2003.
XX
PF   23-SEP-2002; 2002WO-US030262.
XX
PR   21-SEP-2001; 2001US-0323844P.
PR   04-SEP-2002; 2002US-0408253P.
XX
PA   (RAVE-) RAVEN BIOTECHNOLOGIES INC.
XX
PI   Mather JP;
XX
DR   WPI; 2003-354547/33.
XX
PT   New antibodies that bind to cancer-associated antigen cytokeratin 8,
PT   useful for diagnosing or inhibiting proliferation of cancer cells, e.g.
PT   thyroid, ovarian, prostate, lung, colon, pancreas, breast or renal cancer
PT   cells.
XX
PS   Claim 1; Page 65; 74pp; English.
XX
CC   The present sequence is that of a peptide fragment of human cytokeratin 8
CC   (CK8), an antigen present on a variety of human cancers, including
CC   ovarian, breast, lung, prostate, colon, kidney, thyroid, bone, upper
CC   digestive tract and pancreatic cancers. The invention provides antibodies
CC   that bind to CK8, but not to cytokeratin 18. A preferred antibody is mhoe
CC   -4, which is produced by a host cell deposited as ATCC PTA-3159. Antibody
CC   mhoe-4 preferentially binds to CK8 and to the CK8 peptides given in
CC   ABP72812-18 including the present peptide. The antibody may be linked to
CC   a therapeutic agent, and a humanised mhoe-4 antibody is also claimed. The
CC   antibody is used in claimed methods of detecting the presence or absence
CC   of thyroid cancer cells, and for detecting the presence or absence of
CC   ovarian, prostate, lung, colon, pancreas, breast and renal cancerous
CC   cells. A claimed method of inhibiting proliferation of cancerous cells
CC   comprises administering the antibody linked to a therapeutic agent, such
CC   as saponin, where the cancer cells are ovarian or prostate cancer cells
XX
SQ   Sequence 12 AA;

  Query Match             25.0%;  Score 5;  DB 6;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          14 MLETK 18
                |||||
Db           8 MLETK 12


RESULT 39
AAR93209
ID   AAR93209 standard; peptide; 15 AA.
XX
AC   AAR93209;
XX
DT   04-OCT-1996  (first entry)
XX
DE   New contraceptive peptide #5 derived from Zona Pellucida ZP3 protein.
XX
KW   Zona pellucida; ZP3; vaccine; humoral response; contraception; epitope;
KW   pathogenic T cell response; ovary; assay; autoimmune; antibody;
KW   passive immunisation.
XX
OS   Synthetic.
XX
PN   WO9606113-A1.
XX
PD   29-FEB-1996.
XX
PF   18-AUG-1995;   95WO-EP003311.
XX
PR   22-AUG-1994;   94EP-00202392.
XX
PA   (ALKU ) AKZO NOBEL NV.
XX
PI   Van Duin M,  Grootenhuis AJ,  Bunschoten EJ;
XX
DR   WPI; 1996-151331/15.
XX
PT   Immuno:contraceptive peptide(s) derived from Zona Pellucida protein ZP3 -
PT   used to prepare contraceptive vaccine and in assays to measure autoimmune
PT   antibodies.
XX
PS   Claim 5; Page 31; 43pp; English.
XX
CC   Peptides AAR93205-9 are examples of peptides derived from the sequence of
CC   the Zona Pellucida protein ZP3 which contain the amino acid sequences
CC   AAR93210 or AAR93214-5. The peptides are esp. based on amino acids 23-30
CC   of the ZP3 protein. The novel peptides can be used in vaccines to induce
CC   a humoral response against the ZP3 protein e.g. for contraception, esp.
CC   as they do not raise a pathogenic T cell response since they do not
CC   contain T cell epitopes. The novel peptides thus avoid potential ovarian
CC   damage caused by some peptides used as vaccines. The peptides are also
CC   useful in assays for detecting autoimmune antibodies or for generating
CC   antibodies for passive immunisation
XX
SQ   Sequence 15 AA;

  Query Match             25.0%;  Score 5;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          3 GAPMW 7
              |||||
Db          3 GAPMW 7


RESULT 40
AAW96728
ID   AAW96728 standard; peptide; 15 AA.
XX
AC   AAW96728;
XX
DT   15-APR-1999  (first entry)
XX
DE   ENA-78 derived peptide used to stimulate angiogenesis.
XX
```

```
KW   Epithelial neutrophil activating protein-78; ENA-78; CXC chemokine;
KW   angiogenesis inhibitor; angiostasis inducer; tumour growth inhibition;
KW   haemangiomas; rheumatoid arthritis; atherosclerosis; meningioma;
KW   idiopathic pulmonary fibrosis; benign prostatic hypertrophy; psoriasis;
KW   vascular restenosis; arteriovenous malformation; neovascular glaucoma;
KW   angiofibroma; haemophilic joint; hypertrophic scar; Osler-Weber syndrome;
KW   pyogenic granuloma retrolental fibroplasia; scleroderma; trachoma;
KW   vascular adhesion; synovitis; dermatitis; endometriosis; pterygium;
KW   diabetic retinopathy; neovascularisation; chronic bronchitis;
KW   adult respiratory distress syndrome; ARDS; pseudogout; metastasis;
KW   cystic fibrosis.
XX
OS   Homo sapiens.
XX
PN   US5871723-A.
XX
PD   16-FEB-1999.
XX
PF   06-JUN-1995;   95US-00468819.
XX
PR   06-JUN-1995;   95US-00468819.
XX
PA   (UNMI ) UNIV MICHIGAN.
XX
PI   Kunkel SL,  Strieter RM,  Polverini PJ;
XX
DR   WPI; 1999-166569/14.
XX
PT   Use of chemokines with a conserved Cys Xaa Cys (CXC) sequence - which do
PT   not contain amino acid sequence ELR, for inhibiting angiogenesis in
PT   tumours, rheumatoid arthritis, restenosis or glaucoma.
XX
PS   Disclosure; Col 16; 145pp; English.
XX
CC   The present sequence represents a peptide derived from epithelial
CC   neutrophil activating protein-78 (ENA-78). The present peptide stimulates
CC   angiogenesis. The specification describes methods for inhibiting
CC   angiogenesis or for inducing angiostasis, using chemokines (with a
CC   conserved Cys Xaa Cys (CXC) sequence at the N-terminal) other than
CC   platelet factor-4, and which do not contain the amino acid sequence ELR.
CC   The methods are useful for inhibiting tumour growth and metastasis and
CC   for treating diseases such as haemangiomas, rheumatoid arthritis,
CC   atherosclerosis and idiopathic pulmonary fibrosis (IPF), benign prostatic
CC   hypertrophy (BPH), vascular restenosis, arteriovenous malformations
CC   (AVM), meningioma, neovascular glaucoma, psoriasis, angiofibroma,
CC   haemophilic joints, hypertrophic scars, Osler-Weber syndrome, pyogenic
CC   granuloma retrolental fibroplasia, scleroderma, trachoma, vascular
CC   adhesions, synovitis, dermatitis, endometriosis, pterygium, diabetic
CC   retinopathy neovascularisation associated with corneal injury or grafts,
CC   adult respiratory distress syndrome (ARDS), chronic bronchitis,
CC   pseudogout and cystic fibrosis
XX
SQ   Sequence 15 AA;

  Query Match             25.0%;  Score 5;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 41
ABU67730
ID   ABU67730 standard; peptide; 15 AA.
XX
AC   ABU67730;
XX
DT   30-MAY-2003  (first entry)
XX
DE   Human angiogenesis stimulatory peptide from ENA-78.
XX
KW   CXC chemokine; angiogenesis; tumour; platelet factor 4 (PF4);
KW   ELR CXC chemokine; IP-10; benign tumour; haemangioma; BPH; angiofibroma;
KW   rheumatoid arthritis; atherosclerosis; idiopathic pulmonary fibrosis;
KW   benign prostatic hyperplasia; vascular restenosis; meningioma;
KW   arteriovenous malformation; neovascular glaucoma; psoriaisis;
KW   haemophilic joint; hypertrophic scar; oslerweber syndrome;
KW   pyogenic granuloma retrolental fibroplasia; scleroderma; trachoma;
KW   vascular adhesion; synovitis; dermatitis; endometriosis; wound healing;
KW   sore healing; vascular graft; transplant; skin ulcer; gastric ulcer;
KW   duodenal ulcer; human.
XX
OS   Homo sapiens.
XX
PN   US6491906-B1.
XX
PD   10-DEC-2002.
XX
PF   09-DEC-1998;   98US-00213383.
XX
PR   06-JUN-1995;   95US-00468819.
XX
PA   (UNMI ) UNIV MICHIGAN.
XX
PI   Strieter RM,  Polverini PJ,  Kunkel SL;
XX
DR   WPI; 2003-327304/31.
XX
PT   Inhibition of angiogenesis in human having tumor, by administering to
PT   human, composition comprising recombinant adenovirus having nucleic acid
PT   segment that encodes chemokine other than platelet factor.
XX
PS   Disclosure; Col 16; 148pp; English.
XX
CC   The invention relates to an angiogenesis inhibited by administering to a
CC   human having a tumour, a composition comprising a recombinant adenovirus
CC   that comprises and expresses a nucleic acid segment that encodes a non-
CC   ELR-CXC (Glu-Leu-Arg, Cys-Xaa-Cys) chemokine other than platelet factor 4
CC   (PF4). The non-ELR CXC chemokine lacks the amino acid sequence ELR e.g.
CC   IP-10 or a CXC chemokine protein where the ELR sequence has been replaced
CC   with TVR or DLQ. The method is for inhibiting angiogenesis. It is also
CC   useful for treating benign tumours, haemangiomas, rheumatoid arthritis,
CC   atherosclerosis, idiopathic pulmonary fibrosis, BPH, (benign prostatic
CC   hypertrophy or hyperplasia), vascular restenosis, arteriovenous
CC   malformations, meningioma, neovascular glaucoma, psoriasis, angiofibroma,
CC   haemophilic joints, hypertrophic scars, oslerweber syndrome, pyogenic
CC   granuloma retrolental fibroplasia, scleroderma, trachoma, vascular
CC   adhesions, synovitis, dermatitis, or endometriosis. It is also useful in
CC   wound or sore healing, treatment of vascular grafts or transplants, and
CC   treatment of skin, gastric, or duodenal ulcers. The invention allows
CC   angiogenic or angiostatic chemokines to be identified or designed without
CC   laborious experimentation and avoiding the expense of trial and error
CC   screening. It inhibits or reduces angiogenesis in the animal or in a
CC   defined biological site within the animal. The present sequence
CC   represents an angiogenesis stimulatory peptide derived from a CXC
CC   chemokine
XX
SQ   Sequence 15 AA;

  Query Match             25.0%;  Score 5;  DB 6;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 2.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 42
ABO07364
ID   ABO07364 standard; peptide; 15 AA.
XX
AC   ABO07364;
XX
```

DT 14-AUG-2003 (first entry)
XX
DE Angiogenesis stimulating peptide #5.
XX
KW Human; inhibiting angiogenesis; Cys-Xaa-Cys chemokine; CXC chemokine;
KW platelet factor 4; PF4; interleukin-8; IL-8; IP-10; GROalpha;
KW gamma interferon-inducible protein-10; growth related oncogene; GRObeta;
KW GROgamma; monokine induced by gamma interferon; MIG;
KW epithelial neutrophil activating protein-78; ENA-78; GCP-2;
KW granulocyte chemotactic protein-2; platelet basic protein; PBP;
KW connective tissue activating protein-III; CTAP-III; betaTG;
KW beta-thromboglobulin; neutrophil activating peptide-2; NAP-2; tumour;
KW sarcoma; lung; ovary; pancreas; stomach; prostate; haemangioma;
KW rheumatoid arthritis; atherosclerosis; IPF; AVM;
KW idiopathic pulmonary fibrosis; vascular restenosis; meningioma;
KW arteriovenous malformation; neovascular glaucoma; psoriasis;
KW angiofibroma; haemophilic joint; hypertrophic scar; scleroderma;
KW osler-weber syndrome; pyogenic granuloma retrolental fibroplasia;
KW trachoma; vascular adhesion; synovitis; dermatitis; endometriosis;
KW inducing angiostasis; stimulating angiogenesis; wound healing; vulnerary;
KW antiulcer; vasotropic; antirheumatic; antiarthritic; antiatherosclerotic;
KW ophthalmological; antipsoriatic; dermatological; antiinflammatory;
KW antiallergic.
XX
OS Homo sapiens.
XX
PN US2003031645-A1.
XX
PD 13-FEB-2003.
XX
PF 21-MAR-2002; 2002US-00104755.
XX
PR 06-JUN-1995; 95US-00468819.
PR 09-DEC-1998; 98US-00213383.
XX
PA (UNMI) UNIV MICHIGAN.
XX
PI Strieter RM, Kunkel SL;
XX
DR WPI; 2003-466212/44.
XX
PT Inhibiting angiogenesis, by administering a pharmaceutical chemokine
PT composition that comprises a chemokine other than platelet factor 4.
XX
PS Disclosure; Page 9; 156pp; English.
XX
CC The present invention relates to a method of inhibiting angiogenesis. The
CC method comprises administering to an animal, preferably human, a
CC biological amount of a pharmaceutical CXC (Cys-Xaa-Cys) chemokine
CC composition that comprises chemokines other than platelet factor 4 (PF4),
CC e.g. interleukin-8 (IL-8), gamma interferon-inducible protein-10 (IP-10),
CC the growth related oncogene (GRO) peptides GROalpha, GRObeta, and
CC GROgamma, monokine induced by gamma interferon (MIG), epithelial
CC neutrophil activating protein-78 (ENA-78), granulocyte chemotactic
CC protein-2 (GCP-2), and the NH2-terminal truncated forms of platelet basic
CC protein (PBP) such as connective tissue activating protein-III (CTAP-
CC III), beta-thromboglobulin (betaTG) and neutrophil activating peptide-2
CC (NAP-2). The method is useful for inhibiting angiogenesis in humans, and
CC is useful for treating tumours and even sarcomas of the lung, ovary,
CC pancreas, stomach, and prostate. The method is also useful for treating
CC haemangiomas, rheumatoid arthritis, atherosclerosis, idiopathic pulmonary
CC fibrosis (IPF), vascular restenosis, arteriovenous malformations (AVM),
CC meningioma, neovascular glaucoma, psoriasis, angiofibroma, haemophilic
CC joints, hypertrophic scars, osler-weber syndrome, pyogenic granuloma
CC retrolental fibroplasia, scleroderma, trachoma, vascular adhesions,
CC synovitis, dermatitis and endometriosis. Also disclosed are methods for
CC inducing angiostasis, stimulating angiogenesis, and promoting wound
CC healing. The present sequence represents a peptide for stimulating
CC angiogenesis
XX
SQ Sequence 15 AA;

Query Match 25.0%; Score 5; DB 7; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVC 12
|||||
Db 11 LRCVC 15

RESULT 43
AAR91628
ID AAR91628 standard; peptide; 16 AA.
XX
AC AAR91628;
XX
DT 30-OCT-1996 (first entry)
XX
DE Alpha chemokine ENA-78 peptide analogue 11.
XX
KW Alpha chemokine; peptide analogue; agonist activity; treatment;
KW infection; arthritis; leukaemia; solid tumour; protective agent;
KW immune system; chemotherapy; radiation therapy; interleukin-8; IL-8;
KW rapid; extensive; tissue distribution; ENA-78.
XX
OS Synthetic.
XX
PN WO9609062-A1.
XX
PD 28-MAR-1996.
XX
PF 22-SEP-1995; 95WO-US012099.
XX
PR 23-SEP-1994; 94US-00311307.
PR 23-SEP-1994; 94US-00311380.
XX
PA (UYNE-) UNIV NEBRASKA.
XX
PI Talmadge JE;
XX
DR WPI; 1996-188211/19.
XX
PT New human interleukin-8 peptide analogues - useful as agonists or
PT antagonists for alpha chemokines for treating e.g. neoplasms, infection
PT and auto-immune disease.
XX
PS Claim 4; Page 52; 75pp; English.
XX
CC The present peptide is an alpha chemokine derived peptide analogue, with
CC alpha chemokine agonist activity. It can be used for the treatment of,
CC e.g. viral, bacterial, fungal, yeast or parasitic infections, arthritis,
CC leukaemia or solid tumours including primary and metastatic disease. The
CC peptide can also be used as a protective agent for the immune system
CC during chemotherapy and radiation-therapy. In contrast to the claimed
CC invention in WO9311159, which describes a 77 residue amino acid
CC interleukin-8 antagonist, the present peptide is more efficiently prepd.
CC (solid phase synthesis) and has a more rapid and extensive tissue
CC distribution
XX
SQ Sequence 16 AA;

Query Match 25.0%; Score 5; DB 2; Length 16;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVC 12
|||||
Db 2 LRCVC 6

RESULT 44
ADK01531
ID ADK01531 standard; peptide; 20 AA.
XX
AC ADK01531;

XX
DT 06-MAY-2004 (first entry)
XX
DE Hepatitis C virus 1b peptide SeqID183.
XX
KW pathogenic virus; alternative reading frame; antigenic determinant;
KW virucide; vaccine; therapeutic agent; infection.
XX
OS Hepatitis C virus.
XX
PN WO2004011650-A2.
XX
PD 05-FEB-2004.
XX
PF 24-JUL-2003; 2003WO-EP008112.
XX
PR 24-JUL-2002; 2002AT-00001124.
PR 11-JUL-2003; 2003EP-00450171.
XX
PA (INTE-) INTERCELL AG.
XX
PI Mattner F, Schmidt W, Habel A;
XX
DR WPI; 2004-169243/16.
XX
PT New polypeptide encoded by an alternative reading frame of a pathogenic
PT virus comprising an antigenic determinant, useful for treating or
PT preventing an infection with the pathogenic virus.
XX
PS Claim 7; SEQ ID NO 183; 220pp; English.
XX
CC This invention relates to a novel polypeptide encoded by an alternative
CC reading frame of a pathogenic virus, where the polypeptide starts with a
CC methionine amino acid residue, which comprises an antigenic determinant
CC and more than 7 amino acid residues. The invention may be useful for the
CC production of compounds with a virucide activity or the development of a
CC vaccine. The polypeptide or its fragments may be useful as a therapeutic
CC agent. It is also useful for the manufacture of a medicament for treating
CC or preventing an infection with the pathogenic virus. The present
CC sequence is that of a hepatitis C virus peptide of the invention.
XX
SQ Sequence 20 AA;

Query Match 25.0%; Score 5; DB 8; Length 20;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
|||||
Db 7 PRGAP 11

RESULT 45
ABG69986
ID ABG69986 standard; peptide; 22 AA.
XX
AC ABG69986;
XX
DT 21-OCT-2002 (first entry)
XX
DE Rabbit platelet microbicidal protein, PMP-2, based peptide #98.
XX
KW Antimicrobial; platelet microbiocidal protein; PMP-1; PMP-2;
KW bacterial infection; fungal infection; fungicide; disinfectant;
KW preservative; foods; cosmetic; multiple antibiotic resistance; rabbit;
KW mutant; mutein.
XX
OS Oryctolagus cuniculus.
OS Synthetic.
XX
PN WO200255554-A2.
XX
PD 18-JUL-2002.
XX
PF 24-AUG-2001; 2001WO-US041877.
XX
PR 25-AUG-2000; 2000US-00648816.
XX
PA (HARB-) HARBOR-UCLA RES & EDUCATION INST.
XX
PI Yeaman MR, Shen AJ;
XX
DR WPI; 2002-590659/63.
XX
PT New antimicrobial peptide composition for the prevention and treatment of
PT infections caused by organisms, such as bacteria and fungi, exhibiting
PT multiple antibiotic resistance.
XX
PS Example; Page 66; 221pp; English.
XX
CC The invention relates to an antimicrobial peptide composition for use
CC against organisms such as bacteria and fungi comprising a peptide of 5-
CC 150 amino acids containing a 7-13 amino acid core sequence (derived from
CC PMP-1 and PMP-2, platelet microbiocidal protein), and retromers,
CC truncations, extensions, combinations, fusions and their derivatives. The
CC possible structures are fully described in the specification. Also
CC included are (1) an antimicrobial peptide composition for direct activity
CC or for potentiating antimicrobial agents active against organisms such as
CC bacteria and fungi comprising a peptide of 13-74 containing an amino acid
CC core sequence selected from truncations of the peptides described above,
CC and retromers, extensions, combinations and fusions; and (2)
CC antimicrobial peptides for potentiating antimicrobial activity of
CC leukocytes against organisms such as bacteria and fungi. The
CC antimicrobial peptides are useful as individual antimicrobial agents,
CC specifically against bacteria and fungi, agents in combination with other
CC antimicrobials, agents that enhance, potentiate or restore efficacy of
CC conventional antimicrobials, agents that enhance the antimicrobial
CC functions of leukocytes, as disinfectants or preservatives for use in
CC foods and cosmetics and as agents to improve efficiency of molecular
CC biology techniques. Antimicrobial peptides of prior art have generally
CC been considered to have undesirable toxicity, immunogenicity and short
CC half-lives due to biodegradation. The peptides of the present invention
CC are based upon natural antimicrobial peptides that have potent and broad
CC spectrum activity against pathogens exhibiting multiple antibiotic
CC resistance. They exhibit lower inherent mammalian cell toxicities and
CC overcome problems of toxicity, immunogenicity, and shortness of duration
CC of effectiveness due to biodegradation, retaining activity in plasma and
CC serum. The present sequence is a rabbit PMP based antimicrobial peptide
XX
SQ Sequence 22 AA;

Query Match 25.0%; Score 5; DB 5; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVC 12
|||||
Db 11 LRCVC 15

RESULT 46
ABG69985
ID ABG69985 standard; peptide; 22 AA.
XX
AC ABG69985;
XX
DT 21-OCT-2002 (first entry)
XX
DE Rabbit platelet microbicidal protein, PMP-2, based peptide #97.
XX
KW Antimicrobial; platelet microbiocidal protein; PMP-1; PMP-2;
KW bacterial infection; fungal infection; fungicide; disinfectant;
KW preservative; foods; cosmetic; multiple antibiotic resistance; rabbit;
KW mutant; mutein.
XX
OS Oryctolagus cuniculus.

OS Synthetic.
XX
PN WO200255554-A2.
XX
PD 18-JUL-2002.
XX
PF 24-AUG-2001; 2001WO-US041877.
XX
PR 25-AUG-2000; 2000US-00648816.
XX
PA (HARB-) HARBOR-UCLA RES & EDUCATION INST.
XX
PI Yeaman MR, Shen AJ;
XX
DR WPI; 2002-590659/63.
XX
PT New antimicrobial peptide composition for the prevention and treatment of
PT infections caused by organisms, such as bacteria and fungi, exhibiting
PT multiple antibiotic resistance.
XX
PS Example; Page 65; 221pp; English.
XX
CC The invention relates to an antimicrobial peptide composition for use
CC against organisms such as bacteria and fungi comprising a peptide of 5-
CC 150 amino acids containing a 7-13 amino acid core sequence (derived from
CC PMP-1 and PMP-2, platelet microbiocidal protein), and retromers,
CC truncations, extensions, combinations, fusions and their derivatives. The
CC possible structures are fully described in the specification. Also
CC included are (1) an antimicrobial peptide composition for direct activity
CC or for potentiating antimicrobial agents active against organisms such as
CC bacteria and fungi comprising a peptide of 13-74 containing an amino acid
CC core sequence selected from truncations of the peptides described above,
CC and retromers, extensions, combinations and fusions; and (2)
CC antimicrobial peptides for potentiating antimicrobial activity of
CC leukocytes against organisms such as bacteria and fungi. The
CC antimicrobial peptides are useful as individual antimicrobial agents,
CC specifically against bacteria and fungi, agents in combination with other
CC antimicrobials, agents that enhance, potentiate or restore efficacy of
CC conventional antimicrobials, agents that enhance the antimicrobial
CC functions of leukocytes, as disinfectants or preservatives for use in
CC foods and cosmetics and as agents to improve efficiency of molecular
CC biology techniques. Antimicrobial peptides of prior art have generally
CC been considered to have undesirable toxicity, immunogenicity and short
CC half-lives due to biodegradation. The peptides of the present invention
CC are based upon natural antimicrobial peptides that have potent and broad
CC spectrum activity against pathogens exhibiting multiple antibiotic
CC resistance. They exhibit lower inherent mammalian cell toxicities and
CC overcome problems of toxicity, immunogenicity, and shortness of duration
CC of effectiveness due to biodegradation, retaining activity in plasma and
CC serum. The present sequence is a rabbit PMP based antimicrobial peptide
XX
SQ Sequence 22 AA;

```
  Query Match             25.0%;  Score 5;  DB 5;  Length 22;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15
```

RESULT 47
ADM32132
ID ADM32132 standard; protein; 25 AA.
XX
AC ADM32132;
XX
DT 17-JUN-2004 (first entry)
XX
DE EphB4 blocking peptide 6, seq id 7.
XX
KW Cytostatic; gene therapy; Inhibititor; cancerous growth; cancer; breast;
KW prostate; ephrin type-B receptor 4 precursor; EphB4; human.
XX
OS Homo sapiens.
XX
PN WO2004024773-A1.
XX
PD 25-MAR-2004.
XX
PF 16-SEP-2003; 2003WO-AU001209.
XX
PR 16-SEP-2002; 2002AU-00951409.
XX
PA (QUEE-) QUEEN ELIZABETH HOSPITAL.
XX
PI Stephenson S;
XX
DR WPI; 2004-270012/25.
XX
PT Inhibiting cancerous growth of a cell by contacting the cell with an
PT antibody, or its antigen-binding portion, that binds to an epitope of
PT EphB4 polypeptide.
XX
PS Example 6; SEQ ID NO 7; 73pp; English.
XX
CC The invention relates to a method of inhibiting cancerous growth of a
CC cell, comprising contacting the cell with at least one antibody, or its
CC antigen-binding portion, where the antibody or antigen-binding portion
CC binds to an epitope located within residues 200-400 of EphB4, which
CC consists of the sequence of 984 amino acids (S1) fully defined in the
CC specification, or to an epitope located in a sequence at least 85%
CC identical to residues 200-400, 201-245, 220-244 or 220-230 of EphB4. The
CC composition and methods are useful for treating or preventing cancer
CC (e.g. breast or prostate cancer) or for identifying agents that inhibit
CC cancerous growth of a cell. The current sequence represents an EphB4
CC blocking peptide used in an example from the invention in EphB4 epitope
CC mapping.
XX
SQ Sequence 25 AA;

```
  Query Match             25.0%;  Score 5;  DB 8;  Length 25;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         15 PRGAP 19
```

RESULT 48
AAY20230
ID AAY20230 standard; protein; 26 AA.
XX
AC AAY20230;
XX
DT 22-JUL-1999 (first entry)
XX
DE Human beta-amyloid precursor protein mutant fragment 55.
XX
KW Human; beta-amyloid precursor protein; beta-APP; diagnosis; cancer;
KW frameshift mutation; age-related disease; neurodegenerative disorder;
KW Alzheimer's disease; Down's syndrome; myotonic dystrophy; neuronal;
KW Huntington's disease; multiple sclerosis; alcoholic liver disease;
KW diabetes mellitus type II; microtubule associated protein; Tau; Big Tau;
KW ubiquitin B; apolipoprotein E; MAP2; neurofilament-L; neurofilament-M;
KW neurofilament-F; presenilin I; presenilin II; cellular tumour antigen;
KW glial fibrillary acidic protein; GFAP; p53; semaphorin III; HUPF-1;
KW bcl-2; B-cell leukemia/lymphoma 2 proto-oncogene; HMGP-C; NSP-A;
KW high mobility group protein-C; neuroendocrine specific protein A.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO9845322-A2.

XX
PD 15-OCT-1998.
XX
PF 02-APR-1998; 98WO-IB000705.
XX
PR 10-APR-1997; 97US-0043163P.
XX
PA (ROYA-) ROYAL NETHERLANDS ACAD ARTS & SCI.
PA (UYRO-) UNIV ROTTERDAM ERASMUS.
PA (UYUT-) RIJKSUNIV UTRECHT.
XX
PI Van Leeuwen FW, Grosveld FG, Burbach JPH;
XX
DR WPI; 1998-609901/51.
DR N-PSDB; AAX75753.
XX
PT Diagnosing disease by detecting frameshift mutations in RNA or
PT corresponding protein mutations - used to diagnose cancer and
PT neurological diseases, particularly Alzheimer's disease, and also for
PT treatment and prevention with specific ribozymes or wild-type RNA.
XX
PS Disclosure; Fig 2; 258pp; English.
XX
CC This invention describes a novel method for the diagnosis of a disease
CC caused by, or associated with, an RNA molecule that has a frameshift
CC mutation. The method is used to diagnose age-related diseases, especially
CC cancer and a wide range of neurodegenerative disorders (e.g. Alzheimer's
CC disease, Down's syndrome, myotonic dystrophy, Huntington's disease,
CC multiple sclerosis, alcoholic liver disease, diabetes mellitus type II
CC and many others listed) or susceptibility to these disorders. The method
CC allows a definitive diagnosis of Alzheimer's disease in living patients,
CC at an early stage. It is based on the observation that disease may be
CC caused by mutations in RNA rather than DNA. The invention describes the
CC used of neuronal system RNA molecules, specifically proteins including
CC beta-amyloid precursor protein (beta-APP), the microtubule associated
CC proteins Tau and Big Tau, ubiquitin B, apolipoprotein E, microtubule
CC associated protein 2 (MAP2), neurofilament-L, neurofilament-M,
CC neurofilament-F, presenilin I, presenilin II, glial fibrillary acidic
CC protein (GFAP), the cellular tumour antigen p53, B-cell leukemia/lymphoma
CC 2 (bcl-2) proto-oncogene, semaphorin III, HUPF-1, high mobility group
CC protein-C (HMGP-C) and neuroendocrine specific protein A
XX
SQ Sequence 26 AA;

Query Match 25.0%; Score 5; DB 2; Length 26;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
|||||
Db 5 PRGAP 9

RESULT 49
AAY19651
ID AAY19651 standard; protein; 28 AA.
XX
AC AAY19651;
XX
DT 14-JUL-1999 (first entry)
XX
DE SEQ ID NO 369 from WO9922243.
XX
KW Human secreted protein; cancer; tumour; neurodegenerative disorder;
KW developmental abnormality; fetal deficiency; blood disorder; leukemia;
KW immune system disease; autoimmune disease; hepatic disease;
KW renal disease; lymphoma; inflammation; allergy; ischemic shock;
KW Alzheimer's; cognitive disorder; schizophrenia; prostate disease;
KW obesity; osteoclast; osteoporosis; arthritis; malignancy; testes disease;
KW lung disease; thymus disease; digestive disorder; endocrine disorder;
KW infection; AIDS.
XX
OS Homo sapiens.

XX
PN WO9922243-A1.
XX
PD 06-MAY-1999.
XX
PF 23-OCT-1998; 98WO-US022376.
XX
PR 24-OCT-1997; 97US-0062784P.
PR 24-OCT-1997; 97US-0063088P.
PR 24-OCT-1997; 97US-0063089P.
PR 24-OCT-1997; 97US-0063090P.
PR 24-OCT-1997; 97US-0063091P.
PR 24-OCT-1997; 97US-0063092P.
PR 24-OCT-1997; 97US-0063097P.
PR 24-OCT-1997; 97US-0063098P.
PR 24-OCT-1997; 97US-0063099P.
PR 24-OCT-1997; 97US-0063100P.
PR 24-OCT-1997; 97US-0063101P.
PR 24-OCT-1997; 97US-0063109P.
PR 24-OCT-1997; 97US-0063110P.
PR 24-OCT-1997; 97US-0063111P.
PR 24-OCT-1997; 97US-0063148P.
PR 24-OCT-1997; 97US-0063386P.
PR 24-OCT-1997; 97US-0063387P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Feng P, Rosen CA, Ruben SM, Ni J, Wei Y, Soppet DR, Moore PA;
PI Kayw H, Lafleur DW, Olsen HS, Brewer LA, Shi Y, Ebner R, Young P;
PI Greene JM, Florence KA, Florence C, Duan DR, Janat F, Endress GA;
PI Carter KC;
XX
DR WPI; 1999-303069/25.
XX
PT New isolated human genes and the secreted polypeptides they encode.
XX
PS Disclosure; Page 485; 546pp; English.
XX
CC The specification describes human secreted proteins. The polynucleotides
CC and their corresponding secreted polypeptides are useful for preventing,
CC treating or ameliorating medical conditions, e.g. by protein or gene
CC therapy. Pathological conditions can also be diagnosed by determining the
CC amount of the polypeptides in a sample or by determining the presence of
CC mutations in the polynucleotides. Specific uses are described for each of
CC the polynucleotides, based on which tissues they are most highly
CC expressed in, and include developing products for the diagnosis or
CC treatment of cancer, tumours, neurodegenerative disorders, developmental
CC abnormalities and fetal deficiencies, blood disorders, leukemias,
CC diseases of the immune system, autoimmune diseases, hepatic and renal
CC disease, lymphomas, inflammation, allergies, ischemic shock, Alzheimer's
CC and cognitive disorders, schizophrenia, prostate diseases, obesity,
CC disorders involving osteoclasts such as osteoporosis, arthritis or
CC malignancies, diseases of testes, lung or thymus, digestive/endocrine
CC disorders, infections and AIDS. The polypeptides are also useful for
CC identifying their binding partners
XX
SQ Sequence 28 AA;

Query Match 25.0%; Score 5; DB 2; Length 28;
Best Local Similarity 100.0%; Pred. No. 3.4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 12 CQMLE 16
|||||
Db 3 CQMLE 7

RESULT 50
AAG56952
ID AAG56952 standard; protein; 33 AA.
XX
AC AAG56952;
XX

DT 18-OCT-2000 (first entry)
XX
DE Arabidopsis thaliana protein fragment SEQ ID NO: 73318.
XX
KW Protein identification; signal transduction pathway; metabolic pathway;
KW hybridisation assay; genetic mapping; gene expression control; promoter;
KW termination sequence.
XX
OS Arabidopsis thaliana.
XX
PN EP1033405-A2.
XX
PD 06-SEP-2000.
XX
PF 25-FEB-2000; 2000EP-00301439.
XX
PR 25-FEB-1999; 99US-0121825P.
PR 05-MAR-1999; 99US-0123180P.
PR 09-MAR-1999; 99US-0123548P.
PR 23-MAR-1999; 99US-0125788P.
PR 25-MAR-1999; 99US-0126264P.
PR 29-MAR-1999; 99US-0126785P.
PR 01-APR-1999; 99US-0127462P.
PR 06-APR-1999; 99US-0128234P.
PR 08-APR-1999; 99US-0128714P.
PR 16-APR-1999; 99US-0129845P.
PR 19-APR-1999; 99US-0130077P.
PR 21-APR-1999; 99US-0130449P.
PR 23-APR-1999; 99US-0130510P.
PR 23-APR-1999; 99US-0130891P.
PR 28-APR-1999; 99US-0131449P.
PR 30-APR-1999; 99US-0132048P.
PR 30-APR-1999; 99US-0132407P.
PR 04-MAY-1999; 99US-0132484P.
PR 05-MAY-1999; 99US-0132485P.
PR 06-MAY-1999; 99US-0132486P.
PR 06-MAY-1999; 99US-0132487P.
PR 07-MAY-1999; 99US-0132863P.
PR 11-MAY-1999; 99US-0134256P.
PR 14-MAY-1999; 99US-0134218P.
PR 14-MAY-1999; 99US-0134219P.
PR 14-MAY-1999; 99US-0134221P.
PR 14-MAY-1999; 99US-0134370P.
PR 18-MAY-1999; 99US-0134768P.
PR 19-MAY-1999; 99US-0134941P.
PR 20-MAY-1999; 99US-0135124P.
PR 21-MAY-1999; 99US-0135353P.
PR 24-MAY-1999; 99US-0135629P.
PR 25-MAY-1999; 99US-0136021P.
PR 27-MAY-1999; 99US-0136392P.
PR 28-MAY-1999; 99US-0136782P.
PR 01-JUN-1999; 99US-0137222P.
PR 03-JUN-1999; 99US-0137528P.
PR 04-JUN-1999; 99US-0137502P.
PR 07-JUN-1999; 99US-0137724P.
PR 08-JUN-1999; 99US-0138094P.
PR 10-JUN-1999; 99US-0138540P.
PR 10-JUN-1999; 99US-0138847P.
PR 14-JUN-1999; 99US-0139119P.
PR 16-JUN-1999; 99US-0139452P.
PR 16-JUN-1999; 99US-0139453P.
PR 17-JUN-1999; 99US-0139492P.
PR 18-JUN-1999; 99US-0139454P.
PR 18-JUN-1999; 99US-0139455P.
PR 18-JUN-1999; 99US-0139456P.
PR 18-JUN-1999; 99US-0139457P.
PR 18-JUN-1999; 99US-0139458P.
PR 18-JUN-1999; 99US-0139459P.
PR 18-JUN-1999; 99US-0139460P.
PR 18-JUN-1999; 99US-0139461P.
PR 18-JUN-1999; 99US-0139462P.
PR 18-JUN-1999; 99US-0139463P.
PR 18-JUN-1999; 99US-0139750P.
PR 18-JUN-1999; 99US-0139763P.
PR 21-JUN-1999; 99US-0139817P.
PR 22-JUN-1999; 99US-0139899P.
PR 23-JUN-1999; 99US-0140353P.
PR 23-JUN-1999; 99US-0140354P.
PR 24-JUN-1999; 99US-0140695P.
PR 28-JUN-1999; 99US-0140823P.
PR 29-JUN-1999; 99US-0140991P.
PR 30-JUN-1999; 99US-0141287P.
PR 01-JUL-1999; 99US-0141842P.
PR 01-JUL-1999; 99US-0142154P.
PR 02-JUL-1999; 99US-0142055P.
PR 06-JUL-1999; 99US-0142390P.
PR 08-JUL-1999; 99US-0142803P.
PR 09-JUL-1999; 99US-0142920P.
PR 12-JUL-1999; 99US-0142977P.
PR 13-JUL-1999; 99US-0143542P.
PR 14-JUL-1999; 99US-0143624P.
PR 15-JUL-1999; 99US-0144005P.
PR 16-JUL-1999; 99US-0144085P.
PR 16-JUL-1999; 99US-0144086P.
PR 19-JUL-1999; 99US-0144325P.
PR 19-JUL-1999; 99US-0144331P.
PR 19-JUL-1999; 99US-0144332P.
PR 19-JUL-1999; 99US-0144333P.
PR 19-JUL-1999; 99US-0144334P.
PR 19-JUL-1999; 99US-0144335P.
PR 20-JUL-1999; 99US-0144352P.
PR 20-JUL-1999; 99US-0144632P.
PR 20-JUL-1999; 99US-0144884P.
PR 21-JUL-1999; 99US-0144814P.
PR 21-JUL-1999; 99US-0145086P.
PR 21-JUL-1999; 99US-0145088P.
PR 22-JUL-1999; 99US-0145085P.
PR 22-JUL-1999; 99US-0145087P.
PR 22-JUL-1999; 99US-0145089P.
PR 22-JUL-1999; 99US-0145192P.
PR 23-JUL-1999; 99US-0145145P.
PR 23-JUL-1999; 99US-0145218P.
PR 23-JUL-1999; 99US-0145224P.
PR 26-JUL-1999; 99US-0145276P.
PR 27-JUL-1999; 99US-0145913P.
PR 27-JUL-1999; 99US-0145918P.
PR 27-JUL-1999; 99US-0145919P.
PR 28-JUL-1999; 99US-0145951P.
PR 02-AUG-1999; 99US-0146386P.
PR 02-AUG-1999; 99US-0146388P.
PR 02-AUG-1999; 99US-0146389P.
PR 03-AUG-1999; 99US-0147038P.
PR 04-AUG-1999; 99US-0147204P.
PR 04-AUG-1999; 99US-0147302P.
PR 05-AUG-1999; 99US-0147192P.
PR 05-AUG-1999; 99US-0147260P.
PR 06-AUG-1999; 99US-0147303P.
PR 06-AUG-1999; 99US-0147416P.
PR 09-AUG-1999; 99US-0147493P.
PR 09-AUG-1999; 99US-0147935P.
PR 10-AUG-1999; 99US-0148171P.
PR 11-AUG-1999; 99US-0148319P.
PR 12-AUG-1999; 99US-0148341P.
PR 13-AUG-1999; 99US-0148565P.
PR 13-AUG-1999; 99US-0148684P.
PR 16-AUG-1999; 99US-0149368P.
PR 17-AUG-1999; 99US-0149175P.
PR 18-AUG-1999; 99US-0149426P.
PR 20-AUG-1999; 99US-0149722P.
PR 20-AUG-1999; 99US-0149723P.
PR 20-AUG-1999; 99US-0149929P.
PR 23-AUG-1999; 99US-0149902P.
PR 23-AUG-1999; 99US-0149930P.
PR 25-AUG-1999; 99US-0150566P.
PR 26-AUG-1999; 99US-0150884P.
PR 27-AUG-1999; 99US-0151065P.

```
PR   27-AUG-1999;   99US-0151066P.
PR   27-AUG-1999;   99US-0151080P.
PR   30-AUG-1999;   99US-0151303P.
PR   31-AUG-1999;   99US-0151438P.
PR   01-SEP-1999;   99US-0151930P.
PR   07-SEP-1999;   99US-0152363P.
PR   10-SEP-1999;   99US-0153070P.
PR   13-SEP-1999;   99US-0153758P.
PR   15-SEP-1999;   99US-0154018P.
PR   16-SEP-1999;   99US-0154039P.
PR   20-SEP-1999;   99US-0154779P.
PR   22-SEP-1999;   99US-0155139P.
PR   23-SEP-1999;   99US-0155486P.
PR   24-SEP-1999;   99US-0155659P.
PR   28-SEP-1999;   99US-0156458P.
PR   29-SEP-1999;   99US-0156596P.
PR   04-OCT-1999;   99US-0157117P.
PR   05-OCT-1999;   99US-0157753P.
PR   06-OCT-1999;   99US-0157865P.
PR   07-OCT-1999;   99US-0158029P.
PR   08-OCT-1999;   99US-0158232P.
PR   12-OCT-1999;   99US-0158369P.
PR   13-OCT-1999;   99US-0159293P.
PR   13-OCT-1999;   99US-0159294P.
PR   13-OCT-1999;   99US-0159295P.
PR   14-OCT-1999;   99US-0159329P.
PR   14-OCT-1999;   99US-0159330P.
PR   14-OCT-1999;   99US-0159331P.
PR   14-OCT-1999;   99US-0159637P.
PR   14-OCT-1999;   99US-0159638P.
PR   18-OCT-1999;   99US-0159584P.
PR   21-OCT-1999;   99US-0160741P.
PR   21-OCT-1999;   99US-0160767P.
PR   21-OCT-1999;   99US-0160768P.
PR   21-OCT-1999;   99US-0160770P.
PR   21-OCT-1999;   99US-0160814P.
PR   21-OCT-1999;   99US-0160815P.
PR   22-OCT-1999;   99US-0160980P.
PR   22-OCT-1999;   99US-0160981P.
PR   22-OCT-1999;   99US-0160989P.
PR   25-OCT-1999;   99US-0161404P.
PR   25-OCT-1999;   99US-0161405P.
PR   25-OCT-1999;   99US-0161406P.
PR   26-OCT-1999;   99US-0161359P.
PR   26-OCT-1999;   99US-0161360P.
PR   26-OCT-1999;   99US-0161361P.
PR   28-OCT-1999;   99US-0161920P.
PR   28-OCT-1999;   99US-0161992P.
PR   28-OCT-1999;   99US-0161993P.
PR   29-OCT-1999;   99US-0162142P.

  Query Match             25.0%;  Score 5;  DB 3;  Length 33;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          13 QMLET 17
               |||||
Db          26 QMLET 30


RESULT 51
ABG69992
ID   ABG69992 standard; peptide; 40 AA.
XX
AC   ABG69992;
XX
DT   21-OCT-2002  (first entry)
XX
DE   Rabbit platelet microbicidal protein, PMP-2, based peptide #104.
XX
KW   Antimicrobial; platelet microbiocidal protein; PMP-1; PMP-2;
KW   bacterial infection; fungal infection; fungicide; disinfectant;
KW   preservative; foods; cosmetic; multiple antibiotic resistance; rabbit;
KW   mutant; mutein.
XX
OS   Oryctolagus cuniculus.
OS   Synthetic.
XX
PN   WO200255554-A2.
XX
PD   18-JUL-2002.
XX
PF   24-AUG-2001; 2001WO-US041877.
XX
PR   25-AUG-2000; 2000US-00648816.
XX
PA   (HARB-) HARBOR-UCLA RES & EDUCATION INST.
XX
PI   Yeaman MR,  Shen AJ;
XX
DR   WPI; 2002-590659/63.
XX
PT   New antimicrobial peptide composition for the prevention and treatment of
PT   infections caused by organisms, such as bacteria and fungi, exhibiting
PT   multiple antibiotic resistance.
XX
PS   Example; Page 67; 221pp; English.
XX
CC   The invention relates to an antimicrobial peptide composition for use
CC   against organisms such as bacteria and fungi comprising a peptide of 5-
CC   150 amino acids containing a 7-13 amino acid core sequence (derived from
CC   PMP-1 and PMP-2, platelet microbiocidal protein), and retromers,
CC   truncations, extensions, combinations, fusions and their derivatives. The
CC   possible structures are fully described in the specification. Also
CC   included are (1) an antimicrobial peptide composition for direct activity
CC   or for potentiating antimicrobial agents active against organisms such as
CC   bacteria and fungi comprising a peptide of 13-74 containing an amino acid
CC   core sequence selected from truncations of the peptides described above,
CC   and retromers, extensions, combinations and fusions; and (2)
CC   antimicrobial peptides for potentiating antimicrobial activity of
CC   leukocytes against organisms such as bacteria and fungi. The
CC   antimicrobial peptides are useful as individual antimicrobial agents,
CC   specifically against bacteria and fungi, agents in combination with other
CC   antimicrobials, agents that enhance, potentiate or restore efficacy of
CC   conventional antimicrobials, agents that enhance the antimicrobial
CC   functions of leukocytes, as disinfectants or preservatives for use in
CC   foods and cosmetics and as agents to improve efficiency of molecular
CC   biology techniques. Antimicrobial peptides of prior art have generally
CC   been considered to have undesirable toxicity, immunogenicity and short
CC   half-lives due to biodegradation. The peptides of the present invention
CC   are based upon natural antimicrobial peptides that have potent and broad
CC   spectrum activity against pathogens exhibiting multiple antibiotic
CC   resistance. They exhibit lower inherent mammalian cell toxicities and
CC   overcome problems of toxicity, immunogenicity, and shortness of duration
CC   of effectiveness due to biodegradation, retaining activity in plasma and
CC   serum. The present sequence is a rabbit PMP based antimicrobial peptide
XX
SQ   Sequence 40 AA;

  Query Match             25.0%;  Score 5;  DB 5;  Length 40;
  Best Local Similarity   100.0%;  Pred. No. 4.4e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           8 LRCVC 12
               |||||
Db          29 LRCVC 33


RESULT 52
ADF94734
ID   ADF94734 standard; protein; 42 AA.
XX
AC   ADF94734;
XX
DT   26-FEB-2004  (first entry)
XX
```

DE Hepatitis D virus type III antigen protein fragment, SEQ ID 9.
XX
KW Virucide; hepatitis D virus antigen; HDV antigen; RNA polymerase II.
XX
OS Hepatitis D virus.
XX
PN WO200268655-A1.
XX
PD 06-SEP-2002.
XX
PF 27-FEB-2002; 2002WO-JP001817.
XX
PR 27-FEB-2001; 2001JP-00053163.
XX
PA (CIRC-) CIRCLE PROMOTION SCI & ENG.
PA (KYOW) KYOWA HAKKO KOGYO KK.
XX
PI Handa H, Yamaguchi Y;
XX
DR WPI; 2002-698673/75.
XX
PT Non-infective cell-requiring method of searching for hepatitis D remedies
PT in a system containing e.g. polypeptide binding to RNA polymerase II with
PT measuring of binding level for indication.
XX
PS Claim 5; SEQ ID NO 9; 84pp; Japanese.
XX
CC The present invention relates to a method for searching hepatitis D
CC remedies. The method comprises adding a test compound to a system
CC containing e.g. a hepatitis D virus antigen (HDV antigen) and RNA
CC polymerase II, measuring the binding level of HDV antigen binding to RNA
CC polymerase II, and comparing with a control for selection of a compound
CC inhibiting the binding. The method is for screening remedies for
CC hepatitis D including for hepatitis virus D accompanying hepatitis B,
CC such as gene expression promoters applicable in regeneration medicine for
CC treating organs or tissues. The present sequence is a HDV antigen
CC sequence.
XX
SQ Sequence 42 AA;

Query Match 25.0%; Score 5; DB 5; Length 42;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
|||||
Db 14 PRGAP 18

RESULT 53
ADF94732
ID ADF94732 standard; protein; 42 AA.
XX
AC ADF94732;
XX
DT 26-FEB-2004 (first entry)
XX
DE Hepatitis D virus type II antigen protein fragment, SEQ ID 7.
XX
KW Virucide; hepatitis D virus antigen; HDV antigen; RNA polymerase II.
XX
OS Hepatitis D virus.
XX
PN WO200268655-A1.
XX
PD 06-SEP-2002.
XX
PF 27-FEB-2002; 2002WO-JP001817.
XX
PR 27-FEB-2001; 2001JP-00053163.
XX
PA (CIRC-) CIRCLE PROMOTION SCI & ENG.
PA (KYOW) KYOWA HAKKO KOGYO KK.
XX
PI Handa H, Yamaguchi Y;
XX
DR WPI; 2002-698673/75.
XX
PT Non-infective cell-requiring method of searching for hepatitis D remedies
PT in a system containing e.g. polypeptide binding to RNA polymerase II with
PT measuring of binding level for indication.
XX
PS Claim 5; SEQ ID NO 7; 84pp; Japanese.
XX
CC The present invention relates to a method for searching hepatitis D
CC remedies. The method comprises adding a test compound to a system
CC containing e.g. a hepatitis D virus antigen (HDV antigen) and RNA
CC polymerase II, measuring the binding level of HDV antigen binding to RNA
CC polymerase II, and comparing with a control for selection of a compound
CC inhibiting the binding. The method is for screening remedies for
CC hepatitis D including for hepatitis virus D accompanying hepatitis B,
CC such as gene expression promoters applicable in regeneration medicine for
CC treating organs or tissues. The present sequence is a HDV antigen
CC sequence.
XX
SQ Sequence 42 AA;

Query Match 25.0%; Score 5; DB 5; Length 42;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
|||||
Db 14 PRGAP 18

RESULT 54
AAW57222
ID AAW57222 standard; protein; 44 AA.
XX
AC AAW57222;
XX
DT 04-AUG-1998 (first entry)
XX
DE Targeting vector Tg-2/Not containing PGK-neomycin-resistant gene protein.
XX
KW Targeting vector; Tg-2/Not; nucleobindin; screening; nephritis;
KW blood vessel; inflammation; PGK-neomycin-resistant gene.
XX
OS Synthetic.
XX
PN JP10117633-A.
XX
PD 12-MAY-1998.
XX
PF 21-OCT-1996; 96JP-00298219.
XX
PR 21-OCT-1996; 96JP-00298219.
XX
PA (MITS-) MITSUI SEIYAKU KOGYO KK.
PA (KANA/) KANAI Y.
PA (FUJI-) FUJITA GAKUEN.
XX
DR WPI; 1998-325762/29.
DR N-PSDB; AAV28851.
XX
PT Gene-deleted animal e.g. mouse - useful for screening therapeutic agents
PT for diseases such as blood vessel inflammation and nephritis.
XX
PS Example 2; Fig 3; 11pp; Japanese.
XX
CC The present sequence represents a protein from a targeting vector Tg-
CC 2/Not containing a PGK-neomycin-resistant gene, from the present
CC invention. The targeting vector is used in an example of the present
CC invention for producing a gene-deleted animal e.g. a mouse comprising no
CC gene to encode nucleobindin in which all or part of nucleobindin gene is

```
CC   deleted or replaced by another gene. The mouse can be used for screening
CC   therapeutic agents against diseases such as blood vessel inflammation and
CC   nephritis
XX
SQ   Sequence 44 AA;

  Query Match             25.0%;  Score 5;  DB 2;  Length 44;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db          6 PRGAP 10


RESULT 55
AAE38084
ID   AAE38084 standard; protein; 44 AA.
XX
AC   AAE38084;
XX
DT   06-NOV-2003  (first entry)
XX
DE   Human cytokeratin K8 protein fragment #1.
XX
KW   Human; cancer-associated epitope; cytokeratin K8; cytokeratin K18;
KW   adenocarcinoma; therapy; cancer.
XX
OS   Homo sapiens.
XX
PN   WO2003057168-A2.
XX
PD   17-JUL-2003.
XX
PF   03-JAN-2003; 2003WO-US000297.
XX
PR   03-JAN-2002; 2002US-0345208P.
XX
PA   (SCRI ) SCRIPPS RES INST.
XX
PI   Ditzel H,  Jensenius JC;
XX
DR   WPI; 2003-598315/56.
XX
PT   Novel isolated cancer-associated epitope comprising two separate
PT   polypeptides, a cytokeratin 8 polypeptide and a cytokeratin 18
PT   polypeptide, useful as component of vaccine for preventing or treating
PT   adenocarcinoma.
XX
PS   Claim 1; Page 20; 155pp; English.
XX
CC   The invention provides a cancer-associated epitope comprising two
CC   separate polypeptides, a cytokeratin 8 polypeptide and a cytokeratin 18
CC   polypeptide. Vaccine composition of the invention is useful for treating
CC   or preventing colon adenocarcinoma, ovarian adenocarcinoma, renal
CC   adenocarcinoma, mammary adenocarcinoma, lung adenocarcinoma, pancreatic
CC   adenocarcinoma or non-seminomal testis carcinoma. The invention is also
CC   useful for preparing a medicament for treating or preventing cancer in a
CC   mammal. The present sequence is human cytokeratin K8 protein fragment
XX
SQ   Sequence 44 AA;

  Query Match             25.0%;  Score 5;  DB 6;  Length 44;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         14 MLETK 18
              |||||
Db         33 MLETK 37


RESULT 56
AAB39249
ID   AAB39249 standard; protein; 46 AA.
XX
AC   AAB39249;
XX
DT   02-FEB-2001  (first entry)
XX
DE   Gene 11 human secreted protein homologous amino acid sequence #129.
XX
KW   Human; secreted protein; immunosuppressive; antiarthritic; antirheumatic;
KW   antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
KW   nootropic; neuroprotective; antibacterial; virucide; fungicide; neoplasm;
KW   opthalmalogical; autoimmune disease; rheumatoid arthritis; angiogenesis;
KW   hyperproliferative disorder; cardiovascular disorder; infection;
KW   cerebrovascular disorder; nervous system disorder; ocular disorder;
KW   wound healing; chemotaxis.
XX
OS   Homo sapiens.
XX
PN   WO200056754-A1.
XX
PD   28-SEP-2000.
XX
PF   16-MAR-2000; 2000WO-US006792.
XX
PR   19-MAR-1999;   99US-0125362P.
PR   10-DEC-1999;   99US-0169980P.
XX
PA   (HUMA-) HUMAN GENOME SCI INC.
XX
PI   Rosen GA,  Ruben SM,  Komatsoulis G;
XX
DR   WPI; 2000-579483/54.
XX
PT   Isolated nucleic acid molecule encoding a human secreted protein is used
PT   in preventing, treating or ameliorating a medical condition.
XX
PS   Disclosure; Page 27; 434pp; English.
XX
CC   The polynucleotide sequences given in AAC74223-C74279 encode the human
CC   secreted proteins represented in AAB39179-B39226. Sequences AAB39227-
CC   B39308 are alternative proteins encoded by the genes, and also protein
CC   sequences with which they share homology. The proteins have activities
CC   based on the tissues and cells in which they are expressed. Examples of
CC   activities include: immunosuppressive; antiarthritic; antirheumatic;
CC   antiproliferative; cytostatic; cardiant; vasotropic; cerebroprotective;
CC   nootropic; neuroprotective; antibacterial; virucide; fungicide; and
CC   opthalmalogical. The human secreted proteins, polynucleotides,
CC   antagonists and agonists of the invention may be useful in the treatment,
CC   prevention, and/or diagnosis of various disease, disorders and conditions
CC   such as autoimmune diseases e.g. rheumatoid arthritis, hyperproliferative
CC   disorders e.g. neoplasms of the breast or liver, cardiovascular disorders
CC   e.g. cardiac arrest, cerebrovascular disorders e.g. cerebral ischaemia,
CC   angiogenesis, nervous system disorders e.g. Alzheimer's disease,
CC   infections caused by bacteria, viruses and fungi and ocular disorders
CC   e.g. corneal infection. The polypeptides can also be used to aid wound
CC   healing and epithelial cell proliferation, to regenerate tissues,
CC   maintain organs before transplantation, in chemotaxis and as a food
CC   additive or preservative e.g. to increase storage capabilities. Sequences
CC   AAC74214-C74222 and AAB39178 are used during the isolation and
CC   characterisation of the genes of the invention
XX
SQ   Sequence 46 AA;

  Query Match             25.0%;  Score 5;  DB 3;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         41 LRCVC 45


RESULT 57
```

```
AAM21142
ID   AAM21142 standard; protein; 46 AA.
XX
AC   AAM21142;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Peptide #7576 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000670.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human cervical epithelial cells.
XX
PS   Claim 27; SEQ ID NO 25968; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC   by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC   can be used to produce a single exon microarray, which can be used for
CC   measuring human gene expression in a sample derived from human cervical
CC   epithelial cells. By measuring gene expression, the probes are therefore
CC   useful in grading and/or staging of diseases of the cervix, notably
CC   cervical cancer. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 46 AA;

  Query Match             25.0%;  Score 5;  DB 4;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLET 17
              |||||
Db         32 QMLET 36


RESULT 58
AAM15409
ID   AAM15409 standard; protein; 46 AA.
XX
AC   AAM15409;
XX
DT   12-OCT-2001  (first entry)
XX
DE   Peptide #1843 encoded by probe for measuring cervical gene expression.
XX
KW   Probe; human; microarray; gene expression; cervical epithelial cell;
KW   cervical cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157278-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000670.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488901/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human cervical epithelial cells.
XX
PS   Claim 27; SEQ ID NO 20235; 487pp; English.
XX
CC   The present invention relates to human single exon nucleic acid probes
CC   (SENP: see AAI10068-AAI28459). The present sequence is a peptide encoded
CC   by one such probe. The SENPs are derived from human HeLa cells. The SENPs
CC   can be used to produce a single exon microarray, which can be used for
CC   measuring human gene expression in a sample derived from human cervical
CC   epithelial cells. By measuring gene expression, the probes are therefore
CC   useful in grading and/or staging of diseases of the cervix, notably
CC   cervical cancer. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 46 AA;

  Query Match             25.0%;  Score 5;  DB 4;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 RGAPM 6
              |||||
Db         20 RGAPM 24


RESULT 59
ABB43459
ID   ABB43459 standard; peptide; 46 AA.
XX
AC   ABB43459;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #10965 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000669.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
```

```
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human fetal liver.
XX
PS   Claim 27; SEQ ID NO 36094; 639pp + Sequence Listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for measuring
CC   human gene expression in a sample derived from human foetal liver. The
CC   single exon nucleic acid probes may be used for predicting, measuring and
CC   displaying gene expression in samples derived from human fetal liver. The
CC   present sequence is a peptide encoded by a single exon nucleic acid probe
CC   of the invention. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 46 AA;

  Query Match             25.0%;  Score 5;  DB 4;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          13 QMLET 17
               |||||
Db          32 QMLET 36


RESULT 60
ABB34414
ID   ABB34414 standard; peptide; 46 AA.
XX
AC   ABB34414;
XX
DT   04-FEB-2002  (first entry)
XX
DE   Peptide #1920 encoded by human foetal liver single exon probe.
XX
KW   Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS   Homo sapiens.
XX
PN   WO200157277-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000669.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483447/52.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human fetal liver.
XX
PS   Claim 27; SEQ ID NO 27049; 639pp + Sequence Listing; English.
XX
CC   The invention relates to a single exon nucleic acid probe for measuring
CC   human gene expression in a sample derived from human foetal liver. The
CC   single exon nucleic acid probes may be used for predicting, measuring and
CC   displaying gene expression in samples derived from human fetal liver. The
CC   present sequence is a peptide encoded by a single exon nucleic acid probe
CC   of the invention. Note: The sequence data for this patent did not form
CC   part of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 46 AA;

  Query Match             25.0%;  Score 5;  DB 4;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           2 RGAPM 6
                 |||||
Db          20 RGAPM 24


RESULT 61
AAM27897
ID   AAM27897 standard; protein; 46 AA.
XX
AC   AAM27897;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #1934 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000663.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488897/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human placenta.
XX
PS   Claim 27; SEQ ID NO 28166; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP:
CC   see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for producing a microarray for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from human placenta. The probes are useful for antenatal diagnosis of
CC   human genetic disorders
XX
SQ   Sequence 46 AA;

  Query Match             25.0%;  Score 5;  DB 4;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
```

```
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 RGAPM 6
              |||||
Db         20 RGAPM 24


RESULT 62
AAM37347
ID   AAM37347 standard; protein; 46 AA.
XX
AC   AAM37347;
XX
DT   17-OCT-2001  (first entry)
XX
DE   Peptide #11384 encoded by probe for measuring placental gene expression.
XX
KW   Probe; microarray; human; placenta; antenatal diagnosis;
KW   genetic disorder.
XX
OS   Homo sapiens.
XX
PN   WO200157272-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000663.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488897/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human placenta.
XX
PS   Claim 27; SEQ ID NO 37616; 654pp; English.
XX
CC   The present invention relates to single exon nucleic acid probes (SENP:
CC   see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC   such probe. The probes are useful for producing a microarray for
CC   predicting, measuring and displaying gene expression in samples derived
CC   from human placenta. The probes are useful for antenatal diagnosis of
CC   human genetic disorders
XX
SQ   Sequence 46 AA;

  Query Match             25.0%;  Score 5;  DB 4;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLET 17
              |||||
Db         32 QMLET 36


RESULT 63
ABB29251
ID   ABB29251 standard; peptide; 46 AA.
XX
AC   ABB29251;
XX
DT   01-FEB-2002  (first entry)
XX
DE   Peptide #1902 encoded by breast cell single exon nucleic acid probe.
XX
KW   Human; microarray; single exon probe; gene expression; breast; disease;
KW   cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157271-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000662.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-496933/54.
XX
PT   New spatially-addressable set of single exon nucleic acid probes, useful
PT   for measuring gene expression in sample derived from human breast,
PT   comprises number of single exon nucleic acid probes.
XX
PS   Claim 27; SEQ ID NO 12219; 327pp + Sequence Listing; English.
XX
CC   The invention relates to a spatially-addressable set of single exon
CC   nucleic acid probes for measuring gene expression in a sample derived
CC   from human breast and BT 474 cells. The method involves contacting the
CC   probes with a collection of detectably labelled nucleic acids derived
CC   from mRNA of human breast, and then measuring the label bound to each
CC   probe of the microarray. The probes are useful for verifying the
CC   expression of regions of genomic DNA predicted to encode proteins. They
CC   are useful for gene discovery, and for determining predisposition and/or
CC   prognosing breast disease. Gene expression analysis is useful for
CC   assessing the toxicity of chemical agents on cells. The microarray of
CC   this invention presents a far greater diversity of probes for measuring
CC   gene expression, with far less bias than expressed sequence tag
CC   microarrays. The method is suitable for rapid production of functional
CC   information from genomic sequence. The present sequence is a peptide
CC   encoded by a single exon nucleic acid probe of the invention. Note: The
CC   sequence data for this patent did not form part of the printed
CC   specification, but was obtained in electronic format directly from WIPO
CC   at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 46 AA;

  Query Match             25.0%;  Score 5;  DB 4;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 RGAPM 6
              |||||
Db         20 RGAPM 24


RESULT 64
AAU17884
ID   AAU17884 standard; protein; 46 AA.
XX
AC   AAU17884;
XX
DT   07-NOV-2001  (first entry)
XX
DE   Novel human respiratory antigen #200.
XX
```

KW Human; respiratory antigen; respiratory disorder; throat disorder;
KW lung disorder; nose disorder; lung cancer; gene therapy; cytostatic;
KW anti allergic; anti asthmatic; anti inflammatory; olfactory;
KW respiratory active.
XX
OS Homo sapiens.
XX
PN WO200155448-A1.
XX
PD 02-AUG-2001.
XX
PF 17-JAN-2001; 2001WO-US001333.
XX
PR 31-JAN-2000; 2000US-0179065P.
PR 04-FEB-2000; 2000US-0180628P.
PR 24-FEB-2000; 2000US-0184664P.
PR 02-MAR-2000; 2000US-0186350P.
PR 16-MAR-2000; 2000US-0189874P.
PR 17-MAR-2000; 2000US-0190076P.
PR 18-APR-2000; 2000US-0198123P.
PR 19-MAY-2000; 2000US-0205515P.
PR 07-JUN-2000; 2000US-0209467P.
PR 28-JUN-2000; 2000US-0214886P.
PR 30-JUN-2000; 2000US-0215135P.
PR 07-JUL-2000; 2000US-0216647P.
PR 07-JUL-2000; 2000US-0216880P.
PR 11-JUL-2000; 2000US-0217487P.
PR 11-JUL-2000; 2000US-0217496P.
PR 14-JUL-2000; 2000US-0218290P.
PR 26-JUL-2000; 2000US-0220963P.
PR 26-JUL-2000; 2000US-0220964P.
PR 14-AUG-2000; 2000US-0224518P.
PR 14-AUG-2000; 2000US-0224519P.
PR 14-AUG-2000; 2000US-0225213P.
PR 14-AUG-2000; 2000US-0225214P.
PR 14-AUG-2000; 2000US-0225266P.
PR 14-AUG-2000; 2000US-0225267P.
PR 14-AUG-2000; 2000US-0225268P.
PR 14-AUG-2000; 2000US-0225270P.
PR 14-AUG-2000; 2000US-0225447P.
PR 14-AUG-2000; 2000US-0225757P.
PR 14-AUG-2000; 2000US-0225758P.
PR 14-AUG-2000; 2000US-0225759P.
PR 18-AUG-2000; 2000US-0226279P.
PR 22-AUG-2000; 2000US-0226681P.
PR 22-AUG-2000; 2000US-0226868P.
PR 22-AUG-2000; 2000US-0227182P.
PR 23-AUG-2000; 2000US-0227009P.
PR 30-AUG-2000; 2000US-0228924P.
PR 01-SEP-2000; 2000US-0229287P.
PR 01-SEP-2000; 2000US-0229343P.
PR 01-SEP-2000; 2000US-0229344P.
PR 01-SEP-2000; 2000US-0229345P.
PR 05-SEP-2000; 2000US-0229509P.
PR 05-SEP-2000; 2000US-0229513P.
PR 06-SEP-2000; 2000US-0230437P.
PR 06-SEP-2000; 2000US-0230438P.
PR 08-SEP-2000; 2000US-0231242P.
PR 08-SEP-2000; 2000US-0231243P.
PR 08-SEP-2000; 2000US-0231244P.
PR 08-SEP-2000; 2000US-0231413P.
PR 08-SEP-2000; 2000US-0231414P.
PR 08-SEP-2000; 2000US-0232080P.
PR 08-SEP-2000; 2000US-0232081P.
PR 12-SEP-2000; 2000US-0231968P.
PR 14-SEP-2000; 2000US-0232397P.
PR 14-SEP-2000; 2000US-0232398P.
PR 14-SEP-2000; 2000US-0232399P.
PR 14-SEP-2000; 2000US-0232400P.
PR 14-SEP-2000; 2000US-0232401P.
PR 14-SEP-2000; 2000US-0233063P.
PR 14-SEP-2000; 2000US-0233064P.
PR 14-SEP-2000; 2000US-0233065P.
PR 21-SEP-2000; 2000US-0234223P.
PR 21-SEP-2000; 2000US-0234274P.
PR 25-SEP-2000; 2000US-0234997P.
PR 25-SEP-2000; 2000US-0234998P.
PR 26-SEP-2000; 2000US-0235484P.
PR 27-SEP-2000; 2000US-0235834P.
PR 27-SEP-2000; 2000US-0235836P.
PR 29-SEP-2000; 2000US-0236327P.
PR 29-SEP-2000; 2000US-0236367P.
PR 29-SEP-2000; 2000US-0236368P.
PR 29-SEP-2000; 2000US-0236369P.
PR 29-SEP-2000; 2000US-0236370P.
PR 02-OCT-2000; 2000US-0236802P.
PR 02-OCT-2000; 2000US-0237037P.
PR 02-OCT-2000; 2000US-0237038P.
PR 02-OCT-2000; 2000US-0237039P.
PR 02-OCT-2000; 2000US-0237040P.
PR 13-OCT-2000; 2000US-0239935P.
PR 13-OCT-2000; 2000US-0239937P.
PR 20-OCT-2000; 2000US-0240960P.
PR 20-OCT-2000; 2000US-0241221P.
PR 20-OCT-2000; 2000US-0241785P.
PR 20-OCT-2000; 2000US-0241786P.
PR 20-OCT-2000; 2000US-0241787P.
PR 20-OCT-2000; 2000US-0241808P.
PR 20-OCT-2000; 2000US-0241809P.
PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.

PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Barash SC, Ruben SM;
XX
DR WPI; 2001-476224/51.
DR N-PSDB; AAS28068.
XX
PT Isolated polypeptide for treating, preventing and/ or prognosing
PT disorders related to the respiratory system including respiratory cancers
PT and also for testing and detection e.g. diagnosis.
XX
PS Claim 11; SED ID No 502; 546pp; English.
XX
CC The present invention relates to the isolation of novel human respiratory
CC antigens, and cDNA (AAS27869-AAS28159) and genomic sequences encoding for
CC these polypeptides. The sequences of the invention are useful for
CC preventing, treating and/or prognosing disorders related to the
CC respiratory system including throat disorders (e.g. vocal cord paralysis,
CC tonsillitis, and laryngitis), lung disorders e.g. pneumonia, allergic
CC disorders e.g. asthma, pleurisy, cystic fibrosis, emphysema, nose
CC disorders and cancers of the respiratory tissues e.g. lung cancer. The
CC polynucleotide sequences of the invention are useful in gene therapy and
CC antisense therapy. AAU17685-AAU17975 represent novel human respiratory
CC antigens. Note: The sequence data for this patent did not form part of
CC the printed specification, but was obtained in electronic format directly
CC from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 46 AA;

Query Match 25.0%; Score 5; DB 4; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 15 LETKF 19
|||||
Db 2 LETKF 6

RESULT 65
ABB19826
ID ABB19826 standard; protein; 46 AA.
XX
AC ABB19826;
XX
DT 23-JAN-2002 (first entry)
XX
DE Protein #1825 encoded by probe for measuring heart cell gene expression.
XX
KW Human; gene expression; heart; microarray; vascular system;
KW cardiovascular disease; hypertension; cardiac arrhythmia;
KW congenital heart disease.
XX
OS Homo sapiens.
XX
PN WO200157274-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000666.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488899/53.
XX
PT Single exon nucleic acid probes for analyzing gene expression in human
PT hearts.
XX
PS Claim 15; SEQ ID NO 21596; 530pp; English.
XX
CC The present invention relates to single exon nucleic acid probes for
CC measuring human gene expression in a sample derived from human heart (see
CC ABA21535-ABA41305). The present sequence is a protein encoded by one such
CC probe. The probes may be used for predicting, measuring and displaying
CC gene expression in samples derived from the human heart via microarrays.
CC By measuring gene expression, the probes are useful for predicting,
CC diagnosing, grading, staging, monitoring and prognosing diseases of the
CC human heart and vascular system e.g. cardiovascular disease,
CC hypertension, cardiac arrhythmias and congenital heart disease. Note: The
CC sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 46 AA;

Query Match 25.0%; Score 5; DB 4; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 RGAPM 6
|||||
Db 20 RGAPM 24

RESULT 66
AAM67599
ID AAM67599 standard; protein; 46 AA.
XX
AC AAM67599;
XX
DT 06-NOV-2001 (first entry)
XX
DE Human bone marrow expressed probe encoded protein SEQ ID NO: 27905.
XX
KW Human; bone marrow expressed exon; gene expression analysis; probe;
KW microarray; cancer; leukaemia; lymphoma; myeloma.
XX
OS Homo sapiens.
XX
PN WO200157276-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000668.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488900/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human bone marrow.
XX
PS Example 4; SEQ ID NO 27905; 658pp + Sequence Listing; English.

```
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   bone marrow. They can be used to measure gene expression in bone marrow
CC   samples, which may enable the improved diagnosis and treatment of cancers
CC   such as lymphoma, leukaemia and myeloma. The present sequence is a
CC   protein encoded by one of the probes of the invention
XX
SQ   Sequence 46 AA;

  Query Match             25.0%;  Score 5;  DB 4;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 RGAPM 6
              |||||
Db         20 RGAPM 24


RESULT 67
AAM64389
ID   AAM64389 standard; protein; 46 AA.
XX
AC   AAM64389;
XX
DT   05-NOV-2001  (first entry)
XX
DE   Human brain expressed single exon probe encoded protein SEQ ID NO: 36494.
XX
KW   Human; brain expressed exon; gene expression analysis; probe; microarray;
KW   Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer.
XX
OS   Homo sapiens.
XX
PN   WO200157275-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000667.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-483446/52.
XX
PT   Single exon nucleic acid probes for analyzing gene expression in human
PT   brains.
XX
PS   Example 4; SEQ ID NO 36494; 650pp + Sequence Listing; English.
XX
CC   The present invention provides a number of single exon nucleic acid
CC   probes which are derived from genomic sequences expressed in the human
CC   brain. They can be used to measure gene expression in brain cell samples,
CC   which may enable the diagnosis and improved treatment of nervous system
CC   diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
CC   epilepsy and cancers. The present sequence is a protein encoded by one of
CC   the probes of the invention
XX
SQ   Sequence 46 AA;

  Query Match             25.0%;  Score 5;  DB 4;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLET 17
              |||||
Db         32 QMLET 36


RESULT 68
ABG58835
ID   ABG58835 standard; peptide; 46 AA.
XX
AC   ABG58835;
XX
DT   25-FEB-2003  (first entry)
XX
DE   Human liver peptide, SEQ ID No 37483.
XX
KW   Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW   hypercholesterolaemia; coronary heart disease.
XX
OS   Homo sapiens.
XX
PN   WO200157273-A2.
XX
PD   09-AUG-2001.
XX
PF   30-JAN-2001; 2001WO-US000664.
XX
PR   04-FEB-2000; 2000US-0180312P.
PR   26-MAY-2000; 2000US-0207456P.
PR   30-JUN-2000; 2000US-00608408.
PR   03-AUG-2000; 2000US-00632366.
PR   21-SEP-2000; 2000US-0234687P.
PR   27-SEP-2000; 2000US-0236359P.
PR   04-OCT-2000; 2000GB-00024263.
XX
PA   (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI   Penn SG,  Hanzel DK,  Chen W,  Rank DR;
XX
DR   WPI; 2001-488898/53.
XX
PT   Human genome-derived single exon nucleic acid probes useful for analyzing
PT   gene expression in human adult liver.
XX
PS   Claim 27; SEQ ID NO 37483; 658pp; English.
XX
CC   The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC   measuring human gene expression in a sample derived from human adult
CC   liver, comprising one of 13109 defined nucleotide sequences given in the
CC   specification (or complements/ fragments). The probe hybridises at high
CC   stringency to a nucleic acid molecule expressed in the human adult liver.
CC   (I) may be used for predicting, measuring and displaying gene expression
CC   in samples derived from human adult liver. The genes identified may be
CC   involved in genetic liver diseases such as cirrhosis,
CC   hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC   associated with coronary heart disease. ABG47348-ABG59930 represent human
CC   liver single exon encoded peptides of the invention. Note: The sequence
CC   information for this patent does not appear in the printed specification
CC   but was obtained in electronic format directly from WIPO at
CC   ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 46 AA;

  Query Match             25.0%;  Score 5;  DB 4;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLET 17
              |||||
Db         32 QMLET 36


RESULT 69
ABG49246
```

ID ABG49246 standard; peptide; 46 AA.
XX
AC ABG49246;
XX
DT 25-FEB-2003 (first entry)
XX
DE Human liver peptide, SEQ ID No 27894.
XX
KW Human; liver; cirrhosis; hyperlipoproteinaemia; hyperlipidaemia;
KW hypercholesterolaemia; coronary heart disease.
XX
OS Homo sapiens.
XX
PN WO200157273-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000664.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488898/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human adult liver.
XX
PS Claim 27; SEQ ID NO 27894; 658pp; English.
XX
CC The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC measuring human gene expression in a sample derived from human adult
CC liver, comprising one of 13109 defined nucleotide sequences given in the
CC specification (or complements/ fragments). The probe hybridises at high
CC stringency to a nucleic acid molecule expressed in the human adult liver.
CC (I) may be used for predicting, measuring and displaying gene expression
CC in samples derived from human adult liver. The genes identified may be
CC involved in genetic liver diseases such as cirrhosis,
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is
CC associated with coronary heart disease. ABG47348-ABG59930 represent human
CC liver single exon encoded peptides of the invention. Note: The sequence
CC information for this patent does not appear in the printed specification
CC but was obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 46 AA;

Query Match 25.0%; Score 5; DB 4; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 RGAPM 6
|||||
Db 20 RGAPM 24

RESULT 70
AAM03170
ID AAM03170 standard; protein; 46 AA.
XX
AC AAM03170;
XX
DT 09-OCT-2001 (first entry)
XX
DE Peptide #1852 encoded by probe for measuring breast gene expression.
XX
KW Probe; human; breast disease; breast cancer; development disorder;
KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.
XX
OS Homo sapiens.
XX
PN WO200157270-A2.
XX
PD 09-AUG-2001.
XX
PF 29-JAN-2001; 2001WO-US000661.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-476286/51.
XX
PT Novel single exon nucleic acid probe used to measuring gene expression in
PT a human breast.
XX
PS Claim 27; SEQ ID NO 11910; 322pp; English.
XX
CC The present invention relates to novel single exon nucleic acid probes
CC (see AAI00010-AAI10067). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for measuring human gene expression in
CC a human breast sample, where the probe hybridises at high stringency to a
CC nucleic acid expressed in the human breast. The probes are useful for
CC predicting, diagnosing, grading, staging, monitoring and prognosing
CC diseases of the human breast, particularly those diseases with polygenic
CC aetiology. The diseases include: breast cancer, disorders of development,
CC inflammatory diseases of the breast, fibrocystic changes, proliferative
CC breast disease and non-carcinoma tumours. Note: The sequence data for
CC this patent did not form part of the printed specification, but was
CC obtained in electronic format directly from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 46 AA;

Query Match 25.0%; Score 5; DB 4; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 RGAPM 6
|||||
Db 20 RGAPM 24

RESULT 71
ABG46222
ID ABG46222 standard; peptide; 46 AA.
XX
AC ABG46222;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human peptide encoded by genome-derived single exon probe SEQ ID 35887.
XX
KW Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;

KW primary ciliary dyskinesis; pulmonary hypertension;
KW hyaline membrane disease.
XX
OS Homo sapiens.
XX
PN WO200186003-A2.
XX
PD 15-NOV-2001.
XX
PF 30-JAN-2001; 2001WO-US000665.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2002-114183/15.
XX
PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples.
XX
PS Claim 27; SEQ ID NO 35887; 634pp; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human lung comprising single exon nucleic acid probes having one of
CC 12614 nucleic acid sequences mentioned in the specification, or their
CC complements or the 12387 open reading frames derived from the 12614
CC probes. Also included are a microarray comprising the novel set of probes
CC ; the novel set of probes which hybridise at high stringency to a nucleic
CC acid expressed in the human lung; measuring gene expression in a sample
CC derived from human lung, comprising (a) contacting the array with a
CC collection of detectably labeled nucleic acids derived from human lung
CC mRNA, and (b) measuring the label detectably bound to each probe of the
CC array; identifying exons in a eukaryotic genome, comprising (a)
CC algorithmically predicting at least one exon from genomic sequences of
CC the eukaryote; and (b) detecting specific hybridisation of detectably
CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC having a fragment identical to the predicted exon, the probe is included
CC in the above mentioned microarray; assigning exons to a single gene,
CC comprising (a) identifying exons from genomic sequence by the method
CC above and (b) measuring the expression of each of the exons in several
CC tissues and/or cell types using hybridisation to a single exon
CC microarrays having a probe with the exon, where a common pattern of
CC expression of the exons in the tissues and/or cell types indicates that
CC the exons should be assigned to a single gene; a peptide comprising one
CC of 12011 sequences, mentioned in the specification, or encoded by the
CC probes/open reading frames (ORF). The probes are used for gene expression
CC analysis, and for identifying exons in a gene, particularly using human
CC lung derived mRNA and for the study of lung diseases such as asthma, lung
CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC present sequence is a peptide/protein encoded by a single exon probe of
CC the invention. Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 46 AA;

Query Match 25.0%; Score 5; DB 5; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;

Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLET 17
||||
Db 32 QMLET 36

RESULT 72
ABG37192
ID ABG37192 standard; peptide; 46 AA.
XX
AC ABG37192;
XX
DT 19-AUG-2002 (first entry)
XX
DE Human peptide encoded by genome-derived single exon probe SEQ ID 26857.
XX
KW Human; single exon probe; asthma; lung cancer; COPD; ILD;
KW chronic obstructive pulmonary disease; interstitial lung disease;
KW familial idiopathic pulmonary fibrosis; neurofibromatosis;
KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;
KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;
KW pulmonary histiocytosis; lymphangioleiomyomtosis; Karagener syndrome;
KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;
KW primary ciliary dyskinesis; pulmonary hypertension;
KW hyaline membrane disease.
XX
OS Homo sapiens.
XX
PN WO200186003-A2.
XX
PD 15-NOV-2001.
XX
PF 30-JAN-2001; 2001WO-US000665.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2002-114183/15.
XX
PT Spatially-addressable set of single exon nucleic acid probes, used to
PT measure gene expression in human lung samples.
XX
PS Claim 27; SEQ ID NO 26857; 634pp; English.
XX
CC The invention relates to a spatially-addressable set of single exon
CC nucleic acid probes for measuring gene expression in a sample derived
CC from human lung comprising single exon nucleic acid probes having one of
CC 12614 nucleic acid sequences mentioned in the specification, or their
CC complements or the 12387 open reading frames derived from the 12614
CC probes. Also included are a microarray comprising the novel set of probes
CC ; the novel set of probes which hybridise at high stringency to a nucleic
CC acid expressed in the human lung; measuring gene expression in a sample
CC derived from human lung, comprising (a) contacting the array with a
CC collection of detectably labeled nucleic acids derived from human lung
CC mRNA, and (b) measuring the label detectably bound to each probe of the
CC array; identifying exons in a eukaryotic genome, comprising (a)
CC algorithmically predicting at least one exon from genomic sequences of
CC the eukaryote; and (b) detecting specific hybridisation of detectably
CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,
CC having a fragment identical to the predicted exon, the probe is included
CC in the above mentioned microarray; assigning exons to a single gene,
CC comprising (a) identifying exons from genomic sequence by the method
CC above and (b) measuring the expression of each of the exons in several

```
CC   tissues and/or cell types using hybridisation to a single exon
CC   microarrays having a probe with the exon, where a common pattern of
CC   expression of the exons in the tissues and/or cell types indicates that
CC   the exons should be assigned to a single gene; a peptide comprising one
CC   of 12011 sequences, mentioned in the specification, or encoded by the
CC   probes/open reading frames (ORF). The probes are used for gene expression
CC   analysis, and for identifying exons in a gene, particularly using human
CC   lung derived mRNA and for the study of lung diseases such as asthma, lung
CC   cancer, chronic obstructive pulmonary disease (COPD), interstitial lung
CC   disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,
CC   tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-
CC   Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary
CC   histiocytosis, lymphangioleiomyomtosis, pulmonary alveolar proteinosis,
CC   Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary
CC   dyskinesis, pulmonary hypertension and hyaline membrane disease. The
CC   present sequence is a peptide/protein encoded by a single exon probe of
CC   the invention. Note: The sequence data for this patent did not form part
CC   of the printed specification, but was obtained in electronic format
CC   directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ   Sequence 46 AA;

  Query Match             25.0%;  Score 5;  DB 5;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 RGAPM 6
              |||||
Db         20 RGAPM 24


RESULT 73
ADG41264
ID   ADG41264 standard; protein; 46 AA.
XX
AC   ADG41264;
XX
DT   26-FEB-2004  (first entry)
XX
DE   Human respiratory system associated protein seq id 502.
XX
KW   antiinflammatory; antiallergic; antiasthmatic; cytostatic; gene therapy;
KW   respiratory system antigen;
KW   human respiratory system associated polynucleotide;
KW   respiratory system disorder; throat disorder; vocal cord paralysis;
KW   tonsillitis; laryngitis; lung disorder; pneumonia; allergic disorder;
KW   asthma; eosinophilic pneumonia; pleurisy; cystic fibrosis; emphysema;
KW   histiocytosis; sarcoidosis; nose disorder; rhinitis; sinusitis; neoplasm;
KW   cancer; respiratory tissue cancer; throat cancer; lung cancer;
KW   cancer of the nose; gene therapy; chromosome identification; forensic;
KW   human respiratory system associated protein; human.
XX
OS   Homo sapiens.
XX
PN   US2003215893-A1.
XX
PD   20-NOV-2003.
XX
PF   07-AUG-2002; 2002US-00212872.
XX
PR   31-JAN-2000; 2000US-0179065P.
PR   04-FEB-2000; 2000US-0180628P.
PR   24-FEB-2000; 2000US-0184664P.
PR   02-MAR-2000; 2000US-0186350P.
PR   16-MAR-2000; 2000US-0189874P.
PR   17-MAR-2000; 2000US-0190076P.
PR   18-APR-2000; 2000US-0198123P.
PR   19-MAY-2000; 2000US-0205515P.
PR   07-JUN-2000; 2000US-0209467P.
PR   28-JUN-2000; 2000US-0214886P.
PR   30-JUN-2000; 2000US-0215135P.
PR   07-JUL-2000; 2000US-0216647P.
PR   07-JUL-2000; 2000US-0216880P.
PR   11-JUL-2000; 2000US-0217487P.
PR   11-JUL-2000; 2000US-0217496P.
PR   14-JUL-2000; 2000US-0218290P.
PR   26-JUL-2000; 2000US-0220963P.
PR   26-JUL-2000; 2000US-0220964P.
PR   14-AUG-2000; 2000US-0224518P.
PR   14-AUG-2000; 2000US-0224519P.
PR   14-AUG-2000; 2000US-0225213P.
PR   14-AUG-2000; 2000US-0225214P.
PR   14-AUG-2000; 2000US-0225266P.
PR   14-AUG-2000; 2000US-0225267P.
PR   14-AUG-2000; 2000US-0225268P.
PR   14-AUG-2000; 2000US-0225270P.
PR   14-AUG-2000; 2000US-0225447P.
PR   14-AUG-2000; 2000US-0225757P.
PR   14-AUG-2000; 2000US-0225758P.
PR   14-AUG-2000; 2000US-0225759P.
PR   18-AUG-2000; 2000US-0226279P.
PR   22-AUG-2000; 2000US-0226681P.
PR   22-AUG-2000; 2000US-0226868P.
PR   22-AUG-2000; 2000US-0227182P.
PR   23-AUG-2000; 2000US-0227009P.
PR   30-AUG-2000; 2000US-0228924P.
PR   01-SEP-2000; 2000US-0229287P.
PR   01-SEP-2000; 2000US-0229343P.
PR   01-SEP-2000; 2000US-0229344P.
PR   01-SEP-2000; 2000US-0229345P.
PR   05-SEP-2000; 2000US-0229509P.
PR   05-SEP-2000; 2000US-0229513P.
PR   06-SEP-2000; 2000US-0230437P.
PR   06-SEP-2000; 2000US-0230438P.
PR   08-SEP-2000; 2000US-0231242P.
PR   08-SEP-2000; 2000US-0231243P.
PR   08-SEP-2000; 2000US-0231244P.
PR   08-SEP-2000; 2000US-0231413P.
PR   08-SEP-2000; 2000US-0231414P.
PR   08-SEP-2000; 2000US-0232080P.
PR   08-SEP-2000; 2000US-0232081P.
PR   12-SEP-2000; 2000US-0231968P.
PR   14-SEP-2000; 2000US-0232397P.
PR   14-SEP-2000; 2000US-0232398P.
PR   14-SEP-2000; 2000US-0232399P.
PR   14-SEP-2000; 2000US-0232400P.
PR   14-SEP-2000; 2000US-0232401P.
PR   14-SEP-2000; 2000US-0233063P.
PR   14-SEP-2000; 2000US-0233064P.
PR   14-SEP-2000; 2000US-0233065P.
PR   21-SEP-2000; 2000US-0234223P.
PR   21-SEP-2000; 2000US-0234274P.
PR   25-SEP-2000; 2000US-0234997P.
PR   25-SEP-2000; 2000US-0234998P.
PR   26-SEP-2000; 2000US-0235484P.
PR   27-SEP-2000; 2000US-0235834P.
PR   27-SEP-2000; 2000US-0235836P.
PR   28-SEP-2000; 2000US-0235935P.
PR   29-SEP-2000; 2000US-0236327P.
PR   29-SEP-2000; 2000US-0236367P.
PR   29-SEP-2000; 2000US-0236368P.
PR   29-SEP-2000; 2000US-0236369P.
PR   29-SEP-2000; 2000US-0236370P.
PR   02-OCT-2000; 2000US-0236802P.
PR   02-OCT-2000; 2000US-0237037P.
PR   02-OCT-2000; 2000US-0237038P.
PR   02-OCT-2000; 2000US-0237039P.
PR   02-OCT-2000; 2000US-0237040P.
PR   13-OCT-2000; 2000US-0239937P.
PR   20-OCT-2000; 2000US-0240960P.
PR   20-OCT-2000; 2000US-0241221P.
PR   20-OCT-2000; 2000US-0241785P.
PR   20-OCT-2000; 2000US-0241786P.
PR   20-OCT-2000; 2000US-0241787P.
PR   20-OCT-2000; 2000US-0241808P.
PR   20-OCT-2000; 2000US-0241809P.
```

PR 20-OCT-2000; 2000US-0241826P.
PR 01-NOV-2000; 2000US-0244617P.
PR 08-NOV-2000; 2000US-0246474P.
PR 08-NOV-2000; 2000US-0246475P.
PR 08-NOV-2000; 2000US-0246476P.
PR 08-NOV-2000; 2000US-0246477P.
PR 08-NOV-2000; 2000US-0246478P.
PR 08-NOV-2000; 2000US-0246523P.
PR 08-NOV-2000; 2000US-0246524P.
PR 08-NOV-2000; 2000US-0246525P.
PR 08-NOV-2000; 2000US-0246526P.
PR 08-NOV-2000; 2000US-0246527P.
PR 08-NOV-2000; 2000US-0246528P.
PR 08-NOV-2000; 2000US-0246532P.
PR 08-NOV-2000; 2000US-0246609P.
PR 08-NOV-2000; 2000US-0246610P.
PR 08-NOV-2000; 2000US-0246611P.
PR 08-NOV-2000; 2000US-0246613P.
PR 17-NOV-2000; 2000US-0249207P.
PR 17-NOV-2000; 2000US-0249208P.
PR 17-NOV-2000; 2000US-0249209P.
PR 17-NOV-2000; 2000US-0249210P.
PR 17-NOV-2000; 2000US-0249211P.
PR 17-NOV-2000; 2000US-0249212P.
PR 17-NOV-2000; 2000US-0249213P.
PR 17-NOV-2000; 2000US-0249214P.
PR 17-NOV-2000; 2000US-0249215P.
PR 17-NOV-2000; 2000US-0249216P.
PR 17-NOV-2000; 2000US-0249217P.
PR 17-NOV-2000; 2000US-0249218P.
PR 17-NOV-2000; 2000US-0249244P.
PR 17-NOV-2000; 2000US-0249245P.
PR 17-NOV-2000; 2000US-0249264P.
PR 17-NOV-2000; 2000US-0249265P.
PR 17-NOV-2000; 2000US-0249297P.
PR 17-NOV-2000; 2000US-0249299P.
PR 17-NOV-2000; 2000US-0249300P.
PR 01-DEC-2000; 2000US-0250160P.
PR 01-DEC-2000; 2000US-0250391P.
PR 05-DEC-2000; 2000US-0251030P.
PR 05-DEC-2000; 2000US-0251988P.
PR 05-DEC-2000; 2000US-0256719P.
PR 06-DEC-2000; 2000US-0251479P.
PR 08-DEC-2000; 2000US-0251856P.
PR 08-DEC-2000; 2000US-0251868P.
PR 08-DEC-2000; 2000US-0251869P.
PR 08-DEC-2000; 2000US-0251989P.
PR 08-DEC-2000; 2000US-0251990P.
PR 11-DEC-2000; 2000US-0254097P.
PR 05-JAN-2001; 2001US-0259678P.
PR 17-JAN-2001; 2001US-00764860.
PR 14-FEB-2002; 2002US-00074095.
XX
PA (HUMA-) HUMAN GENOME SCI INC.
XX
PI Rosen CA, Ruben SM, Barash SC;
XX
DR WPI; 2003-902033/82.
DR N-PSDB; ADG40972.
XX
PT Novel respiratory system antigen and polynucleotides encoding the
PT polypeptides, useful for treating diagnosing, treating or preventing
PT tonsillitis, pneumonia, asthma and cystic fibrosis, emphysema, throat
PT cancer.
XX
PS Claim 11; SEQ ID NO 502; 236pp; English.
XX
CC The invention describes an isolated polypeptide (I) comprising an amino
CC acid sequence that is at least 90% identical to polypeptide fragment of
CC any one of 299 respiratory system antigen sequences (PS) and having
CC biological activity, polypeptide domain or epitope of PS, full-length
CC protein of PS, or variant, allelic variant or species homolog of PS. (I)
CC or a polynucleotide (II) encoding (I) is also useful for diagnosing a
CC pathological condition or a susceptibility to a pathological condition in
CC a subject which involves determining the presence or absence of mutation
CC in (II) or determining the presence or amount of expression of (I) in a
CC biological sample and diagnosing a pathological condition based on the
CC result. The human respiratory system associated polynucleotides, the
CC polypeptides encoded by them, and antibodies that immunospecifically bind
CC these polypeptides are useful in diagnosis, treatment, prevention and/or
CC prognosis of disorders of respiratory system such as throat disorders
CC (e.g., vocal cord paralysis, tonsillitis, and laryngitis), lung disorders
CC (e.g., pneumonia), allergic disorders, (e.g., asthma and eosinophilic
CC pneumonia), pleurisy, cystic fibrosis, emphysema, histiocytosis,
CC sarcoidosis, nose disorders (rhinitis and sinusitis), neoplasms and/or
CC cancers of respiratory tissues (e.g., throat cancer, lung cancer, and
CC cancer of the nose). The polynucleotides are useful in gene therapy

Query Match 25.0%; Score 5; DB 7; Length 46;
Best Local Similarity 100.0%; Pred. No. 4.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 15 LETKF 19
|||||
Db 2 LETKF 6

RESULT 74
ABB38152
ID ABB38152 standard; peptide; 47 AA.
XX
AC ABB38152;
XX
DT 04-FEB-2002 (first entry)
XX
DE Peptide #5658 encoded by human foetal liver single exon probe.
XX
KW Human; foetal liver; gene expression; single exon nucleic acid probe.
XX
OS Homo sapiens.
XX
PN WO200157277-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000669.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-483447/52.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human fetal liver.
XX
PS Claim 27; SEQ ID NO 30787; 639pp + Sequence Listing; English.
XX
CC The invention relates to a single exon nucleic acid probe for measuring
CC human gene expression in a sample derived from human foetal liver. The
CC single exon nucleic acid probes may be used for predicting, measuring and
CC displaying gene expression in samples derived from human fetal liver. The
CC present sequence is a peptide encoded by a single exon nucleic acid probe
CC of the invention. Note: The sequence data for this patent did not form
CC part of the printed specification, but was obtained in electronic format
CC directly from WIPO at ftp.wipo.int/pub/published_pct_sequences
XX
SQ Sequence 47 AA;

Query Match 25.0%; Score 5; DB 4; Length 47;
Best Local Similarity 100.0%; Pred. No. 5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 PRGAP 5
              |||||
Db         13 PRGAP 17
```

RESULT 75
AAM31580
ID AAM31580 standard; protein; 47 AA.
XX
AC AAM31580;
XX
DT 17-OCT-2001 (first entry)
XX
DE Peptide #5617 encoded by probe for measuring placental gene expression.
XX
KW Probe; microarray; human; placenta; antenatal diagnosis;
KW genetic disorder.
XX
OS Homo sapiens.
XX
PN WO200157272-A2.
XX
PD 09-AUG-2001.
XX
PF 30-JAN-2001; 2001WO-US000663.
XX
PR 04-FEB-2000; 2000US-0180312P.
PR 26-MAY-2000; 2000US-0207456P.
PR 30-JUN-2000; 2000US-00608408.
PR 03-AUG-2000; 2000US-00632366.
PR 21-SEP-2000; 2000US-0234687P.
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
XX
PA (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX
DR WPI; 2001-488897/53.
XX
PT Human genome-derived single exon nucleic acid probes useful for analyzing
PT gene expression in human placenta.
XX
PS Claim 27; SEQ ID NO 31849; 654pp; English.
XX
CC The present invention relates to single exon nucleic acid probes (SENP:
CC see AAI31315-AAI57546). The present sequence is a peptide encoded by one
CC such probe. The probes are useful for producing a microarray for
CC predicting, measuring and displaying gene expression in samples derived
CC from human placenta. The probes are useful for antenatal diagnosis of
CC human genetic disorders
XX
SQ Sequence 47 AA;

Query Match 25.0%; Score 5; DB 4; Length 47;
Best Local Similarity 100.0%; Pred. No. 5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 PRGAP 5
              |||||
Db         13 PRGAP 17
```

Search completed: October 26, 2004, 07:16:23
Job time : 88 secs

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: October 26, 2004, 07:22:37 ; Search time 65 Seconds
(without alignments)
99.618 Million cell updates/sec

Title: US-10-066-965A-4
Perfect score: 20
Sequence: 1 PRGAPMWLRCVCQMLETKFL 20

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 1364641 seqs, 323758627 residues

Word size : 0

Total number of hits satisfying chosen parameters: 1364641

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 100 summaries

Database : Published_Applications_AA:*
1: /cgn2_6/ptodata/2/pubpaa/US07_PUBCOMB.pep:*
2: /cgn2_6/ptodata/2/pubpaa/PCT_NEW_PUB.pep:*
3: /cgn2_6/ptodata/2/pubpaa/US06_NEW_PUB.pep:*
4: /cgn2_6/ptodata/2/pubpaa/US06_PUBCOMB.pep:*
5: /cgn2_6/ptodata/2/pubpaa/US07_NEW_PUB.pep:*
6: /cgn2_6/ptodata/2/pubpaa/PCTUS_PUBCOMB.pep:*
7: /cgn2_6/ptodata/2/pubpaa/US08_NEW_PUB.pep:*
8: /cgn2_6/ptodata/2/pubpaa/US08_PUBCOMB.pep:*
9: /cgn2_6/ptodata/2/pubpaa/US09A_PUBCOMB.pep:*
10: /cgn2_6/ptodata/2/pubpaa/US09B_PUBCOMB.pep:*
11: /cgn2_6/ptodata/2/pubpaa/US09C_PUBCOMB.pep:*
12: /cgn2_6/ptodata/2/pubpaa/US09_NEW_PUB.pep:*
13: /cgn2_6/ptodata/2/pubpaa/US10A_PUBCOMB.pep:*
14: /cgn2_6/ptodata/2/pubpaa/US10B_PUBCOMB.pep:*
15: /cgn2_6/ptodata/2/pubpaa/US10C_PUBCOMB.pep:*
16: /cgn2_6/ptodata/2/pubpaa/US10D_PUBCOMB.pep:*
17: /cgn2_6/ptodata/2/pubpaa/US10_NEW_PUB.pep:*
18: /cgn2_6/ptodata/2/pubpaa/US11_NEW_PUB.pep:*
19: /cgn2_6/ptodata/2/pubpaa/US60_NEW_PUB.pep:*
20: /cgn2_6/ptodata/2/pubpaa/US60_PUBCOMB.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	20	100.0	20	14	US-10-066-965A-4	Sequence 4, Appli
2	20	100.0	20	14	US-10-066-965A-23	Sequence 23, Appl
3	7	35.0	20	14	US-10-066-965A-3	Sequence 3, Appli
4	7	35.0	20	14	US-10-066-965A-22	Sequence 22, Appl
5	6	30.0	81	16	US-10-437-963-181184	Sequence 181184,
6	6	30.0	278	14	US-10-369-493-17206	Sequence 17206, A
7	6	30.0	285	15	US-10-264-049-3133	Sequence 3133, Ap
8	6	30.0	395	14	US-10-094-749-3019	Sequence 3019, Ap
9	6	30.0	395	16	US-10-408-765A-2509	Sequence 2509, Ap
10	6	30.0	434	15	US-10-282-122A-76949	Sequence 76949, A
11	6	30.0	571	15	US-10-262-839-180	Sequence 180, App
12	6	30.0	577	15	US-10-262-839-196	Sequence 196, App
13	6	30.0	731	16	US-10-408-765A-2869	Sequence 2869, Ap
14	6	30.0	1490	15	US-10-262-839-184	Sequence 184, App
15	6	30.0	1545	15	US-10-262-839-182	Sequence 182, App
16	6	30.0	1549	15	US-10-262-839-186	Sequence 186, App
17	6	30.0	1568	15	US-10-263-929-117	Sequence 117, App
18	6	30.0	1588	13	US-10-000-512-2	Sequence 2, Appli
19	6	30.0	1588	14	US-10-074-566-2	Sequence 2, Appli
20	6	30.0	1588	14	US-10-074-566-41	Sequence 41, Appl
21	6	30.0	1588	15	US-10-262-839-176	Sequence 176, App
22	6	30.0	1588	15	US-10-262-839-188	Sequence 188, App
23	6	30.0	1588	15	US-10-262-839-194	Sequence 194, App
24	6	30.0	1588	15	US-10-262-839-200	Sequence 200, App
25	5	25.0	9	9	US-09-834-765-528	Sequence 528, App
26	5	25.0	9	9	US-09-834-765-634	Sequence 634, App
27	5	25.0	10	9	US-09-834-765-583	Sequence 583, App
28	5	25.0	12	14	US-10-253-118-1	Sequence 1, Appli
29	5	25.0	15	14	US-10-104-755-20	Sequence 20, Appl
30	5	25.0	28	14	US-10-231-417-416	Sequence 416, App
31	5	25.0	44	15	US-10-424-599-167866	Sequence 167866,
32	5	25.0	44	16	US-10-437-963-120828	Sequence 120828,
33	5	25.0	45	15	US-10-424-599-186275	Sequence 186275,
34	5	25.0	46	9	US-09-864-761-35124	Sequence 35124, A
35	5	25.0	46	9	US-09-864-761-45993	Sequence 45993, A
36	5	25.0	46	9	US-09-764-860-502	Sequence 502, App
37	5	25.0	46	14	US-10-074-095-502	Sequence 502, App
38	5	25.0	46	14	US-10-212-872-502	Sequence 502, App
39	5	25.0	46	16	US-10-437-963-161908	Sequence 161908,
40	5	25.0	47	9	US-09-864-761-38656	Sequence 38656, A
41	5	25.0	47	16	US-10-437-963-202542	Sequence 202542,
42	5	25.0	50	16	US-10-387-346B-94	Sequence 94, Appl
43	5	25.0	50	16	US-10-437-963-204604	Sequence 204604,
44	5	25.0	50	16	US-10-686-947-94	Sequence 94, Appl
45	5	25.0	51	15	US-10-424-599-267231	Sequence 267231,
46	5	25.0	51	15	US-10-424-599-275966	Sequence 275966,
47	5	25.0	52	15	US-10-424-599-284525	Sequence 284525,
48	5	25.0	53	15	US-10-424-599-177624	Sequence 177624,
49	5	25.0	54	14	US-10-152-031-13	Sequence 13, Appl
50	5	25.0	56	15	US-10-424-599-262093	Sequence 262093,
51	5	25.0	57	9	US-09-867-550-1954	Sequence 1954, Ap
52	5	25.0	58	15	US-10-424-599-240745	Sequence 240745,
53	5	25.0	60	15	US-10-424-599-205956	Sequence 205956,
54	5	25.0	61	15	US-10-424-599-176161	Sequence 176161,
55	5	25.0	62	15	US-10-424-599-239535	Sequence 239535,
56	5	25.0	63	14	US-10-029-386-32143	Sequence 32143, A
57	5	25.0	64	15	US-10-424-599-282344	Sequence 282344,
58	5	25.0	66	15	US-10-424-599-210941	Sequence 210941,
59	5	25.0	67	9	US-09-867-550-1576	Sequence 1576, Ap
60	5	25.0	68	15	US-10-424-599-154428	Sequence 154428,
61	5	25.0	72	9	US-09-864-761-34034	Sequence 34034, A
62	5	25.0	72	13	US-10-001-879-175	Sequence 175, App
63	5	25.0	72	15	US-10-424-599-221140	Sequence 221140,
64	5	25.0	74	16	US-10-437-963-102863	Sequence 102863,
65	5	25.0	76	16	US-10-293-252C-102	Sequence 102, App
66	5	25.0	76	16	US-10-340-861B-102	Sequence 102, App
67	5	25.0	78	9	US-09-792-793A-90	Sequence 90, Appl
68	5	25.0	78	11	US-09-864-408A-5972	Sequence 5972, Ap
69	5	25.0	78	14	US-10-375-209A-90	Sequence 90, Appl
70	5	25.0	78	16	US-10-437-963-135152	Sequence 135152,
71	5	25.0	78	16	US-10-437-963-167155	Sequence 167155,
72	5	25.0	79	15	US-10-424-599-144203	Sequence 144203,
73	5	25.0	79	15	US-10-424-599-149863	Sequence 149863,
74	5	25.0	80	9	US-09-922-261-464	Sequence 464, App
75	5	25.0	80	16	US-10-437-963-105389	Sequence 105389,
76	5	25.0	81	16	US-10-437-963-173123	Sequence 173123,
77	5	25.0	82	15	US-10-424-599-151381	Sequence 151381,
78	5	25.0	83	15	US-10-424-599-240184	Sequence 240184,
79	5	25.0	84	14	US-10-106-698-7816	Sequence 7816, Ap
80	5	25.0	85	9	US-09-867-550-772	Sequence 772, App
81	5	25.0	85	16	US-10-437-963-183176	Sequence 183176,
82	5	25.0	86	9	US-09-864-761-47995	Sequence 47995, A
83	5	25.0	86	9	US-09-764-877-2023	Sequence 2023, Ap
84	5	25.0	86	15	US-10-242-515-2023	Sequence 2023, Ap
85	5	25.0	87	15	US-10-424-599-281783	Sequence 281783,
86	5	25.0	87	16	US-10-437-963-110760	Sequence 110760,

87	5	25.0	88	16	US-10-437-963-102687	Sequence 102687,
88	5	25.0	88	16	US-10-767-701-50033	Sequence 50033, A
89	5	25.0	89	15	US-10-424-599-215851	Sequence 215851,
90	5	25.0	89	16	US-10-437-963-127248	Sequence 127248,
91	5	25.0	91	15	US-10-424-599-236694	Sequence 236694,
92	5	25.0	91	15	US-10-424-599-243343	Sequence 243343,
93	5	25.0	92	16	US-10-437-963-115372	Sequence 115372,
94	5	25.0	92	16	US-10-437-963-124347	Sequence 124347,
95	5	25.0	94	11	US-09-864-408A-7168	Sequence 7168, Ap
96	5	25.0	95	16	US-10-437-963-153530	Sequence 153530,
97	5	25.0	96	15	US-10-424-599-142846	Sequence 142846,
98	5	25.0	96	16	US-10-437-963-157410	Sequence 157410,
99	5	25.0	97	15	US-10-424-599-159333	Sequence 159333,
100	5	25.0	97	16	US-10-437-963-134702	Sequence 134702,

ALIGNMENTS

RESULT 1
US-10-066-965A-4
; Sequence 4, Application US/10066965A
; Publication No. US20030143626A1
; GENERAL INFORMATION:
; APPLICANT: COLAS, PIERRE
; APPLICANT: BRENT, ROGER
; APPLICANT: COHEN, BARAK A.
; TITLE OF INVENTION: TARGETED MODIFICATION OF INTRACELLULAR COMPOUNDS
; FILE REFERENCE: EGYP 3.0-015
; CURRENT APPLICATION NUMBER: US/10/066,965A
; CURRENT FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-066-965A-4

Query Match 100.0%; Score 20; DB 14; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e-14;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAPMWLRCVCQMLETKFL 20
||||||||||||||||||||
Db 1 PRGAPMWLRCVCQMLETKFL 20

RESULT 2
US-10-066-965A-23
; Sequence 23, Application US/10066965A
; Publication No. US20030143626A1
; GENERAL INFORMATION:
; APPLICANT: COLAS, PIERRE
; APPLICANT: BRENT, ROGER
; APPLICANT: COHEN, BARAK A.
; TITLE OF INVENTION: TARGETED MODIFICATION OF INTRACELLULAR COMPOUNDS
; FILE REFERENCE: EGYP 3.0-015
; CURRENT APPLICATION NUMBER: US/10/066,965A
; CURRENT FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 23
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-066-965A-23

Query Match 100.0%; Score 20; DB 14; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.1e-14;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAPMWLRCVCQMLETKFL 20
||||||||||||||||||||
Db 1 PRGAPMWLRCVCQMLETKFL 20

RESULT 3
US-10-066-965A-3
; Sequence 3, Application US/10066965A
; Publication No. US20030143626A1
; GENERAL INFORMATION:
; APPLICANT: COLAS, PIERRE
; APPLICANT: BRENT, ROGER
; APPLICANT: COHEN, BARAK A.
; TITLE OF INVENTION: TARGETED MODIFICATION OF INTRACELLULAR COMPOUNDS
; FILE REFERENCE: EGYP 3.0-015
; CURRENT APPLICATION NUMBER: US/10/066,965A
; CURRENT FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-066-965A-3

Query Match 35.0%; Score 7; DB 14; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAPMW 7
|||||||
Db 1 PRGAPMW 7

RESULT 4
US-10-066-965A-22
; Sequence 22, Application US/10066965A
; Publication No. US20030143626A1
; GENERAL INFORMATION:
; APPLICANT: COLAS, PIERRE
; APPLICANT: BRENT, ROGER
; APPLICANT: COHEN, BARAK A.
; TITLE OF INVENTION: TARGETED MODIFICATION OF INTRACELLULAR COMPOUNDS
; FILE REFERENCE: EGYP 3.0-015
; CURRENT APPLICATION NUMBER: US/10/066,965A
; CURRENT FILING DATE: 2002-12-09
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 22
; LENGTH: 20
; TYPE: PRT
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
; OTHER INFORMATION: peptide
US-10-066-965A-22

Query Match 35.0%; Score 7; DB 14; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.2;
Matches 7; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAPMW 7
|||||||
Db 1 PRGAPMW 7

RESULT 5
US-10-437-963-181184
; Sequence 181184, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 181184
; LENGTH: 81
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_78482C.1.pep
US-10-437-963-181184

Query Match 30.0%; Score 6; DB 16; Length 81;
Best Local Similarity 100.0%; Pred. No. 41;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 15 LETKFL 20
||||||
Db 18 LETKFL 23

RESULT 6
US-10-369-493-17206
; Sequence 17206, Application US/10369493
; Publication No. US20030233675A1
; GENERAL INFORMATION:
; APPLICANT: Cao, Yongwei
; APPLICANT: Hinkle, Gregory J.
; APPLICANT: Slater, Steven C.
; APPLICANT: Goldman, Barry S.
; APPLICANT: Chen, Xianfeng
; TITLE OF INVENTION: EXPRESSION OF MICROBIAL PROTEINS IN PLANTS FOR PRODUCTION OF
; TITLE OF INVENTION: PLANTS WITH IMPROVED PROPERTIES
; FILE REFERENCE: 38-10(52052)B
; CURRENT APPLICATION NUMBER: US/10/369,493
; CURRENT FILING DATE: 2003-02-28
; PRIOR APPLICATION NUMBER: US 60/360,039
; PRIOR FILING DATE: 2002-02-21
; NUMBER OF SEQ ID NOS: 47374
; SEQ ID NO 17206
; LENGTH: 278
; TYPE: PRT
; ORGANISM: Bacillus halodurans
US-10-369-493-17206

Query Match 30.0%; Score 6; DB 14; Length 278;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 15 LETKFL 20
||||||
Db 225 LETKFL 230

RESULT 7
US-10-264-049-3133
; Sequence 3133, Application US/10264049
; Publication No. US20040005579A1
; GENERAL INFORMATION:
; APPLICANT: Birse et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PA133P1
; CURRENT APPLICATION NUMBER: US/10/264,049
; CURRENT FILING DATE: 2002-10-04
; PRIOR APPLICATION NUMBER: PCT/US01/18569
; PRIOR FILING DATE: 2001-06-07
; PRIOR APPLICATION NUMBER: US 60/209,467
; PRIOR FILING DATE: 2000-06-07
; NUMBER OF SEQ ID NOS: 4360
; SOFTWARE: PatentIn Ver. 3.1
; SEQ ID NO 3133
; LENGTH: 285
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-264-049-3133

Query Match 30.0%; Score 6; DB 15; Length 285;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 15 LETKFL 20
||||||
Db 178 LETKFL 183

RESULT 8
US-10-094-749-3019
; Sequence 3019, Application US/10094749
; Publication No. US20030219741A1
; GENERAL INFORMATION:
; APPLICANT: ISOGAI, TAKAO
; APPLICANT: SUGIYAMA, TOMOYASU
; APPLICANT: OTSUKI, TETSUJI
; APPLICANT: WAKAMATSU, AI
; APPLICANT: SATO, HIROYUKI
; APPLICANT: ISHII, SHIZUKO
; APPLICANT: YAMAMOTO, JUN-ICHI
; APPLICANT: ISONO, YUUKO
; APPLICANT: HIO, YURI
; APPLICANT: OTSUKA, KAORU
; APPLICANT: NAGAI, KEIICHI
; APPLICANT: IRIE, RYOTARO
; APPLICANT: TAMECHIKA, ICHIRO
; APPLICANT: SEKI, NAOHIKO
; APPLICANT: YOSHIKAWA, TSUTOMU
; APPLICANT: OTSUKA, MOTOYUKI
; APPLICANT: NAGAHARI, KENJI
; APPLICANT: MASUHO, YASUHIKO
; TITLE OF INVENTION: NOVEL FULL-LENGTH cDNA
; FILE REFERENCE: 084335/0160
; CURRENT APPLICATION NUMBER: US/10/094,749
; CURRENT FILING DATE: 2002-03-12
; PRIOR APPLICATION NUMBER: 60/350,435
; PRIOR FILING DATE: 2002-01-24
; PRIOR APPLICATION NUMBER: JP 2001-328381
; PRIOR FILING DATE: 2001-09-14
; NUMBER OF SEQ ID NOS: 3381
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3019
; LENGTH: 395
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-094-749-3019

Query Match 30.0%; Score 6; DB 14; Length 395;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18
||||||

```
Db        365 QMLETK 370


RESULT 9
US-10-408-765A-2509
; Sequence 2509, Application US/10408765A
; Publication No. US20040101874A1
; GENERAL INFORMATION:
;  APPLICANT: Ghosh, Soumitra S.
;  APPLICANT:  Fahy, Eoin D.
;  APPLICANT:  Zhang, Bing
;  APPLICANT:  Gibson, Bradford W.
;  APPLICANT:  Taylor, Steven W.
;  APPLICANT:  Glenn, Gary M.
;  APPLICANT:  Warnock, Dale E.
;  TITLE OF INVENTION: TARGETS FOR THERAPEUTIC INTERVENTION
;  TITLE OF INVENTION:  IDENTIFIED IN THE MITOCHONDRIAL PROTEOME
;  FILE REFERENCE: 660088.465
;  CURRENT APPLICATION NUMBER: US/10/408,765A
;  CURRENT FILING DATE:  2003-04-04
;  NUMBER OF SEQ ID NOS: 3077
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2509
;   LENGTH: 395
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-408-765A-2509

  Query Match             30.0%;  Score 6;  DB 16;  Length 395;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db        365 QMLETK 370


RESULT 10
US-10-282-122A-76949
; Sequence 76949, Application US/10282122A
; Publication No. US20040029129A1
; GENERAL INFORMATION:
;  APPLICANT: Wang, Liangsu
;  APPLICANT:  Zamudio, Carlos
;  APPLICANT:  Malone, Cheryl
;  APPLICANT:  Haselbeck, Robert
;  APPLICANT:  Ohlsen, Kari
;  APPLICANT:  Zyskind, Judith
;  APPLICANT:  Wall, Daniel
;  APPLICANT:  Trawick, John
;  APPLICANT:  Carr, Grant
;  APPLICANT:  Yamamoto, Robert
;  APPLICANT:  Forsyth, R.
;  APPLICANT:  Xu, H.
;  TITLE OF INVENTION: Identification of Essential Genes in Microorganisms
;  FILE REFERENCE: ELITRA.034A
;  CURRENT APPLICATION NUMBER: US/10/282,122A
;  CURRENT FILING DATE:  2003-02-20
;  PRIOR APPLICATION NUMBER: 60/191,078
;  PRIOR FILING DATE: 2000-03-21
;  PRIOR APPLICATION NUMBER: 60/206,848
;  PRIOR FILING DATE: 2000-05-23
;  PRIOR APPLICATION NUMBER: 60/207,727
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: 60/230,335
;  PRIOR FILING DATE: 2000-09-06
;  PRIOR APPLICATION NUMBER: 60/230,347
;  PRIOR FILING DATE: 2000-09-09
;  PRIOR APPLICATION NUMBER: 60/242,578
;  PRIOR FILING DATE: 2000-10-23
;  PRIOR APPLICATION NUMBER: 60/253,625
;  PRIOR FILING DATE: 2000-11-27
;  PRIOR APPLICATION NUMBER: 60/257,931
;  PRIOR FILING DATE: 2000-12-22
;  PRIOR APPLICATION NUMBER: 60/267,636
;  PRIOR FILING DATE: 2001-02-09
;  PRIOR APPLICATION NUMBER: 60/269,308
;  PRIOR FILING DATE: 2001-02-16
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 78614
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 76949
;   LENGTH: 434
;   TYPE: PRT
;   ORGANISM: Vibrio cholerae
US-10-282-122A-76949

  Query Match             30.0%;  Score 6;  DB 15;  Length 434;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          4 APMWLR 9
              ||||||
Db        177 APMWLR 182


RESULT 11
US-10-262-839-180
; Sequence 180, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, John,
;  APPLICANT:  Anderson, David W.,
;  APPLICANT:  Boldog, Ferenc,
;  APPLICANT:  Burgess, Catherine,
;  APPLICANT:  Catterton, Elina,
;  APPLICANT:  Edinger, Shlomit,
;  APPLICANT:  Ellerman, Karen,
;  APPLICANT:  Gerlach, Valerie,
;  APPLICANT:  Gorman, Linda,
;  APPLICANT:  Guo, Xiaojia,
;  APPLICANT:  Ji, Weizhen,
;  APPLICANT:  Kekuda, Ramesh,
;  APPLICANT:  Leach, Martin,
;  APPLICANT:  Li, Li,
;  APPLICANT:  Miller, Charles,
;  APPLICANT:  Patturajan, Meera,
;  APPLICANT:  Reiger, Daniel,
;  APPLICANT:  Rothenberg, Mark,
;  APPLICANT:  Shimkets, Richard,
;  APPLICANT:  Smithson, Glennda,
;  APPLICANT:  Spytek, Kimberly,
;  APPLICANT:  Taupier, Raymond, jr.,
;  APPLICANT:  Vernet, Corine,
;  APPLICANT:  Voss, Edward,
;  APPLICANT:  Zerhusen, Brian,
;  APPLICANT:  Zhong, Mei
;  TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
;  FILE REFERENCE: 21402-462A
;  CURRENT APPLICATION NUMBER: US/10/262,839
;  CURRENT FILING DATE:  2002-10-01
;  PRIOR APPLICATION NUMBER: 60/326,483
;  PRIOR FILING DATE: 2001-10-02
;  PRIOR APPLICATION NUMBER: 60/327,917
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,029
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,056
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/381,101
;  PRIOR FILING DATE: 2002-05-16
;  PRIOR APPLICATION NUMBER: 60/371,972
;  PRIOR FILING DATE: 2002-04-12
;  PRIOR APPLICATION NUMBER: 60/327,342
;  PRIOR FILING DATE: 2001-10-05
;  PRIOR APPLICATION NUMBER: 60/328,044
```

```
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,849
;  PRIOR FILING DATE: 2001-10-12
;  PRIOR APPLICATION NUMBER: 60/374,738
;  PRIOR FILING DATE: 2002-04-23
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 367
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 180
;   LENGTH: 571
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-262-839-180

  Query Match             30.0%;  Score 6;  DB 15;  Length 571;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          13 QMLETK 18
               ||||||
Db         545 QMLETK 550


RESULT 12
US-10-262-839-196
; Sequence 196, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, John,
;  APPLICANT:  Anderson, David W.,
;  APPLICANT:  Boldog, Ferenc,
;  APPLICANT:  Burgess, Catherine,
;  APPLICANT:  Catterton, Elina,
;  APPLICANT:  Edinger, Shlomit,
;  APPLICANT:  Ellerman, Karen,
;  APPLICANT:  Gerlach, Valerie,
;  APPLICANT:  Gorman, Linda,
;  APPLICANT:  Guo, Xiaojia,
;  APPLICANT:  Ji, Weizhen,
;  APPLICANT:  Kekuda, Ramesh,
;  APPLICANT:  Leach, Martin,
;  APPLICANT:  Li, Li,
;  APPLICANT:  Miller, Charles,
;  APPLICANT:  Patturajan, Meera,
;  APPLICANT:  Reiger, Daniel,
;  APPLICANT:  Rothenberg, Mark,
;  APPLICANT:  Shimkets, Richard,
;  APPLICANT:  Smithson, Glennda,
;  APPLICANT:  Spytek, Kimberly,
;  APPLICANT:  Taupier, Raymond, jr.,
;  APPLICANT:  Vernet, Corine,
;  APPLICANT:  Voss, Edward,
;  APPLICANT:  Zerhusen, Brian,
;  APPLICANT:  Zhong, Mei
;  TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
;  FILE REFERENCE: 21402-462A
;  CURRENT APPLICATION NUMBER: US/10/262,839
;  CURRENT FILING DATE:  2002-10-01
;  PRIOR APPLICATION NUMBER: 60/326,483
;  PRIOR FILING DATE: 2001-10-02
;  PRIOR APPLICATION NUMBER: 60/327,917
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,029
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,056
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/381,101
;  PRIOR FILING DATE: 2002-05-16
;  PRIOR APPLICATION NUMBER: 60/371,972
;  PRIOR FILING DATE: 2002-04-12
;  PRIOR APPLICATION NUMBER: 60/327,342
;  PRIOR FILING DATE: 2001-10-05
;  PRIOR APPLICATION NUMBER: 60/328,044
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,849
;  PRIOR FILING DATE: 2001-10-12
;  PRIOR APPLICATION NUMBER: 60/374,738
;  PRIOR FILING DATE: 2002-04-23
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 367
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 196
;   LENGTH: 577
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-262-839-196

  Query Match             30.0%;  Score 6;  DB 15;  Length 577;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          13 QMLETK 18
               ||||||
Db         546 QMLETK 551


RESULT 13
US-10-408-765A-2869
; Sequence 2869, Application US/10408765A
; Publication No. US20040101874A1
; GENERAL INFORMATION:
;  APPLICANT: Ghosh, Soumitra S.
;  APPLICANT:  Fahy, Eoin D.
;  APPLICANT:  Zhang, Bing
;  APPLICANT:  Gibson, Bradford W.
;  APPLICANT:  Taylor, Steven W.
;  APPLICANT:  Glenn, Gary M.
;  APPLICANT:  Warnock, Dale E.
;  TITLE OF INVENTION: TARGETS FOR THERAPEUTIC INTERVENTION
;  TITLE OF INVENTION:  IDENTIFIED IN THE MITOCHONDRIAL PROTEOME
;  FILE REFERENCE: 660088.465
;  CURRENT APPLICATION NUMBER: US/10/408,765A
;  CURRENT FILING DATE:  2003-04-04
;  NUMBER OF SEQ ID NOS: 3077
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2869
;   LENGTH: 731
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-408-765A-2869

  Query Match             30.0%;  Score 6;  DB 16;  Length 731;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           1 PRGAPM 6
               ||||||
Db         542 PRGAPM 547


RESULT 14
US-10-262-839-184
; Sequence 184, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, John,
;  APPLICANT:  Anderson, David W.,
;  APPLICANT:  Boldog, Ferenc,
;  APPLICANT:  Burgess, Catherine,
;  APPLICANT:  Catterton, Elina,
;  APPLICANT:  Edinger, Shlomit,
;  APPLICANT:  Ellerman, Karen,
;  APPLICANT:  Gerlach, Valerie,
;  APPLICANT:  Gorman, Linda,
;  APPLICANT:  Guo, Xiaojia,
;  APPLICANT:  Ji, Weizhen,
```

```
;  APPLICANT:  Kekuda, Ramesh,
;  APPLICANT:  Leach, Martin,
;  APPLICANT:  Li, Li,
;  APPLICANT:  Miller, Charles,
;  APPLICANT:  Patturajan, Meera,
;  APPLICANT:  Reiger, Daniel,
;  APPLICANT:  Rothenberg, Mark,
;  APPLICANT:  Shimkets, Richard,
;  APPLICANT:  Smithson, Glennda,
;  APPLICANT:  Spytek, Kimberly,
;  APPLICANT:  Taupier, Raymond, jr.,
;  APPLICANT:  Vernet, Corine,
;  APPLICANT:  Voss, Edward,
;  APPLICANT:  Zerhusen, Brian,
;  APPLICANT:  Zhong, Mei
;  TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
;  FILE REFERENCE: 21402-462A
;  CURRENT APPLICATION NUMBER: US/10/262,839
;  CURRENT FILING DATE:  2002-10-01
;  PRIOR APPLICATION NUMBER: 60/326,483
;  PRIOR FILING DATE: 2001-10-02
;  PRIOR APPLICATION NUMBER: 60/327,917
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,029
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,056
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/381,101
;  PRIOR FILING DATE: 2002-05-16
;  PRIOR APPLICATION NUMBER: 60/371,972
;  PRIOR FILING DATE: 2002-04-12
;  PRIOR APPLICATION NUMBER: 60/327,342
;  PRIOR FILING DATE: 2001-10-05
;  PRIOR APPLICATION NUMBER: 60/328,044
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,849
;  PRIOR FILING DATE: 2001-10-12
;  PRIOR APPLICATION NUMBER: 60/374,738
;  PRIOR FILING DATE: 2002-04-23
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 367
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 184
;   LENGTH: 1490
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-262-839-184

  Query Match             30.0%;  Score 6;  DB 15;  Length 1490;
  Best Local Similarity   100.0%;  Pred. No. 3.9e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db       1393 QMLETK 1398


RESULT 15
US-10-262-839-182
; Sequence 182, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, John,
;  APPLICANT:  Anderson, David W.,
;  APPLICANT:  Boldog, Ferenc,
;  APPLICANT:  Burgess, Catherine,
;  APPLICANT:  Catterton, Elina,
;  APPLICANT:  Edinger, Shlomit,
;  APPLICANT:  Ellerman, Karen,
;  APPLICANT:  Gerlach, Valerie,
;  APPLICANT:  Gorman, Linda,
;  APPLICANT:  Guo, Xiaojia,
;  APPLICANT:  Ji, Weizhen,
```

```
;  APPLICANT:  Kekuda, Ramesh,
;  APPLICANT:  Leach, Martin,
;  APPLICANT:  Li, Li,
;  APPLICANT:  Miller, Charles,
;  APPLICANT:  Patturajan, Meera,
;  APPLICANT:  Reiger, Daniel,
;  APPLICANT:  Rothenberg, Mark,
;  APPLICANT:  Shimkets, Richard,
;  APPLICANT:  Smithson, Glennda,
;  APPLICANT:  Spytek, Kimberly,
;  APPLICANT:  Taupier, Raymond, jr.,
;  APPLICANT:  Vernet, Corine,
;  APPLICANT:  Voss, Edward,
;  APPLICANT:  Zerhusen, Brian,
;  APPLICANT:  Zhong, Mei
;  TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
;  FILE REFERENCE: 21402-462A
;  CURRENT APPLICATION NUMBER: US/10/262,839
;  CURRENT FILING DATE:  2002-10-01
;  PRIOR APPLICATION NUMBER: 60/326,483
;  PRIOR FILING DATE: 2001-10-02
;  PRIOR APPLICATION NUMBER: 60/327,917
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,029
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,056
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/381,101
;  PRIOR FILING DATE: 2002-05-16
;  PRIOR APPLICATION NUMBER: 60/371,972
;  PRIOR FILING DATE: 2002-04-12
;  PRIOR APPLICATION NUMBER: 60/327,342
;  PRIOR FILING DATE: 2001-10-05
;  PRIOR APPLICATION NUMBER: 60/328,044
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,849
;  PRIOR FILING DATE: 2001-10-12
;  PRIOR APPLICATION NUMBER: 60/374,738
;  PRIOR FILING DATE: 2002-04-23
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 367
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 182
;   LENGTH: 1545
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-262-839-182

  Query Match             30.0%;  Score 6;  DB 15;  Length 1545;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db       1393 QMLETK 1398


RESULT 16
US-10-262-839-186
; Sequence 186, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, John,
;  APPLICANT:  Anderson, David W.,
;  APPLICANT:  Boldog, Ferenc,
;  APPLICANT:  Burgess, Catherine,
;  APPLICANT:  Catterton, Elina,
;  APPLICANT:  Edinger, Shlomit,
;  APPLICANT:  Ellerman, Karen,
;  APPLICANT:  Gerlach, Valerie,
;  APPLICANT:  Gorman, Linda,
;  APPLICANT:  Guo, Xiaojia,
;  APPLICANT:  Ji, Weizhen,
```

; APPLICANT: Kekuda, Ramesh,
; APPLICANT: Leach, Martin,
; APPLICANT: Li, Li,
; APPLICANT: Miller, Charles,
; APPLICANT: Patturajan, Meera,
; APPLICANT: Reiger, Daniel,
; APPLICANT: Rothenberg, Mark,
; APPLICANT: Shimkets, Richard,
; APPLICANT: Smithson, Glennda,
; APPLICANT: Spytek, Kimberly,
; APPLICANT: Taupier, Raymond, jr.,
; APPLICANT: Vernet, Corine,
; APPLICANT: Voss, Edward,
; APPLICANT: Zerhusen, Brian,
; APPLICANT: Zhong, Mei
; TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
; FILE REFERENCE: 21402-462A
; CURRENT APPLICATION NUMBER: US/10/262,839
; CURRENT FILING DATE: 2002-10-01
; PRIOR APPLICATION NUMBER: 60/326,483
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: 60/327,917
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,029
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,056
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/381,101
; PRIOR FILING DATE: 2002-05-16
; PRIOR APPLICATION NUMBER: 60/371,972
; PRIOR FILING DATE: 2002-04-12
; PRIOR APPLICATION NUMBER: 60/327,342
; PRIOR FILING DATE: 2001-10-05
; PRIOR APPLICATION NUMBER: 60/328,044
; PRIOR FILING DATE: 2001-10-09
; PRIOR APPLICATION NUMBER: 60/328,849
; PRIOR FILING DATE: 2001-10-12
; PRIOR APPLICATION NUMBER: 60/374,738
; PRIOR FILING DATE: 2002-04-23
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 367
; SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 186
; LENGTH: 1549
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-262-839-186

Query Match 30.0%; Score 6; DB 15; Length 1549;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18
||||||
Db 1395 QMLETK 1400

RESULT 17
US-10-263-929-117
; Sequence 117, Application US/10263929
; Publication No. US20040067535A1
; GENERAL INFORMATION:
; APPLICANT: Kim, Jaeseob
; APPLICANT: Galant, Ron
; TITLE OF INVENTION: Alzheimer's Disease Linked Genes
; FILE REFERENCE: LSD-07417
; CURRENT APPLICATION NUMBER: US/10/263,929
; CURRENT FILING DATE: 2002-10-03
; NUMBER OF SEQ ID NOS: 213
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 117
; LENGTH: 1568
; TYPE: PRT
; ORGANISM: Mus musculus
US-10-263-929-117

Query Match 30.0%; Score 6; DB 15; Length 1568;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVCQ 13
||||||
Db 394 LRCVCQ 399

RESULT 18
US-10-000-512-2
; Sequence 2, Application US/10000512
; Publication No. US20020164699A1
; GENERAL INFORMATION:
; APPLICANT: Shimkets, Richard A
; APPLICANT: Fernandes, Elma
; TITLE OF INVENTION: POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME
; FILE REFERENCE: 15966-556
; CURRENT APPLICATION NUMBER: US/10/000,512
; CURRENT FILING DATE: 2001-10-23
; PRIOR APPLICATION NUMBER: 09/619,252
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 60/167,785
; PRIOR FILING DATE: 1999-11-29
; NUMBER OF SEQ ID NOS: 36
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1588
; TYPE: PRT
; ORGANISM: Homo sapiens
US-10-000-512-2

Query Match 30.0%; Score 6; DB 13; Length 1588;
Best Local Similarity 100.0%; Pred. No. 4.1e+02;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLETK 18
||||||
Db 1393 QMLETK 1398

RESULT 19
US-10-074-566-2
; Sequence 2, Application US/10074566
; Publication No. US20030207348A1
; GENERAL INFORMATION:
; APPLICANT: Shimkets, Richard A.
; APPLICANT: Fernandes, Elma R.
; APPLICANT: Li, Li
; APPLICANT: Gorman, Linda
; APPLICANT: Gusev, Vladimir Y.
; APPLICANT: Padigaru, Muralidhara
; APPLICANT: Patturajan, Meera
; APPLICANT: Shenoy, Suresh G.
; APPLICANT: Spytek, Kimberly A.
; TITLE OF INVENTION: Polypeptides and Polynucleotides Encoding Same
; FILE REFERENCE: 15966-556 CIP1
; CURRENT APPLICATION NUMBER: US/10/074,566
; CURRENT FILING DATE: 2002-02-13
; PRIOR APPLICATION NUMBER: 09/619,252
; PRIOR FILING DATE: 2000-07-19
; PRIOR APPLICATION NUMBER: 60/144,722
; PRIOR FILING DATE: 1999-07-20
; PRIOR APPLICATION NUMBER: 60/167,785
; PRIOR FILING DATE: 1999-11-29
; PRIOR APPLICATION NUMBER: 60/276,994
; PRIOR FILING DATE: 2001-03-19
; PRIOR APPLICATION NUMBER: 60/280,898
; PRIOR FILING DATE: 2001-04-02
; PRIOR APPLICATION NUMBER: 60/332,241

```
;  PRIOR FILING DATE: 2001-11-14
;  PRIOR APPLICATION NUMBER: 60/288,062
;  PRIOR FILING DATE: 2001-05-02
;  PRIOR APPLICATION NUMBER: 60/291,766
;  PRIOR FILING DATE: 2001-05-17
;  PRIOR APPLICATION NUMBER: 60/314,007
;  PRIOR FILING DATE: 2001-08-21
;  NUMBER OF SEQ ID NOS: 132
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
;   LENGTH: 1588
;   TYPE: PRT
;   ORGANISM: human
US-10-074-566-2

  Query Match           30.0%;  Score 6;  DB 14;  Length 1588;
  Best Local Similarity  100.0%;  Pred. No. 4.1e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db       1393 QMLETK 1398


RESULT 20
US-10-074-566-41
; Sequence 41, Application US/10074566
; Publication No. US20030207348A1
; GENERAL INFORMATION:
;  APPLICANT: Shimkets, Richard A.
;  APPLICANT:  Fernandes, Elma R.
;  APPLICANT:  Li, Li
;  APPLICANT:  Gorman, Linda
;  APPLICANT:  Gusev, Vladimir Y.
;  APPLICANT:  Padigaru, Muralidhara
;  APPLICANT:  Patturajan, Meera
;  APPLICANT:  Shenoy, Suresh G.
;  APPLICANT:  Spytek, Kimberly A.
;  TITLE OF INVENTION: Polypeptides and Polynucleotides Encoding Same
;  FILE REFERENCE: 15966-556 CIP1
;  CURRENT APPLICATION NUMBER: US/10/074,566
;  CURRENT FILING DATE:  2002-02-13
;  PRIOR APPLICATION NUMBER: 09/619,252
;  PRIOR FILING DATE: 2000-07-19
;  PRIOR APPLICATION NUMBER: 60/144,722
;  PRIOR FILING DATE: 1999-07-20
;  PRIOR APPLICATION NUMBER: 60/167,785
;  PRIOR FILING DATE: 1999-11-29
;  PRIOR APPLICATION NUMBER: 60/276,994
;  PRIOR FILING DATE: 2001-03-19
;  PRIOR APPLICATION NUMBER: 60/280,898
;  PRIOR FILING DATE: 2001-04-02
;  PRIOR APPLICATION NUMBER: 60/332,241
;  PRIOR FILING DATE: 2001-11-14
;  PRIOR APPLICATION NUMBER: 60/288,062
;  PRIOR FILING DATE: 2001-05-02
;  PRIOR APPLICATION NUMBER: 60/291,766
;  PRIOR FILING DATE: 2001-05-17
;  PRIOR APPLICATION NUMBER: 60/314,007
;  PRIOR FILING DATE: 2001-08-21
;  NUMBER OF SEQ ID NOS: 132
;  SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 41
;   LENGTH: 1588
;   TYPE: PRT
;   ORGANISM: human
US-10-074-566-41

  Query Match           30.0%;  Score 6;  DB 14;  Length 1588;
  Best Local Similarity  100.0%;  Pred. No. 4.1e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
              ||||||
Db       1393 QMLETK 1398


RESULT 21
US-10-262-839-176
; Sequence 176, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, John,
;  APPLICANT:  Anderson, David W.,
;  APPLICANT:  Boldog, Ferenc,
;  APPLICANT:  Burgess, Catherine,
;  APPLICANT:  Catterton, Elina,
;  APPLICANT:  Edinger, Shlomit,
;  APPLICANT:  Ellerman, Karen,
;  APPLICANT:  Gerlach, Valerie,
;  APPLICANT:  Gorman, Linda,
;  APPLICANT:  Guo, Xiaojia,
;  APPLICANT:  Ji, Weizhen,
;  APPLICANT:  Kekuda, Ramesh,
;  APPLICANT:  Leach, Martin,
;  APPLICANT:  Li, Li,
;  APPLICANT:  Miller, Charles,
;  APPLICANT:  Patturajan, Meera,
;  APPLICANT:  Reiger, Daniel,
;  APPLICANT:  Rothenberg, Mark,
;  APPLICANT:  Shimkets, Richard,
;  APPLICANT:  Smithson, Glennda,
;  APPLICANT:  Spytek, Kimberly,
;  APPLICANT:  Taupier, Raymond, jr.,
;  APPLICANT:  Vernet, Corine,
;  APPLICANT:  Voss, Edward,
;  APPLICANT:  Zerhusen, Brian,
;  APPLICANT:  Zhong, Mei
;  TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHODS
;  FILE REFERENCE: 21402-462A
;  CURRENT APPLICATION NUMBER: US/10/262,839
;  CURRENT FILING DATE:  2002-10-01
;  PRIOR APPLICATION NUMBER: 60/326,483
;  PRIOR FILING DATE: 2001-10-02
;  PRIOR APPLICATION NUMBER: 60/327,917
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,029
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,056
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/381,101
;  PRIOR FILING DATE: 2002-05-16
;  PRIOR APPLICATION NUMBER: 60/371,972
;  PRIOR FILING DATE: 2002-04-12
;  PRIOR APPLICATION NUMBER: 60/327,342
;  PRIOR FILING DATE: 2001-10-05
;  PRIOR APPLICATION NUMBER: 60/328,044
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,849
;  PRIOR FILING DATE: 2001-10-12
;  PRIOR APPLICATION NUMBER: 60/374,738
;  PRIOR FILING DATE: 2002-04-23
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 367
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 176
;   LENGTH: 1588
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-262-839-176

  Query Match           30.0%;  Score 6;  DB 15;  Length 1588;
  Best Local Similarity  100.0%;  Pred. No. 4.1e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
```

```
                 ||||||
Db       1393 QMLETK 1398


RESULT 22
US-10-262-839-188
; Sequence 188, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, John,
;  APPLICANT:  Anderson, David W.,
;  APPLICANT:  Boldog, Ferenc,
;  APPLICANT:  Burgess, Catherine,
;  APPLICANT:  Catterton, Elina,
;  APPLICANT:  Edinger, Shlomit,
;  APPLICANT:  Ellerman, Karen,
;  APPLICANT:  Gerlach, Valerie,
;  APPLICANT:  Gorman, Linda,
;  APPLICANT:  Guo, Xiaojia,
;  APPLICANT:  Ji, Weizhen,
;  APPLICANT:  Kekuda, Ramesh,
;  APPLICANT:  Leach, Martin,
;  APPLICANT:  Li, Li,
;  APPLICANT:  Miller, Charles,
;  APPLICANT:  Patturajan, Meera,
;  APPLICANT:  Reiger, Daniel,
;  APPLICANT:  Rothenberg, Mark,
;  APPLICANT:  Shimkets, Richard,
;  APPLICANT:  Smithson, Glennda,
;  APPLICANT:  Spytek, Kimberly,
;  APPLICANT:  Taupier, Raymond, jr.,
;  APPLICANT:  Vernet, Corine,
;  APPLICANT:  Voss, Edward,
;  APPLICANT:  Zerhusen, Brian,
;  APPLICANT:  Zhong, Mei
;  TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
;  FILE REFERENCE: 21402-462A
;  CURRENT APPLICATION NUMBER: US/10/262,839
;  CURRENT FILING DATE:  2002-10-01
;  PRIOR APPLICATION NUMBER: 60/326,483
;  PRIOR FILING DATE: 2001-10-02
;  PRIOR APPLICATION NUMBER: 60/327,917
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,029
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,056
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/381,101
;  PRIOR FILING DATE: 2002-05-16
;  PRIOR APPLICATION NUMBER: 60/371,972
;  PRIOR FILING DATE: 2002-04-12
;  PRIOR APPLICATION NUMBER: 60/327,342
;  PRIOR FILING DATE: 2001-10-05
;  PRIOR APPLICATION NUMBER: 60/328,044
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,849
;  PRIOR FILING DATE: 2001-10-12
;  PRIOR APPLICATION NUMBER: 60/374,738
;  PRIOR FILING DATE: 2002-04-23
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 367
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 188
;   LENGTH: 1588
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-262-839-188

  Query Match            30.0%;  Score 6;  DB 15;  Length 1588;
  Best Local Similarity  100.0%;  Pred. No. 4.1e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
```

```
                 ||||||
Db       1393 QMLETK 1398


RESULT 23
US-10-262-839-194
; Sequence 194, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, John,
;  APPLICANT:  Anderson, David W.,
;  APPLICANT:  Boldog, Ferenc,
;  APPLICANT:  Burgess, Catherine,
;  APPLICANT:  Catterton, Elina,
;  APPLICANT:  Edinger, Shlomit,
;  APPLICANT:  Ellerman, Karen,
;  APPLICANT:  Gerlach, Valerie,
;  APPLICANT:  Gorman, Linda,
;  APPLICANT:  Guo, Xiaojia,
;  APPLICANT:  Ji, Weizhen,
;  APPLICANT:  Kekuda, Ramesh,
;  APPLICANT:  Leach, Martin,
;  APPLICANT:  Li, Li,
;  APPLICANT:  Miller, Charles,
;  APPLICANT:  Patturajan, Meera,
;  APPLICANT:  Reiger, Daniel,
;  APPLICANT:  Rothenberg, Mark,
;  APPLICANT:  Shimkets, Richard,
;  APPLICANT:  Smithson, Glennda,
;  APPLICANT:  Spytek, Kimberly,
;  APPLICANT:  Taupier, Raymond, jr.,
;  APPLICANT:  Vernet, Corine,
;  APPLICANT:  Voss, Edward,
;  APPLICANT:  Zerhusen, Brian,
;  APPLICANT:  Zhong, Mei
;  TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHODS
;  FILE REFERENCE: 21402-462A
;  CURRENT APPLICATION NUMBER: US/10/262,839
;  CURRENT FILING DATE:  2002-10-01
;  PRIOR APPLICATION NUMBER: 60/326,483
;  PRIOR FILING DATE: 2001-10-02
;  PRIOR APPLICATION NUMBER: 60/327,917
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,029
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,056
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/381,101
;  PRIOR FILING DATE: 2002-05-16
;  PRIOR APPLICATION NUMBER: 60/371,972
;  PRIOR FILING DATE: 2002-04-12
;  PRIOR APPLICATION NUMBER: 60/327,342
;  PRIOR FILING DATE: 2001-10-05
;  PRIOR APPLICATION NUMBER: 60/328,044
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,849
;  PRIOR FILING DATE: 2001-10-12
;  PRIOR APPLICATION NUMBER: 60/374,738
;  PRIOR FILING DATE: 2002-04-23
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 367
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 194
;   LENGTH: 1588
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-262-839-194

  Query Match            30.0%;  Score 6;  DB 15;  Length 1588;
  Best Local Similarity  100.0%;  Pred. No. 4.1e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
```

```
              ||||||
Db       1393 QMLETK 1398


RESULT 24
US-10-262-839-200
; Sequence 200, Application US/10262839
; Publication No. US20040038877A1
; GENERAL INFORMATION:
;  APPLICANT: Alsobrook, John,
;  APPLICANT:  Anderson, David W.,
;  APPLICANT:  Boldog, Ferenc,
;  APPLICANT:  Burgess, Catherine,
;  APPLICANT:  Catterton, Elina,
;  APPLICANT:  Edinger, Shlomit,
;  APPLICANT:  Ellerman, Karen,
;  APPLICANT:  Gerlach, Valerie,
;  APPLICANT:  Gorman, Linda,
;  APPLICANT:  Guo, Xiaojia,
;  APPLICANT:  Ji, Weizhen,
;  APPLICANT:  Kekuda, Ramesh,
;  APPLICANT:  Leach, Martin,
;  APPLICANT:  Li, Li,
;  APPLICANT:  Miller, Charles,
;  APPLICANT:  Patturajan, Meera,
;  APPLICANT:  Reiger, Daniel,
;  APPLICANT:  Rothenberg, Mark,
;  APPLICANT:  Shimkets, Richard,
;  APPLICANT:  Smithson, Glennda,
;  APPLICANT:  Spytek, Kimberly,
;  APPLICANT:  Taupier, Raymond, jr.,
;  APPLICANT:  Vernet, Corine,
;  APPLICANT:  Voss, Edward,
;  APPLICANT:  Zerhusen, Brian,
;  APPLICANT:  Zhong, Mei
;  TITLE OF INVENTION: THERAPEUTIC POLYPEPTIDES, NUCLEIC ACIDS ENCODING SAME, AND METHOD
;  FILE REFERENCE: 21402-462A
;  CURRENT APPLICATION NUMBER: US/10/262,839
;  CURRENT FILING DATE:  2002-10-01
;  PRIOR APPLICATION NUMBER: 60/326,483
;  PRIOR FILING DATE: 2001-10-02
;  PRIOR APPLICATION NUMBER: 60/327,917
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,029
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,056
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/381,101
;  PRIOR FILING DATE: 2002-05-16
;  PRIOR APPLICATION NUMBER: 60/371,972
;  PRIOR FILING DATE: 2002-04-12
;  PRIOR APPLICATION NUMBER: 60/327,342
;  PRIOR FILING DATE: 2001-10-05
;  PRIOR APPLICATION NUMBER: 60/328,044
;  PRIOR FILING DATE: 2001-10-09
;  PRIOR APPLICATION NUMBER: 60/328,849
;  PRIOR FILING DATE: 2001-10-12
;  PRIOR APPLICATION NUMBER: 60/374,738
;  PRIOR FILING DATE: 2002-04-23
;  Remaining Prior Application data removed - See File Wrapper or PALM.
;  NUMBER OF SEQ ID NOS: 367
;  SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 200
;   LENGTH: 1588
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-262-839-200

  Query Match           30.0%;  Score 6;  DB 15;  Length 1588;
  Best Local Similarity  100.0%;  Pred. No. 4.1e+02;
  Matches    6;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLETK 18
```

```
              ||||||
Db       1393 QMLETK 1398


RESULT 25
US-09-834-765-528
; Sequence 528, Application US/09834765
; Patent No. US20020055478A1
; GENERAL INFORMATION:
;  APPLICANT: Mary Faris
;  APPLICANT:  Pia M. Challita-Eid
;  APPLICANT:  Arthur B. Raitano
;  APPLICANT:  Steve Chappell Mitchell
;  APPLICANT:  Daniel E.H. Afar
;  APPLICANT:  Aya Jakobovits
;  TITLE OF INVENTION: GTP-BINDING PROTEIN USEFUL IN TREATMENT
;  TITLE OF INVENTION:  AND DETECTION OF CANCER
;  FILE REFERENCE: 129.6USU1
;  CURRENT APPLICATION NUMBER: US/09/834,765
;  CURRENT FILING DATE:  2001-09-21
;  PRIOR APPLICATION NUMBER: 60/197,647
;  PRIOR FILING DATE: 2000-04-12
;  NUMBER OF SEQ ID NOS: 770
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 528
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-834-765-528

  Query Match           25.0%;  Score 5;  DB 9;  Length 9;
  Best Local Similarity  100.0%;  Pred. No. 1.2e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db          2 PRGAP 6


RESULT 26
US-09-834-765-634
; Sequence 634, Application US/09834765
; Patent No. US20020055478A1
; GENERAL INFORMATION:
;  APPLICANT: Mary Faris
;  APPLICANT:  Pia M. Challita-Eid
;  APPLICANT:  Arthur B. Raitano
;  APPLICANT:  Steve Chappell Mitchell
;  APPLICANT:  Daniel E.H. Afar
;  APPLICANT:  Aya Jakobovits
;  TITLE OF INVENTION: GTP-BINDING PROTEIN USEFUL IN TREATMENT
;  TITLE OF INVENTION:  AND DETECTION OF CANCER
;  FILE REFERENCE: 129.6USU1
;  CURRENT APPLICATION NUMBER: US/09/834,765
;  CURRENT FILING DATE:  2001-09-21
;  PRIOR APPLICATION NUMBER: 60/197,647
;  PRIOR FILING DATE: 2000-04-12
;  NUMBER OF SEQ ID NOS: 770
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 634
;   LENGTH: 9
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-834-765-634

  Query Match           25.0%;  Score 5;  DB 9;  Length 9;
  Best Local Similarity  100.0%;  Pred. No. 1.2e+06;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db          2 PRGAP 6
```

```
RESULT 27
US-09-834-765-583
; Sequence 583, Application US/09834765
; Patent No. US20020055478A1
; GENERAL INFORMATION:
;  APPLICANT: Mary Faris
;  APPLICANT:  Pia M. Challita-Eid
;  APPLICANT:  Arthur B. Raitano
;  APPLICANT:  Steve Chappell Mitchell
;  APPLICANT:  Daniel E.H. Afar
;  APPLICANT:  Aya Jakobovits
;  TITLE OF INVENTION: GTP-BINDING PROTEIN USEFUL IN TREATMENT
;  TITLE OF INVENTION:  AND DETECTION OF CANCER
;  FILE REFERENCE: 129.6USU1
;  CURRENT APPLICATION NUMBER: US/09/834,765
;  CURRENT FILING DATE:  2001-09-21
;  PRIOR APPLICATION NUMBER: 60/197,647
;  PRIOR FILING DATE: 2000-04-12
;  NUMBER OF SEQ ID NOS: 770
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 583
;   LENGTH: 10
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-834-765-583

  Query Match             25.0%;  Score 5;  DB 9;  Length 10;
  Best Local Similarity   100.0%;  Pred. No. 98;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db          2 PRGAP 6


RESULT 28
US-10-253-118-1
; Sequence 1, Application US/10253118
; Publication No. US20030138425A1
; GENERAL INFORMATION:
;  APPLICANT: Mather, Powell Jennie
;  TITLE OF INVENTION: ANTIBODIES THAT BIND TO
;  TITLE OF INVENTION:  CANCER-ASSOCIATED ANTIGEN CYTOKERATIN 8 AND METHODS OF USE THERE
;  FILE REFERENCE: 415072001000
;  CURRENT APPLICATION NUMBER: US/10/253,118
;  CURRENT FILING DATE:  2003-01-06
;  PRIOR APPLICATION NUMBER: US 60/323,844
;  PRIOR FILING DATE: 2001-09-21
;  PRIOR APPLICATION NUMBER: US 60/408,253
;  PRIOR FILING DATE: 2002-09-04
;  NUMBER OF SEQ ID NOS: 8
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1
;   LENGTH: 12
;   TYPE: PRT
;   ORGANISM: Homo Sapiens
US-10-253-118-1

  Query Match             25.0%;  Score 5;  DB 14;  Length 12;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         14 MLETK 18
              |||||
Db          8 MLETK 12


RESULT 29
US-10-104-755-20
; Sequence 20, Application US/10104755
; Publication No. US20030031645A1
;   GENERAL INFORMATION:
;       APPLICANT: Strieter, Robert M.
;                  Polverini, Peter J.
;                  Kunkel, Steven L.
;       TITLE OF INVENTION: CXC Chemokines as Regulators of
;                           Angiogenesis
;       NUMBER OF SEQUENCES: 93
;       CORRESPONDENCE ADDRESS:
;            ADDRESSEE: Arnold, White & Durkee
;            STREET: P.O. Box 4433
;            CITY: Houston
;            STATE: TX
;            COUNTRY: US
;            ZIP: 77210
;       COMPUTER READABLE FORM:
;            MEDIUM TYPE: Floppy disk
;            COMPUTER: IBM PC compatible
;            OPERATING SYSTEM: PC-DOS/MS-DOS
;            SOFTWARE: PatentIn Release #1.0, Version #1.30
;       CURRENT APPLICATION DATA:
;            APPLICATION NUMBER: US/10/104,755
;            FILING DATE: 21-Mar-2002
;            CLASSIFICATION: <Unknown>
;       PRIOR APPLICATION DATA:
;            APPLICATION NUMBER: US/09/213,383
;            FILING DATE: 09-Dec-1998
;            APPLICATION NUMBER: 08/468,819
;            FILING DATE: <Unknown>
;       ATTORNEY/AGENT INFORMATION:
;            NAME: Highlander, Steven L.
;            REGISTRATION NUMBER: 37,642
;            REFERENCE/DOCKET NUMBER: UMIC:003/HYL
;       TELECOMMUNICATION INFORMATION:
;            TELEPHONE: 512/418-3000
;            TELEFAX: 512/474-7477
;            TELEX: N/A
;   INFORMATION FOR SEQ ID NO: 20:
;       SEQUENCE CHARACTERISTICS:
;            LENGTH: 15 amino acids
;            TYPE: amino acid
;            STRANDEDNESS: single
;            TOPOLOGY: linear
;       MOLECULE TYPE: peptide
;       SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-10-104-755-20

  Query Match             25.0%;  Score 5;  DB 14;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 30
US-10-231-417-416
; Sequence 416, Application US/10231417
; Publication No. US20030176681A1
; GENERAL INFORMATION:
;  APPLICANT: Feng et al.
;  TITLE OF INVENTION: 148 Human Secreted Proteins
;  FILE REFERENCE: PZ019P1
;  CURRENT APPLICATION NUMBER: US/10/231,417
;  CURRENT FILING DATE:  2002-08-30
;  PRIOR APPLICATION NUMBER: US/09/296,622
;  PRIOR FILING DATE: 1999-04-23
;  NUMBER OF SEQ ID NOS: 619
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 416
;   LENGTH: 28
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-10-231-417-416
```

```
  Query Match             25.0%;  Score 5;  DB 14;  Length 28;
  Best Local Similarity   100.0%;  Pred. No. 2.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         12 CQMLE 16
              |||||
Db          3 CQMLE 7


RESULT 31
US-10-424-599-167866
; Sequence 167866, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 167866
;   LENGTH: 44
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_12259C.1.pep
US-10-424-599-167866

  Query Match             25.0%;  Score 5;  DB 15;  Length 44;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          7 WLRCV 11
              |||||
Db         35 WLRCV 39


RESULT 32
US-10-437-963-120828
; Sequence 120828, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 120828
;   LENGTH: 44
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_23912C.1.pep
US-10-437-963-120828

  Query Match             25.0%;  Score 5;  DB 16;  Length 44;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         11 VCQML 15
              |||||
Db         10 VCQML 14


RESULT 33
US-10-424-599-186275
; Sequence 186275, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 186275
;   LENGTH: 45
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_139219C.1.pep
US-10-424-599-186275

  Query Match             25.0%;  Score 5;  DB 15;  Length 45;
  Best Local Similarity   100.0%;  Pred. No. 3.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         25 LRCVC 29


RESULT 34
US-09-864-761-35124
; Sequence 35124, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  APPLICANT:  Chen, Wensheng
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  GENE EXPRESSION ANALYSIS BY MICROARRAY
;  FILE REFERENCE: Aeomica-X-1
;  CURRENT APPLICATION NUMBER: US/09/864,761
;  CURRENT FILING DATE:  2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/180,312
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/632,366
;  PRIOR FILING DATE: 2000-08-03
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
```

```
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 09/608,408
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 09/774,203
;  PRIOR FILING DATE: 2001-01-29
;  NUMBER OF SEQ ID NOS: 49117
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 35124
;   LENGTH: 46
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AC007688.15
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.3
;   OTHER INFORMATION: EXPRESSED IN BT474, SIGNAL = 1.5
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.8
;   OTHER INFORMATION: EXPRESSED IN HBL100, SIGNAL = 1.1
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.2
;   OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 0.99
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.2
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.3
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.1
;   OTHER INFORMATION: EST_HUMAN HIT: R77154.1, EVALUE 1.00e-08
US-09-864-761-35124

  Query Match             25.0%;  Score 5;  DB 9;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 RGAPM 6
              |||||
Db         20 RGAPM 24


RESULT 35
US-09-864-761-45993
; Sequence 45993, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  APPLICANT:  Chen, Wensheng
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  GENE EXPRESSION ANALYSIS BY MICROARRAY
;  FILE REFERENCE: Aeomica-X-1
;  CURRENT APPLICATION NUMBER: US/09/864,761
;  CURRENT FILING DATE:  2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/180,312
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/632,366
;  PRIOR FILING DATE: 2000-08-03
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 09/608,408
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 09/774,203
;  PRIOR FILING DATE: 2001-01-29
;  NUMBER OF SEQ ID NOS: 49117
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 45993
;   LENGTH: 46
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AC005323.1
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 2.2
;   OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 4.6
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.9
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.7
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL =   2
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.2e+02
;   OTHER INFORMATION: EST_HUMAN HIT: BF339300.1, EVALUE 4.00e+00
US-09-864-761-45993

  Query Match             25.0%;  Score 5;  DB 9;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLET 17
              |||||
Db         32 QMLET 36


RESULT 36
US-09-764-860-502
; Sequence 502, Application US/09764860
; Patent No. US20020094953A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PC008
;  CURRENT APPLICATION NUMBER: US/09/764,860
;  CURRENT FILING DATE:  2001-01-17
;  Prior application data removed - consult PALM or file wrapper
;  NUMBER OF SEQ ID NOS: 1198
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 502
;   LENGTH: 46
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-764-860-502

  Query Match             25.0%;  Score 5;  DB 9;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         15 LETKF 19
              |||||
Db          2 LETKF 6
```

RESULT 37
US-10-074-095-502
; Sequence 502, Application US/10074095
; Publication No. US20030077704A1
; GENERAL INFORMATION:
; APPLICANT: Rosen et al.
; TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
; FILE REFERENCE: PC008C1
; CURRENT APPLICATION NUMBER: US/10/074,095
; CURRENT FILING DATE: 2002-02-14
; PRIOR APPLICATION NUMBER: 09/764,860
; PRIOR FILING DATE: 2001-01-17
; PRIOR APPLICATION NUMBER: 60/179,065
; PRIOR FILING DATE: 2000-01-31
; PRIOR APPLICATION NUMBER: 60/180,628
; PRIOR FILING DATE: 2000-02-04
; PRIOR APPLICATION NUMBER: 60/214,886
; PRIOR FILING DATE: 2000-06-28
; PRIOR APPLICATION NUMBER: 60/217,487
; PRIOR FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 60/225,758
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/220,963
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: 60/217,496
; PRIOR FILING DATE: 2000-07-11
; PRIOR APPLICATION NUMBER: 60/225,447
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/218,290
; PRIOR FILING DATE: 2000-07-14
; PRIOR APPLICATION NUMBER: 60/225,757
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/226,868
; PRIOR FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 60/216,647
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: 60/225,267
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/216,880
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: 60/225,270
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/251,869
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/235,834
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: 60/234,274
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: 60/234,223
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: 60/228,924
; PRIOR FILING DATE: 2000-08-30
; PRIOR APPLICATION NUMBER: 60/224,518
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/236,369
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/224,519
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/220,964
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: 60/241,809
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/249,299
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/236,327
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/241,785
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/244,617
; PRIOR FILING DATE: 2000-11-01
; PRIOR APPLICATION NUMBER: 60/225,268
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/236,368
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/251,856
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/251,868
; PRIOR FILING DATE: 2000-12-08
; PRIOR APPLICATION NUMBER: 60/229,344
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 60/234,997
; PRIOR FILING DATE: 2000-09-25
; PRIOR APPLICATION NUMBER: 60/229,343
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 60/229,345
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 60/229,287
; PRIOR FILING DATE: 2000-09-01
; PRIOR APPLICATION NUMBER: 60/229,513
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: 60/231,413
; PRIOR FILING DATE: 2000-09-08
; PRIOR APPLICATION NUMBER: 60/229,509
; PRIOR FILING DATE: 2000-09-05
; PRIOR APPLICATION NUMBER: 60/236,367
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/237,039
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/237,038
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/236,370
; PRIOR FILING DATE: 2000-09-29
; PRIOR APPLICATION NUMBER: 60/236,802
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/237,037
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/237,040
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: 60/240,960
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/239,935
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: 60/239,937
; PRIOR FILING DATE: 2000-10-13
; PRIOR APPLICATION NUMBER: 60/241,787
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: 60/246,474
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 60/246,532
; PRIOR FILING DATE: 2000-11-08
; PRIOR APPLICATION NUMBER: 60/249,216
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,210
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/226,681
; PRIOR FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 60/225,759
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/225,213
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/227,182
; PRIOR FILING DATE: 2000-08-22
; PRIOR APPLICATION NUMBER: 60/225,214
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/235,836
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: 60/230,438
; PRIOR FILING DATE: 2000-09-06
; PRIOR APPLICATION NUMBER: 60/215,135
; PRIOR FILING DATE: 2000-06-30
; PRIOR APPLICATION NUMBER: 60/225,266
; PRIOR FILING DATE: 2000-08-14
; PRIOR APPLICATION NUMBER: 60/249,218
; PRIOR FILING DATE: 2000-11-17
; PRIOR APPLICATION NUMBER: 60/249,208

```
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,213
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,212
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,207
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,245
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,244
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,217
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,211
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,215
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,264
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,214
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/249,297
;  PRIOR FILING DATE: 2000-11-17
;  PRIOR APPLICATION NUMBER: 60/232,400
;  PRIOR FILING DATE: 2000-09-14
;  PRIOR APPLICATION NUMBER: 60/231,242
;  PRIOR FILING DATE: 2000-09-08
;  PRIOR APPLICATION NUMBER: 60/232,081
;  PRIOR FILING DATE: 2000-09-08
;  PRIOR APPLICATION NUMBER: 60/232,080
;  PRIOR FILING DATE: 2000-09-08
;  PRIOR APPLICATION NUMBER: 60/231,414
;  PRIOR FILING DATE: 2000-09-08
;  PRIOR APPLICATION NUMBER: 60/231,244
;  PRIOR FILING DATE: 2000-09-08
;  PRIOR APPLICATION NUMBER: 60/233,064
;  PRIOR FILING DATE: 2000-09-14
;  PRIOR APPLICATION NUMBER: 60/233,063
;  PRIOR FILING DATE: 2000-09-14
;  PRIOR APPLICATION NUMBER: 60/232,397
;  PRIOR FILING DATE: 2000-09-14
;  PRIOR APPLICATION NUMBER: 60/232,399
;  PRIOR FILING DATE: 2000-09-14
;  PRIOR APPLICATION NUMBER: 60/232,401
;  PRIOR FILING DATE: 2000-09-14
;  PRIOR APPLICATION NUMBER: 60/241,808
;  PRIOR FILING DATE: 2000-10-20
;  PRIOR APPLICATION NUMBER: 60/241,826
;  PRIOR FILING DATE: 2000-10-20
;  PRIOR APPLICATION NUMBER: 60/241,786
;  PRIOR FILING DATE: 2000-10-20
;  PRIOR APPLICATION NUMBER: 60/241,221
;  PRIOR FILING DATE: 2000-10-20
;  PRIOR APPLICATION NUMBER: 60/246,475
;  PRIOR FILING DATE: 2000-11-08
;  PRIOR APPLICATION NUMBER: 60/231,243
;  PRIOR FILING DATE: 2000-09-08

  Query Match             25.0%;  Score 5;  DB 14;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         15 LETKF 19
              |||||
Db          2 LETKF 6


RESULT 38
US-10-212-872-502
; Sequence 502, Application US/10212872
; Publication No. US20030215893A1
; GENERAL INFORMATION:
;  APPLICANT: Rosen et al.
;  TITLE OF INVENTION: Nucleic Acids, Proteins, and Antibodies
;  FILE REFERENCE: PC008C2
;  CURRENT APPLICATION NUMBER: US/10/212,872
;  CURRENT FILING DATE:  2002-08-07
;  Prior application removed - See File Wrapper or Palm
;  NUMBER OF SEQ ID NOS: 1198
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 502
;    LENGTH: 46
;    TYPE: PRT
;    ORGANISM: Homo sapiens
US-10-212-872-502

  Query Match             25.0%;  Score 5;  DB 14;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         15 LETKF 19
              |||||
Db          2 LETKF 6


RESULT 39
US-10-437-963-161908
; Sequence 161908, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 161908
;    LENGTH: 46
;    TYPE: PRT
;    ORGANISM: Oryza sativa
;    FEATURE:
;    OTHER INFORMATION: Clone ID: PAT_MRT4530_6104C.1.pep
US-10-437-963-161908

  Query Match             25.0%;  Score 5;  DB 16;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          4 APMWL 8
              |||||
Db         41 APMWL 45


RESULT 40
US-09-864-761-38656
; Sequence 38656, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  APPLICANT:  Chen, Wensheng
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  GENE EXPRESSION ANALYSIS BY MICROARRAY
;  FILE REFERENCE: Aeomica-X-1
;  CURRENT APPLICATION NUMBER: US/09/864,761
;  CURRENT FILING DATE:  2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/180,312
```

```
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/632,366
;  PRIOR FILING DATE: 2000-08-03
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 09/608,408
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 09/774,203
;  PRIOR FILING DATE: 2001-01-29
;  NUMBER OF SEQ ID NOS: 49117
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 38656
;   LENGTH: 47
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AC006024.1
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.6
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.5
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.2
;   OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.4
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.3
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.2
;   OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.4
;   OTHER INFORMATION: EST_HUMAN HIT: BF241410.1, EVALUE 6.00e-01
US-09-864-761-38656

  Query Match             25.0%;  Score 5;  DB 9;  Length 47;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         13 PRGAP 17


RESULT 41
US-10-437-963-202542
; Sequence 202542, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 202542
;   LENGTH: 47
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_97812C.1.pep
US-10-437-963-202542

  Query Match             25.0%;  Score 5;  DB 16;  Length 47;
  Best Local Similarity   100.0%;  Pred. No. 3.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          14 MLETK 18
               |||||
Db          17 MLETK 21


RESULT 42
US-10-387-346B-94
; Sequence 94, Application US/10387346B
; Publication No. US20040117869A1
; GENERAL INFORMATION:
;  APPLICANT: Xu, Dongmei
;  TITLE OF INVENTION: Cloning of Cytochrome P450 Genes from
;  TITLE OF INVENTION:  Nicotiana
;  FILE REFERENCE: 78623
;  CURRENT APPLICATION NUMBER: US/10/387,346B
;  CURRENT FILING DATE:  2003-03-12
;  PRIOR APPLICATION NUMBER: 10/293,252
;  PRIOR FILING DATE: 2002-11-13
;  PRIOR APPLICATION NUMBER: 10/340,861
;  PRIOR FILING DATE: 2003-01-10
;  PRIOR APPLICATION NUMBER: 60/363,684
;  PRIOR FILING DATE: 2002-03-12
;  PRIOR APPLICATION NUMBER: 60/347,444
;  PRIOR FILING DATE: 2002-01-11
;  PRIOR APPLICATION NUMBER: 60/337,684
;  PRIOR FILING DATE: 2001-11-13
;  NUMBER OF SEQ ID NOS: 156
;  SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 94
;   LENGTH: 50
;   TYPE: PRT
;   ORGANISM: Nicotiana
US-10-387-346B-94

  Query Match             25.0%;  Score 5;  DB 16;  Length 50;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          14 MLETK 18
               |||||
Db           5 MLETK 9


RESULT 43
US-10-437-963-204604
; Sequence 204604, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
```

```
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 204604
;   LENGTH: 50
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_99675C.1.pep
US-10-437-963-204604

  Query Match             25.0%;  Score 5;  DB 16;  Length 50;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         44 PRGAP 48


RESULT 44
US-10-686-947-94
; Sequence 94, Application US/10686947
; Publication No. US20040162420A1
; GENERAL INFORMATION:
;  APPLICANT: Profigen Inc.
;  TITLE OF INVENTION: Cloning of Cytochrome P450 Genes from Tobacco
;  FILE REFERENCE: 79601
;  CURRENT APPLICATION NUMBER: US/10/686,947
;  CURRENT FILING DATE:  2003-10-16
;  PRIOR APPLICATION NUMBER: US 10/387346
;  PRIOR FILING DATE: 2003-03-12
;  NUMBER OF SEQ ID NOS: 298
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 94
;   LENGTH: 50
;   TYPE: PRT
;   ORGANISM: NICOTIANATABACUM
US-10-686-947-94

  Query Match             25.0%;  Score 5;  DB 16;  Length 50;
  Best Local Similarity   100.0%;  Pred. No. 3.4e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         14 MLETK 18
              |||||
Db          5 MLETK 9


RESULT 45
US-10-424-599-267231
; Sequence 267231, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 267231
;   LENGTH: 51
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_8332C.1.pep
US-10-424-599-267231

  Query Match             25.0%;  Score 5;  DB 15;  Length 51;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         11 VCQML 15
              |||||
Db         41 VCQML 45


RESULT 46
US-10-424-599-275966
; Sequence 275966, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 275966
;   LENGTH: 51
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_91217C.1.pep
US-10-424-599-275966

  Query Match             25.0%;  Score 5;  DB 15;  Length 51;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         14 MLETK 18
              |||||
Db          1 MLETK 5


RESULT 47
US-10-424-599-284525
; Sequence 284525, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 284525
;   LENGTH: 52
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_98951C.1.pep
US-10-424-599-284525

  Query Match             25.0%;  Score 5;  DB 15;  Length 52;
  Best Local Similarity   100.0%;  Pred. No. 3.5e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          8 LRCVC 12
              |||||
Db         34 LRCVC 38


RESULT 48
US-10-424-599-177624
; Sequence 177624, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 177624
;   LENGTH: 53
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_13140C.1.pep
US-10-424-599-177624

  Query Match             25.0%;  Score 5;  DB 15;  Length 53;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         16 ETKFL 20
              |||||
Db          2 ETKFL 6


RESULT 49
US-10-152-031-13
; Sequence 13, Application US/10152031
; Publication No. US20030044825A1
; GENERAL INFORMATION:
;  APPLICANT: IMAI, Yuji
;  APPLICANT:  AKATSUKA, Hiroyuki
;  APPLICANT:  KAWAI, Eri
;  APPLICANT:  OMORI, Kenji
;  APPLICANT:  YANAKA, No. US20030044825A1iyuki
;  APPLICANT:  SAKURAI, Naoki
;  TITLE OF INVENTION: Bone Metabolism Related Protein and Gene Thereof
;  FILE REFERENCE: 0283-0163P
;  CURRENT APPLICATION NUMBER: US/10/152,031
;  CURRENT FILING DATE:  2002-05-22
;  PRIOR APPLICATION NUMBER: US 60/292,318
;  PRIOR FILING DATE: 2001-05-22
;  PRIOR APPLICATION NUMBER: JP 318226/1998
;  PRIOR FILING DATE: 2000-05-23
;  NUMBER OF SEQ ID NOS: 16
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
;   LENGTH: 54
;   TYPE: PRT
;   ORGANISM: Mus musculus
US-10-152-031-13

  Query Match             25.0%;  Score 5;  DB 14;  Length 54;
  Best Local Similarity   100.0%;  Pred. No. 3.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 RGAPM 6
              |||||
Db          4 RGAPM 8


RESULT 50
US-10-424-599-262093
; Sequence 262093, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 262093
;   LENGTH: 56
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_78692C.1.pep
US-10-424-599-262093

  Query Match             25.0%;  Score 5;  DB 15;  Length 56;
  Best Local Similarity   100.0%;  Pred. No. 3.7e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         13 PRGAP 17


RESULT 51
US-09-867-550-1954
; Sequence 1954, Application US/09867550
; Patent No. US20020082206A1
; GENERAL INFORMATION:
;  APPLICANT: Leach, Martin D.
;  APPLICANT:  Mehraban, Fuad,
;  APPLICANT:  Conley, Pamela
;  APPLICANT:  Law, Debbie
;  APPLICANT:  Topper, James
;  TITLE OF INVENTION: No. US20020082206A1el Polynucleotides from Atherogenic Cells and I
;  TITLE OF INVENTION:  Thereby
;  FILE REFERENCE: 21402-013 (Cura-313)
;  CURRENT APPLICATION NUMBER: US/09/867,550
;  CURRENT FILING DATE:  2001-09-20
;  PRIOR APPLICATION NUMBER: USSN 60/208,427
;  PRIOR FILING DATE: 2000-05-30
;  NUMBER OF SEQ ID NOS: 2125
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1954
;   LENGTH: 57
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-867-550-1954

  Query Match             25.0%;  Score 5;  DB 9;  Length 57;
  Best Local Similarity   100.0%;  Pred. No. 3.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         11 VCQML 15
              |||||
Db         22 VCQML 26


RESULT 52
US-10-424-599-240745
; Sequence 240745, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
```

; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 240745
; LENGTH: 58
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; NAME/KEY: unsure
; LOCATION: (1)..(58)
; OTHER INFORMATION: unsure at all Xaa locations
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_5941C.1.pep
US-10-424-599-240745

Query Match 25.0%; Score 5; DB 15; Length 58;
Best Local Similarity 100.0%; Pred. No. 3.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVC 12
|||||
Db 16 LRCVC 20

RESULT 53
US-10-424-599-205956
; Sequence 205956, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 205956
; LENGTH: 60
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_28005C.1.pep
US-10-424-599-205956

Query Match 25.0%; Score 5; DB 15; Length 60;
Best Local Similarity 100.0%; Pred. No. 3.9e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVC 12
|||||
Db 26 LRCVC 30

RESULT 54
US-10-424-599-176161
; Sequence 176161, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 176161
; LENGTH: 61
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_130090C.1.pep
US-10-424-599-176161

Query Match 25.0%; Score 5; DB 15; Length 61;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 9 RCVCQ 13
|||||
Db 48 RCVCQ 52

RESULT 55
US-10-424-599-239535
; Sequence 239535, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa Thomas J
; APPLICANT: Kovalic David K
; APPLICANT: Zhou Yihua
; APPLICANT: Cao Yongwei
; TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53223)B
; CURRENT APPLICATION NUMBER: US/10/424,599
; CURRENT FILING DATE: 2003-04-28
; NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 239535
; LENGTH: 62
; TYPE: PRT
; ORGANISM: Glycine max
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT3847_58325C.1.pep
US-10-424-599-239535

Query Match 25.0%; Score 5; DB 15; Length 62;
Best Local Similarity 100.0%; Pred. No. 4e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 15 LETKF 19
|||||
Db 46 LETKF 50

RESULT 56
US-10-029-386-32143
; Sequence 32143, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR GE
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 32143
; LENGTH: 63
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO Z98883.3

```
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 1.8
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 0.8
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 4.5
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 1.7
;   OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 2.1
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.9
;   OTHER INFORMATION: SWISSPROT HIT: O43451, EVALUE 2.00e-03
US-10-029-386-32143

  Query Match             25.0%;  Score 5;  DB 14;  Length 63;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         15 PRGAP 19


RESULT 57
US-10-424-599-282344
; Sequence 282344, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 282344
;   LENGTH: 64
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_9697C.1.pep
US-10-424-599-282344

  Query Match             25.0%;  Score 5;  DB 15;  Length 64;
  Best Local Similarity   100.0%;  Pred. No. 4.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         15 LETKF 19
              |||||
Db          4 LETKF 8


RESULT 58
US-10-424-599-210941
; Sequence 210941, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 210941
;   LENGTH: 66
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   NAME/KEY: unsure
;   LOCATION: (1)..(66)
;   OTHER INFORMATION: unsure at all Xaa locations
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_32506C.1.pep
US-10-424-599-210941

  Query Match             25.0%;  Score 5;  DB 15;  Length 66;
  Best Local Similarity   100.0%;  Pred. No. 4.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         15 LETKF 19
              |||||
Db         46 LETKF 50


RESULT 59
US-09-867-550-1576
; Sequence 1576, Application US/09867550
; Patent No. US20020082206A1
; GENERAL INFORMATION:
;  APPLICANT: Leach, Martin D.
;  APPLICANT:  Mehraban, Fuad,
;  APPLICANT:  Conley, Pamela
;  APPLICANT:  Law, Debbie
;  APPLICANT:  Topper, James
;  TITLE OF INVENTION: No. US20020082206A1el Polynucleotides from Atherogenic Cells and
;  TITLE OF INVENTION:  Thereby
;  FILE REFERENCE: 21402-013 (Cura-313)
;  CURRENT APPLICATION NUMBER: US/09/867,550
;  CURRENT FILING DATE:  2001-09-20
;  PRIOR APPLICATION NUMBER: USSN 60/208,427
;  PRIOR FILING DATE: 2000-05-30
;  NUMBER OF SEQ ID NOS: 2125
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 1576
;   LENGTH: 67
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-867-550-1576

  Query Match             25.0%;  Score 5;  DB 9;  Length 67;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         40 PRGAP 44


RESULT 60
US-10-424-599-154428
; Sequence 154428, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 154428
;   LENGTH: 68
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_11046C.1.pep
US-10-424-599-154428

  Query Match             25.0%;  Score 5;  DB 15;  Length 68;
  Best Local Similarity   100.0%;  Pred. No. 4.3e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          15 LETKF 19
               |||||
Db          52 LETKF 56


RESULT 61
US-09-864-761-34034
; Sequence 34034, Application US/09864761
; Patent No. US20020048763A1
; GENERAL INFORMATION:
;  APPLICANT: Penn, Sharron G.
;  APPLICANT:  Rank, David R.
;  APPLICANT:  Hanzel, David K.
;  APPLICANT:  Chen, Wensheng
;  TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR
;  TITLE OF INVENTION:  GENE EXPRESSION ANALYSIS BY MICROARRAY
;  FILE REFERENCE: Aeomica-X-1
;  CURRENT APPLICATION NUMBER: US/09/864,761
;  CURRENT FILING DATE:  2001-05-23
;  PRIOR APPLICATION NUMBER: US 60/180,312
;  PRIOR FILING DATE: 2000-02-04
;  PRIOR APPLICATION NUMBER: US 60/207,456
;  PRIOR FILING DATE: 2000-05-26
;  PRIOR APPLICATION NUMBER: US 09/632,366
;  PRIOR FILING DATE: 2000-08-03
;  PRIOR APPLICATION NUMBER: GB 24263.6
;  PRIOR FILING DATE: 2000-10-04
;  PRIOR APPLICATION NUMBER: US 60/236,359
;  PRIOR FILING DATE: 2000-09-27
;  PRIOR APPLICATION NUMBER: PCT/US01/00666
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00667
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00664
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00669
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00665
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00668
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00663
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00662
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00661
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: PCT/US01/00670
;  PRIOR FILING DATE: 2001-01-30
;  PRIOR APPLICATION NUMBER: US 60/234,687
;  PRIOR FILING DATE: 2000-09-21
;  PRIOR APPLICATION NUMBER: US 09/608,408
;  PRIOR FILING DATE: 2000-06-30
;  PRIOR APPLICATION NUMBER: US 09/774,203
;  PRIOR FILING DATE: 2001-01-29
;  NUMBER OF SEQ ID NOS: 49117
;  SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 34034
;   LENGTH: 72
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: MAP TO AB023057.1
;   OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.2
;   OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 3.1
;   OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL =   1
;   OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 2.1
;   OTHER INFORMATION: EXPRESSED IN HBL100, SIGNAL = 1.8
;   OTHER INFORMATION: EXPRESSED IN FETAL LIVER, SIGNAL = 1.5
;   OTHER INFORMATION: EXPRESSED IN HELA, SIGNAL = 1.5
;   OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1.1
;   OTHER INFORMATION: EXPRESSED IN BT474, SIGNAL = 0.87
;   OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.1
;   OTHER INFORMATION: EST_HUMAN HIT: BE314635.1, EVALUE 5.00e-09
;   OTHER INFORMATION: EST_HUMAN HIT: AU139120.1, EVALUE 1.00e-15
US-09-864-761-34034

  Query Match             25.0%;  Score 5;  DB 9;  Length 72;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           1 PRGAP 5
                |||||
Db          16 PRGAP 20


RESULT 62
US-10-001-879-175
; Sequence 175, Application US/10001879
; Publication No. US20020127237A1
; GENERAL INFORMATION:
;  APPLICANT: Salceda, Susana
;  APPLICANT:  Macina, Roberto
;  APPLICANT:  Recipon, Herve
;  APPLICANT:  Cafferkey, Robert
;  APPLICANT:  Ali, Shujath
;  APPLICANT:  Sun, Yongming
;  APPLICANT:  Liu, Chenghua
;  TITLE OF INVENTION: Compositions and Methods Relating to Prostate Specific Genes and P
;  FILE REFERENCE: DEX-0281
;  CURRENT APPLICATION NUMBER: US/10/001,879
;  CURRENT FILING DATE:  2001-11-20
;  PRIOR APPLICATION NUMBER: 60/252,188
;  PRIOR FILING DATE: 2000-11-21
;  NUMBER OF SEQ ID NOS: 201
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 175
;   LENGTH: 72
;   TYPE: PRT
;   ORGANISM: Homo sapien
US-10-001-879-175

  Query Match             25.0%;  Score 5;  DB 13;  Length 72;
  Best Local Similarity   100.0%;  Pred. No. 4.5e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           2 RGAPM 6
                |||||
Db          10 RGAPM 14


RESULT 63
US-10-424-599-221140
; Sequence 221140, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 221140
;   LENGTH: 72
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_41719C.1.pep
US-10-424-599-221140

  Query Match             25.0%;  Score 5;  DB 15;  Length 72;
```

Best Local Similarity 100.0%; Pred. No. 4.5e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          7 WLRCV 11
              |||||
Db          4 WLRCV 8
```

RESULT 64
US-10-437-963-102863
; Sequence 102863, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
; APPLICANT: La Rosa, Thomas J.
; APPLICANT: Kovalic, David K.
; APPLICANT: Zhou, Yihua
; APPLICANT: Cao, Yongwei
; APPLICANT: Wu, Wei
; APPLICANT: Boukharov, Andrey A.
; APPLICANT: Barbazuk, Brad
; APPLICANT: Li, Ping
; TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
; TITLE OF INVENTION: Plants and Uses Thereof for Plant Improvement
; FILE REFERENCE: 38-21(53221)B
; CURRENT APPLICATION NUMBER: US/10/437,963
; CURRENT FILING DATE: 2003-05-14
; NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 102863
; LENGTH: 74
; TYPE: PRT
; ORGANISM: Oryza sativa
; FEATURE:
; OTHER INFORMATION: Clone ID: PAT_MRT4530_100348C.1.pep
US-10-437-963-102863

Query Match 25.0%; Score 5; DB 16; Length 74;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          1 PRGAP 5
              |||||
Db         30 PRGAP 34
```

RESULT 65
US-10-293-252C-102
; Sequence 102, Application US/10293252C
; Publication No. US20040103449A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Dongemi
; TITLE OF INVENTION: Identification and Use of Cytochrome
; TITLE OF INVENTION: P450 Nucleic Acid Sequences from Tobacco
; FILE REFERENCE: 78127
; CURRENT APPLICATION NUMBER: US/10/293,252C
; CURRENT FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: 60/363,684
; PRIOR FILING DATE: 2002-03-12
; PRIOR APPLICATION NUMBER: 60/347,444
; PRIOR FILING DATE: 2002-01-11
; PRIOR APPLICATION NUMBER: 60/337,684
; PRIOR FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 152
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 102
; LENGTH: 76
; TYPE: PRT
; ORGANISM: Nicotiana
US-10-293-252C-102

Query Match 25.0%; Score 5; DB 16; Length 76;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         14 MLETK 18
              |||||
Db         31 MLETK 35
```

RESULT 66
US-10-340-861B-102
; Sequence 102, Application US/10340861B
; Publication No. US20040111759A1
; GENERAL INFORMATION:
; APPLICANT: Xu, Dongemi
; TITLE OF INVENTION: Identification and Use of Cytochrome
; TITLE OF INVENTION: P450 Nucleic Acid Sequences form Tobacco
; FILE REFERENCE: 78406
; CURRENT APPLICATION NUMBER: US/10/340,861B
; CURRENT FILING DATE: 2003-01-10
; PRIOR APPLICATION NUMBER: 10/293,252
; PRIOR FILING DATE: 2002-11-13
; PRIOR APPLICATION NUMBER: 60/363,684
; PRIOR FILING DATE: 2002-03-12
; PRIOR APPLICATION NUMBER: 60/347,444
; PRIOR FILING DATE: 2002-01-11
; PRIOR APPLICATION NUMBER: 60/337,684
; PRIOR FILING DATE: 2001-11-13
; NUMBER OF SEQ ID NOS: 184
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 102
; LENGTH: 76
; TYPE: PRT
; ORGANISM: Nicotiana
US-10-340-861B-102

Query Match 25.0%; Score 5; DB 16; Length 76;
Best Local Similarity 100.0%; Pred. No. 4.7e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy         14 MLETK 18
              |||||
Db         31 MLETK 35
```

RESULT 67
US-09-792-793A-90
; Sequence 90, Application US/09792793A
; Patent No. US20020168370A1
; GENERAL INFORMATION:
; APPLICANT: McDonald, John R.
; APPLICANT: Coggins, Philip
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING SECONDARY TISSUE DAMAGE AND
; TITLE OF INVENTION: OTHER INFLAMMATORY CONDITIONS AND DISORDERS
; FILE REFERENCE: 25020-601D
; CURRENT APPLICATION NUMBER: US/09/792,793A
; CURRENT FILING DATE: 2001-02-22
; NUMBER OF SEQ ID NOS: 93
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 90
; LENGTH: 78
; TYPE: PRT
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Human Chemokine Polypepetide: ENA-78
; PUBLICATION INFORMATION:
; AUTHORS: Clark-Lewis et. al.,
; JOURNAL: J. Leukoc. Biol.
; VOLUME: 57
; PAGES: 703-711
; DATE: 1995
US-09-792-793A-90

Query Match 25.0%; Score 5; DB 9; Length 78;
Best Local Similarity 100.0%; Pred. No. 4.8e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 68
US-09-864-408A-5972
; Sequence 5972, Application US/09864408A
; Publication No. US20040009474A1
; GENERAL INFORMATION:
;  APPLICANT: Leach, Martin D.
;  APPLICANT:  Shimkets, Richard A.
;  TITLE OF INVENTION: No. US20040009474A1el Human Polynucleotides and Polypeptides Enco
;  FILE REFERENCE: 21402-012
;  CURRENT APPLICATION NUMBER: US/09/864,408A
;  CURRENT FILING DATE:  2001-05-24
;  PRIOR APPLICATION NUMBER: 60/206,690
;  PRIOR FILING DATE: 2000-05-24
;  NUMBER OF SEQ ID NOS: 9068
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 5972
;   LENGTH: 78
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: misc_feature
;   LOCATION: (57)..(57)
;   OTHER INFORMATION: Wherein Xaa may be any naturally occuring amino acid
US-09-864-408A-5972

  Query Match            25.0%;  Score 5;  DB 11;  Length 78;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          5 PMWLR 9
              |||||
Db         74 PMWLR 78


RESULT 69
US-10-375-209A-90
; Sequence 90, Application US/10375209A
; Publication No. US20030215421A1
; GENERAL INFORMATION:
;  APPLICANT: McDonald, John R.
;  APPLICANT:  Coggins, Philip
;  TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR TREATING SECONDARY TISSUE DAMAGE AND
;  TITLE OF INVENTION:  OTHER INFLAMMATORY CONDITIONS AND DISORDERS
;  FILE REFERENCE: 25020-601E
;  CURRENT APPLICATION NUMBER: US/10/375,209A
;  CURRENT FILING DATE:  2003-02-24
;  NUMBER OF SEQ ID NOS: 93
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 90
;   LENGTH: 78
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   OTHER INFORMATION: Human Chemokine Polypepetide: ENA-78
;  PUBLICATION INFORMATION:
;   AUTHORS: Clark-Lewis et. al.,
;   JOURNAL: J. Leukoc. Biol.
;   VOLUME: 57
;   PAGES: 703-711
;   DATE: 1995
US-10-375-209A-90

  Query Match            25.0%;  Score 5;  DB 14;  Length 78;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 70
US-10-437-963-135152
; Sequence 135152, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 135152
;   LENGTH: 78
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_36855C.1.pep
US-10-437-963-135152

  Query Match            25.0%;  Score 5;  DB 16;  Length 78;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         23 PRGAP 27


RESULT 71
US-10-437-963-167155
; Sequence 167155, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 167155
;   LENGTH: 78
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_65794C.1.pep
US-10-437-963-167155

  Query Match            25.0%;  Score 5;  DB 16;  Length 78;
  Best Local Similarity   100.0%;  Pred. No. 4.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         15 LETKF 19
              |||||
Db         72 LETKF 76
```

```
RESULT 72
US-10-424-599-144203
; Sequence 144203, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 144203
;   LENGTH: 79
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_101228C.1.pep
US-10-424-599-144203

  Query Match            25.0%;  Score 5;  DB 15;  Length 79;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         43 PRGAP 47


RESULT 73
US-10-424-599-149863
; Sequence 149863, Application US/10424599
; Publication No. US20040031072A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa Thomas J
;  APPLICANT:  Kovalic David K
;  APPLICANT:  Zhou Yihua
;  APPLICANT:  Cao Yongwei
;  TITLE OF INVENTION: Soy Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53223)B
;  CURRENT APPLICATION NUMBER: US/10/424,599
;  CURRENT FILING DATE:  2003-04-28
;  NUMBER OF SEQ ID NOS: 285684
; SEQ ID NO 149863
;   LENGTH: 79
;   TYPE: PRT
;   ORGANISM: Glycine max
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT3847_106348C.1.pep
US-10-424-599-149863

  Query Match            25.0%;  Score 5;  DB 15;  Length 79;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLET 17
              |||||
Db         20 QMLET 24


RESULT 74
US-09-922-261-464
; Sequence 464, Application US/09922261
; Patent No. US20020111471A1
; GENERAL INFORMATION:
;  APPLICANT: COGENT NEUROSCIENCE, Inc.
;  APPLICANT:  Lo, Donald C.
;  APPLICANT:  Barney, Shawn
;  APPLICANT:  Thomas, Mary Beth
;  APPLICANT:  Portbury, Stuart D.
;  APPLICANT:  Puranam, Kasturi
;  APPLICANT:  Katz, Lawrence C.
;  TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING
;  TITLE OF INVENTION:  AND TREATING CONDITIONS, DISORDERS, OR DISEASES INVOLVING
;  TITLE OF INVENTION:  CELL DEATH
;  FILE REFERENCE: 10001-005-999
;  CURRENT APPLICATION NUMBER: US/09/922,261
;  CURRENT FILING DATE:  2001-08-03
;  PRIOR APPLICATION NUMBER: US/09/461,697
;  PRIOR FILING DATE: 1999-12-14
;  NUMBER OF SEQ ID NOS: 466
;  SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 464
;   LENGTH: 80
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-09-922-261-464

  Query Match            25.0%;  Score 5;  DB 9;  Length 80;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         54 PRGAP 58


RESULT 75
US-10-437-963-105389
; Sequence 105389, Application US/10437963
; Publication No. US20040123343A1
; GENERAL INFORMATION:
;  APPLICANT: La Rosa, Thomas J.
;  APPLICANT:  Kovalic, David K.
;  APPLICANT:  Zhou, Yihua
;  APPLICANT:  Cao, Yongwei
;  APPLICANT:  Wu, Wei
;  APPLICANT:  Boukharov, Andrey A.
;  APPLICANT:  Barbazuk, Brad
;  APPLICANT:  Li, Ping
;  TITLE OF INVENTION: Rice Nucleic Acid Molecules and Other Molecules Associated With
;  TITLE OF INVENTION:  Plants and Uses Thereof for Plant Improvement
;  FILE REFERENCE: 38-21(53221)B
;  CURRENT APPLICATION NUMBER: US/10/437,963
;  CURRENT FILING DATE:  2003-05-14
;  NUMBER OF SEQ ID NOS: 204966
; SEQ ID NO 105389
;   LENGTH: 80
;   TYPE: PRT
;   ORGANISM: Oryza sativa
;   FEATURE:
;   OTHER INFORMATION: Clone ID: PAT_MRT4530_102638C.1.pep
US-10-437-963-105389

  Query Match            25.0%;  Score 5;  DB 16;  Length 80;
  Best Local Similarity   100.0%;  Pred. No. 4.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         24 PRGAP 28


Search completed: October 26, 2004, 07:47:57
Job time : 66 secs
```

GenCore version 5.1.6

OM protein - protein search, using sw model

Run on: October 26, 2004, 07:06:01 ; Search time 22.25 Seconds
(without alignments)
59.612 Million cell updates/sec

Title: US-10-066-965A-4
Perfect score: 20
Sequence: 1 PRGAPMWLRCVCQMLETKFL 20

Scoring table: OLIGO
Gapop 60.0 , Gapext 60.0

Searched: 478139 seqs, 66318000 residues

Word size : 0

Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Listing first 100 summaries

Database : Issued_Patents_AA:*
1: /cgn2_6/ptodata/1/iaa/5A_COMB.pep:*
2: /cgn2_6/ptodata/1/iaa/5B_COMB.pep:*
3: /cgn2_6/ptodata/1/iaa/6A_COMB.pep:*
4: /cgn2_6/ptodata/1/iaa/6B_COMB.pep:*
5: /cgn2_6/ptodata/1/iaa/PCTUS_COMB.pep:*
6: /cgn2_6/ptodata/1/iaa/backfiles1.pep:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	% Query Match	Length	DB	ID	Description
1	6	30.0	169	4	US-09-489-039A-8944	Sequence 8944, Ap
2	6	30.0	173	4	US-09-270-767-41955	Sequence 41955, A
3	6	30.0	394	4	US-09-248-796A-23067	Sequence 23067, A
4	5	25.0	9	1	US-07-972-032-15	Sequence 15, Appl
5	5	25.0	9	1	US-08-642-255-15	Sequence 15, Appl
6	5	25.0	15	2	US-08-468-819-20	Sequence 20, Appl
7	5	25.0	15	4	US-09-213-383-20	Sequence 20, Appl
8	5	25.0	16	1	US-08-311-307B-11	Sequence 11, Appl
9	5	25.0	17	1	US-07-778-413E-3	Sequence 3, Appli
10	5	25.0	17	1	US-08-340-102-3	Sequence 3, Appli
11	5	25.0	34	1	US-07-778-413E-4	Sequence 4, Appli
12	5	25.0	34	1	US-08-340-102-4	Sequence 4, Appli
13	5	25.0	46	2	US-08-436-420-17	Sequence 17, Appl
14	5	25.0	63	4	US-09-248-796A-24632	Sequence 24632, A
15	5	25.0	74	3	US-09-134-001C-3074	Sequence 3074, Ap
16	5	25.0	74	3	US-09-134-001C-4851	Sequence 4851, Ap
17	5	25.0	75	2	US-08-436-420-15	Sequence 15, Appl
18	5	25.0	77	4	US-09-270-767-36912	Sequence 36912, A
19	5	25.0	77	4	US-09-270-767-52129	Sequence 52129, A
20	5	25.0	78	1	US-07-778-413E-12	Sequence 12, Appl
21	5	25.0	78	1	US-08-340-102-12	Sequence 12, Appl
22	5	25.0	78	1	US-08-330-163-8	Sequence 8, Appli
23	5	25.0	78	1	US-08-482-111-8	Sequence 8, Appli
24	5	25.0	78	2	US-08-436-420-32	Sequence 32, Appl
25	5	25.0	80	3	US-09-461-697-464	Sequence 464, App
26	5	25.0	85	4	US-09-270-767-41916	Sequence 41916, A
27	5	25.0	91	4	US-09-252-991A-24182	Sequence 24182, A
28	5	25.0	91	4	US-09-270-767-38667	Sequence 38667, A
29	5	25.0	91	4	US-09-270-767-53884	Sequence 53884, A
30	5	25.0	95	4	US-09-248-796A-27372	Sequence 27372, A
31	5	25.0	105	4	US-09-489-039A-13486	Sequence 13486, A
32	5	25.0	113	4	US-08-816-772-9	Sequence 9, Appli
33	5	25.0	114	1	US-08-352-324A-3	Sequence 3, Appli
34	5	25.0	114	2	US-08-862-607-3	Sequence 3, Appli
35	5	25.0	114	2	US-08-468-819-4	Sequence 4, Appli
36	5	25.0	114	3	US-09-203-235-3	Sequence 3, Appli
37	5	25.0	114	3	US-08-679-493A-149	Sequence 149, App
38	5	25.0	114	4	US-09-213-383-4	Sequence 4, Appli
39	5	25.0	114	4	US-09-588-044-3	Sequence 3, Appli
40	5	25.0	114	5	PCT-US95-16144-3	Sequence 3, Appli
41	5	25.0	119	4	US-09-489-039A-11951	Sequence 11951, A
42	5	25.0	125	4	US-09-270-767-34903	Sequence 34903, A
43	5	25.0	125	4	US-09-270-767-50120	Sequence 50120, A
44	5	25.0	127	4	US-09-270-767-36650	Sequence 36650, A
45	5	25.0	127	4	US-09-270-767-51867	Sequence 51867, A
46	5	25.0	132	4	US-09-583-110-4139	Sequence 4139, Ap
47	5	25.0	133	4	US-09-252-991A-30594	Sequence 30594, A
48	5	25.0	133	4	US-09-312-283C-425	Sequence 425, App
49	5	25.0	135	4	US-10-101-464A-726	Sequence 726, App
50	5	25.0	139	4	US-09-270-767-39768	Sequence 39768, A
51	5	25.0	139	4	US-09-270-767-54985	Sequence 54985, A
52	5	25.0	141	4	US-09-513-999C-6252	Sequence 6252, Ap
53	5	25.0	158	4	US-09-248-796A-18178	Sequence 18178, A
54	5	25.0	158	4	US-09-248-796A-23447	Sequence 23447, A
55	5	25.0	160	4	US-09-252-991A-23275	Sequence 23275, A
56	5	25.0	163	4	US-09-134-000C-3710	Sequence 3710, Ap
57	5	25.0	180	4	US-09-270-767-36562	Sequence 36562, A
58	5	25.0	180	4	US-09-270-767-51779	Sequence 51779, A
59	5	25.0	183	4	US-09-252-991A-21850	Sequence 21850, A
60	5	25.0	185	4	US-09-252-991A-32100	Sequence 32100, A
61	5	25.0	195	4	US-09-270-767-61094	Sequence 61094, A
62	5	25.0	199	4	US-09-270-767-47191	Sequence 47191, A
63	5	25.0	208	4	US-09-615-192A-385	Sequence 385, App
64	5	25.0	215	4	US-09-134-000C-3778	Sequence 3778, Ap
65	5	25.0	220	4	US-09-270-767-60336	Sequence 60336, A
66	5	25.0	233	3	US-09-627-376-12	Sequence 12, Appl
67	5	25.0	233	4	US-10-047-676B-12	Sequence 12, Appl
68	5	25.0	235	4	US-09-198-452A-818	Sequence 818, App
69	5	25.0	237	4	US-09-252-991A-23304	Sequence 23304, A
70	5	25.0	239	3	US-09-134-001C-4165	Sequence 4165, Ap
71	5	25.0	242	4	US-09-252-991A-28343	Sequence 28343, A
72	5	25.0	248	1	US-08-426-819A-37	Sequence 37, Appl
73	5	25.0	257	4	US-09-248-796A-27518	Sequence 27518, A
74	5	25.0	259	4	US-09-252-991A-21547	Sequence 21547, A
75	5	25.0	264	4	US-09-328-352-6699	Sequence 6699, Ap
76	5	25.0	269	4	US-09-270-767-39555	Sequence 39555, A
77	5	25.0	269	4	US-09-270-767-54772	Sequence 54772, A
78	5	25.0	276	4	US-09-710-279-1482	Sequence 1482, Ap
79	5	25.0	283	4	US-09-904-615-106	Sequence 106, App
80	5	25.0	286	4	US-09-270-767-44940	Sequence 44940, A
81	5	25.0	288	4	US-09-252-991A-27676	Sequence 27676, A
82	5	25.0	289	4	US-09-252-991A-25496	Sequence 25496, A
83	5	25.0	301	4	US-09-252-991A-25370	Sequence 25370, A
84	5	25.0	308	4	US-09-248-796A-14594	Sequence 14594, A
85	5	25.0	315	4	US-09-252-991A-19219	Sequence 19219, A
86	5	25.0	315	4	US-09-650-324A-52	Sequence 52, Appl
87	5	25.0	316	4	US-09-248-796A-16974	Sequence 16974, A
88	5	25.0	327	4	US-09-252-991A-19369	Sequence 19369, A
89	5	25.0	339	4	US-09-252-991A-19891	Sequence 19891, A
90	5	25.0	341	4	US-09-270-767-45581	Sequence 45581, A
91	5	25.0	342	4	US-09-248-796A-27396	Sequence 27396, A
92	5	25.0	358	4	US-09-252-991A-20554	Sequence 20554, A
93	5	25.0	359	4	US-09-425-488-2	Sequence 2, Appli
94	5	25.0	359	4	US-09-270-767-36276	Sequence 36276, A
95	5	25.0	359	4	US-09-270-767-51493	Sequence 51493, A
96	5	25.0	362	4	US-09-425-488-8	Sequence 8, Appli
97	5	25.0	363	4	US-09-252-991A-17858	Sequence 17858, A
98	5	25.0	374	4	US-09-252-991A-31139	Sequence 31139, A
99	5	25.0	378	4	US-09-252-991A-23047	Sequence 23047, A
100	5	25.0	394	4	US-09-252-991A-19344	Sequence 19344, A

ALIGNMENTS

RESULT 1
US-09-489-039A-8944
; Sequence 8944, Application US/09489039A
; Patent No. 6610836
; GENERAL INFORMATION:
; APPLICANT: Gary Breton et. al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA
; TITLE OF INVENTION: PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 2709.2004001
; CURRENT APPLICATION NUMBER: US/09/489,039A
; CURRENT FILING DATE: 2000-01-27
; PRIOR APPLICATION NUMBER: US 60/117,747
; PRIOR FILING DATE: 1999-01-29
; NUMBER OF SEQ ID NOS: 14342
; SEQ ID NO 8944
; LENGTH: 169
; TYPE: PRT
; ORGANISM: Klebsiella pneumoniae
US-09-489-039A-8944

Query Match 30.0%; Score 6; DB 4; Length 169;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 GAPMWL 8
||||||
Db 90 GAPMWL 95

RESULT 2
US-09-270-767-41955
; Sequence 41955, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 41955
; LENGTH: 173
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
US-09-270-767-41955

Query Match 30.0%; Score 6; DB 4; Length 173;
Best Local Similarity 100.0%; Pred. No. 17;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 15 LETKFL 20
||||||
Db 17 LETKFL 22

RESULT 3
US-09-248-796A-23067
; Sequence 23067, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
; APPLICANT: Keith Weinstock et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN
; TITLE OF INVENTION: FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.132
; CURRENT APPLICATION NUMBER: US/09/248,796A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,725
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/096,409
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 23067
; LENGTH: 394
; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-23067

Query Match 30.0%; Score 6; DB 4; Length 394;
Best Local Similarity 100.0%; Pred. No. 33;
Matches 6; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 15 LETKFL 20
||||||
Db 87 LETKFL 92

RESULT 4
US-07-972-032-15
; Sequence 15, Application US/07972032
; Patent No. 5496712
; GENERAL INFORMATION:
; APPLICANT: Cappello, Joseph
; APPLICANT: Ferrari, Franco A.
; TITLE OF INVENTION: HIGH MOLECULAR WEIGHT COLLAGEN-LIKE
; TITLE OF INVENTION: PROTEIN POLYMERS
; NUMBER OF SEQUENCES: 85
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bertram I. Rowland
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: CA 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/972,032
; FILING DATE: 19921105
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/791,960
; FILING DATE: 12-NOV-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Rowland, Bertram I.
; REGISTRATION NUMBER: 20,015
; REFERENCE/DOCKET NUMBER: A-55556-1/BIR;PROP-08-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 781-1989
; TELEFAX: (415) 398-3249
; INFORMATION FOR SEQ ID NO: 15:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 9 amino acids
; TYPE: AMINO ACID
; TOPOLOGY: linear
; MOLECULE TYPE: peptide
US-07-972-032-15

Query Match 25.0%; Score 5; DB 1; Length 9;
Best Local Similarity 100.0%; Pred. No. 3.8e+05;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
|||||
Db 5 PRGAP 9

RESULT 5

```
US-08-642-255-15
; Sequence 15, Application US/08642255
; Patent No. 5773249
;  GENERAL INFORMATION:
;    APPLICANT:  CAPPELLO, Joseph
;    APPLICANT:  FERRARI, Franco A.
;    TITLE OF INVENTION:  High Molecular Weight Collagen-Like
;    TITLE OF INVENTION:  Protein Polymers
;    NUMBER OF SEQUENCES:  135
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
;      STREET:  4 Embarcadero Center, Suite 3400
;      CITY:  San Francisco
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  94111-4187
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/642,255
;      FILING DATE:
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  ROWLAND, Bertram I.
;      REGISTRATION NUMBER:  20,015
;      REFERENCE/DOCKET NUMBER:  A55556-3/BIR
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (415) 494-8700
;      TELEFAX:  (415) 494-8771
;      TELEX:  910 277299 FHT UR
;  INFORMATION FOR SEQ ID NO:  15:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  9 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-642-255-15

  Query Match             25.0%;  Score 5;  DB 1;  Length 9;
  Best Local Similarity   100.0%;  Pred. No. 3.8e+05;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db          5 PRGAP 9


RESULT 6
US-08-468-819-20
; Sequence 20, Application US/08468819
; Patent No. 5871723
;  GENERAL INFORMATION:
;    APPLICANT:  Strieter, Robert M.
;    APPLICANT:  Polverini, Peter J.
;    APPLICANT:  Kunkel, Steven L.
;    TITLE OF INVENTION:  CXC Chemokines as Regulators of
;    TITLE OF INVENTION:  Angiogenesis
;    NUMBER OF SEQUENCES:  93
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  TX
;      COUNTRY:  US
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/468,819
;      FILING DATE:  Concurrently herewith
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Highlander, Steven L.
;      REGISTRATION NUMBER:  37,642
;      REFERENCE/DOCKET NUMBER:  UMIC:003/HYL
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  512/418-3000
;      TELEFAX:  512/474-7477
;      TELEX:  N/A
;  INFORMATION FOR SEQ ID NO:  20:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  15 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-468-819-20

  Query Match             25.0%;  Score 5;  DB 2;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 31;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 7
US-09-213-383-20
; Sequence 20, Application US/09213383
; Patent No. 6491906
;   GENERAL INFORMATION:
;        APPLICANT: Strieter, Robert M.
;                   Polverini, Peter J.
;                   Kunkel, Steven L.
;        TITLE OF INVENTION: CXC Chemokines as Regulators of
;                            Angiogenesis
;        NUMBER OF SEQUENCES: 93
;        CORRESPONDENCE ADDRESS:
;             ADDRESSEE: Arnold, White & Durkee
;             STREET: P.O. Box 4433
;             CITY: Houston
;             STATE: TX
;             COUNTRY: US
;             ZIP: 77210
;        COMPUTER READABLE FORM:
;             MEDIUM TYPE: Floppy disk
;             COMPUTER: IBM PC compatible
;             OPERATING SYSTEM: PC-DOS/MS-DOS
;             SOFTWARE: PatentIn Release #1.0, Version #1.30
;        CURRENT APPLICATION DATA:
;             APPLICATION NUMBER: US/09/213,383
;             FILING DATE: 09-Dec-1998
;             CLASSIFICATION: <Unknown>
;        PRIOR APPLICATION DATA:
;             APPLICATION NUMBER: 08/468,819
;             FILING DATE: <Unknown>
;        ATTORNEY/AGENT INFORMATION:
;             NAME: Highlander, Steven L.
;             REGISTRATION NUMBER: 37,642
;             REFERENCE/DOCKET NUMBER: UMIC:003/HYL
;        TELECOMMUNICATION INFORMATION:
;             TELEPHONE: 512/418-3000
;             TELEFAX: 512/474-7477
;             TELEX: N/A
;   INFORMATION FOR SEQ ID NO: 20:
;        SEQUENCE CHARACTERISTICS:
;             LENGTH: 15 amino acids
;             TYPE: amino acid
```

```
;             STRANDEDNESS: single
;             TOPOLOGY: linear
;        MOLECULE TYPE: peptide
;        SEQUENCE DESCRIPTION: SEQ ID NO: 20:
US-09-213-383-20

  Query Match             25.0%;  Score 5;  DB 4;  Length 15;
  Best Local Similarity   100.0%;  Pred. No. 31;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 8
US-08-311-307B-11
; Sequence 11, Application US/08311307B
; Patent No. 5627156
;  GENERAL INFORMATION:
;    APPLICANT:  Talmadge, James E.
;    TITLE OF INVENTION:  Polypeptide Agonist Derived From Human
;    TITLE OF INVENTION:  Interleukin-8
;    NUMBER OF SEQUENCES:  12
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Dann, Dorfman, Herrell and Skillman
;      STREET:  1601 Market Street
;      CITY:  Philadelphia
;      STATE:  PA
;      COUNTRY:  USA
;      ZIP:  19103-2307
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/311,307B
;      FILING DATE:  23-SEP-1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Hagan, Patrick J.
;      REGISTRATION NUMBER:  27,643
;      REFERENCE/DOCKET NUMBER:  63085
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (215)563-4100
;      TELEFAX:  (215)563-4044
;  INFORMATION FOR SEQ ID NO:  11:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  16 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  not relevant
;      TOPOLOGY:  not relevant
;    MOLECULE TYPE:  peptide
;    HYPOTHETICAL:  NO
;    ANTI-SENSE:  NO
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  4..6
;      OTHER INFORMATION:  /note= "The cysteine residues may
;      OTHER INFORMATION:  be substituted with aminobutyric acid, homocysteine, or
;      OTHER INFORMATION:  diaminosuberic acid."
US-08-311-307B-11

  Query Match             25.0%;  Score 5;  DB 1;  Length 16;
  Best Local Similarity   100.0%;  Pred. No. 32;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db          2 LRCVC 6


RESULT 9
US-07-778-413E-3
; Sequence 3, Application US/07778413E
; Patent No. 5401651
;  GENERAL INFORMATION:
;    APPLICANT:  Walz, Alfred
;    TITLE OF INVENTION:  No. 5401651el Neutrophil
;    TITLE OF INVENTION:  Activating Factors
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Amgen Inc.
;      STREET:  Amgen Center
;      STREET:  1840 Dehavilland Drive
;      CITY:  Thousand Oaks
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  91320-1789
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 in., DS, 2.0 MB
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh OS 7.0
;      SOFTWARE:  Microsoft Word Version 5.1a
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/778,413E
;      FILING DATE:  16-OCT-1991
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Cook, Robert R.
;      REGISTRATION NUMBER:  31602
;      REFERENCE/DOCKET NUMBER:  A-204
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (805) 499-5725 EXTENSION 4955
;      TELEFAX:  (805) 499-8011
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  17
;      TYPE:  Amino Acid
;      TOPOLOGY:  Linear
US-07-778-413E-3

  Query Match             25.0%;  Score 5;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 34;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 10
US-08-340-102-3
; Sequence 3, Application US/08340102
; Patent No. 5591718
;  GENERAL INFORMATION:
;    APPLICANT:  Walz, Alfred
;    TITLE OF INVENTION:  No. 5591718el Neutrophil
;    TITLE OF INVENTION:  Activating Factors
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Amgen Inc.
;      STREET:  Amgen Center
;      STREET:  1840 Dehavilland Drive
;      CITY:  Thousand Oaks
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  91320-1789
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 in., DS, 1.4 MB
;      COMPUTER:  MS-DOS
;      OPERATING SYSTEM:  MS-DOS 6.22
;      SOFTWARE:  Microsoft Word Version 5.1a for
;      SOFTWARE:  Macintosh
;    CURRENT APPLICATION DATA:
```

```
;       APPLICATION NUMBER:  US/08/340,102
;       FILING DATE:  15-NOV-1994
;       CLASSIFICATION:  514
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  Cook, Robert R.
;       REGISTRATION NUMBER:  31602
;       REFERENCE/DOCKET NUMBER:  A-204A
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (805) 499-5725 EXTENSION 4955
;       TELEFAX:  (805) 499-8011
;   INFORMATION FOR SEQ ID NO:  3:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  17
;       TYPE:  Amino Acid
;       TOPOLOGY:  Linear
US-08-340-102-3

  Query Match             25.0%;  Score 5;  DB 1;  Length 17;
  Best Local Similarity   100.0%;  Pred. No. 34;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 11
US-07-778-413E-4
; Sequence 4, Application US/07778413E
; Patent No. 5401651
;  GENERAL INFORMATION:
;    APPLICANT:  Walz, Alfred
;    TITLE OF INVENTION:  No. 5401651el Neutrophil
;    TITLE OF INVENTION:  Activating Factors
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Amgen Inc.
;      STREET:  Amgen Center
;      STREET:  1840 Dehavilland Drive
;      CITY:  Thousand Oaks
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  91320-1789
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 in., DS, 2.0 MB
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh OS 7.0
;      SOFTWARE:  Microsoft Word Version 5.1a
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/778,413E
;      FILING DATE:  16-OCT-1991
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Cook, Robert R.
;      REGISTRATION NUMBER:  31602
;      REFERENCE/DOCKET NUMBER:  A-204
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (805) 499-5725 EXTENSION 4955
;      TELEFAX:  (805) 499-8011
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34
;      TYPE:  Amino Acid
;      TOPOLOGY:  Linear
US-07-778-413E-4

  Query Match             25.0%;  Score 5;  DB 1;  Length 34;
  Best Local Similarity   100.0%;  Pred. No. 59;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 12
US-08-340-102-4
; Sequence 4, Application US/08340102
; Patent No. 5591718
;  GENERAL INFORMATION:
;    APPLICANT:  Walz, Alfred
;    TITLE OF INVENTION:  No. 5591718el Neutrophil
;    TITLE OF INVENTION:  Activating Factors
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Amgen Inc.
;      STREET:  Amgen Center
;      STREET:  1840 Dehavilland Drive
;      CITY:  Thousand Oaks
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  91320-1789
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 in., DS, 1.4 MB
;      COMPUTER:  MS-DOS
;      OPERATING SYSTEM:  MS-DOS 6.22
;      SOFTWARE:  Microsoft Word Version 5.1a for
;      SOFTWARE:  Macintosh
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/340,102
;      FILING DATE:  15-NOV-1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Cook, Robert R.
;      REGISTRATION NUMBER:  31602
;      REFERENCE/DOCKET NUMBER:  A-204A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (805) 499-5725 EXTENSION 4955
;      TELEFAX:  (805) 499-8011
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  34
;      TYPE:  Amino Acid
;      TOPOLOGY:  Linear
US-08-340-102-4

  Query Match             25.0%;  Score 5;  DB 1;  Length 34;
  Best Local Similarity   100.0%;  Pred. No. 59;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 13
US-08-436-420-17
; Sequence 17, Application US/08436420
; Patent No. 5840524
;  GENERAL INFORMATION:
;    APPLICANT:  VAN DAMME, Jo; and
;    APPLICANT:  PROOST, Paul
;    TITLE OF INVENTION:  GRANULOCYTE CHEMOTACTIC PROTEIN
;    NUMBER OF SEQUENCES:  45
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  HALE and DORR LLP
;      STREET:  1455 PENNSYLVANIA AVENUE, N.W.
;      CITY:  WASHINGTON
;      STATE:  DISTRICT OF COLUMBIA
;      COUNTRY:  USA
;      ZIP:  20004
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.25 (EPO)
```

```
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/436,420
;      FILING DATE:  24-MAY-1995
;      CLASSIFICATION:  530
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/EP93/03330
;      FILING DATE:  26-NOV-1993
;      CLASSIFICATION:  530
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 07/982,539
;      FILING DATE:  27-NOV-1992
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  BAKER, Hollie L.
;      REGISTRATION NUMBER:  31,321
;      REFERENCE/DOCKET NUMBER:  102378.215
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (202) 942-8400
;      TELEFAX:  (202) 942-8484
;  INFORMATION FOR SEQ ID NO:  17:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  46 amino acids
;      TYPE:  amino acid
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
;    FRAGMENT TYPE:  N-terminal
;    FEATURE:
;      NAME/KEY:  Modified-site
;      LOCATION:  44..46
;      OTHER INFORMATION:  /note= "Xaa was ambiguous at time
;      OTHER INFORMATION:  of determination; later identified as "G..."
US-08-436-420-17

  Query Match             25.0%;  Score 5;  DB 2;  Length 46;
  Best Local Similarity   100.0%;  Pred. No. 76;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db          3 LRCVC 7


RESULT 14
US-09-248-796A-24632
; Sequence 24632, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
;  APPLICANT: Keith Weinstock et al
;  TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN
;  TITLE OF INVENTION:  FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE: 107196.132
;  CURRENT APPLICATION NUMBER: US/09/248,796A
;  CURRENT FILING DATE:  1999-02-12
;  PRIOR APPLICATION NUMBER: US 60/074,725
;  PRIOR FILING DATE: 1998-02-13
;  PRIOR APPLICATION NUMBER: US 60/096,409
;  PRIOR FILING DATE: 1998-08-13
;  NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 24632
;   LENGTH: 63
;   TYPE: PRT
;   ORGANISM: Candida albicans
US-09-248-796A-24632

  Query Match             25.0%;  Score 5;  DB 4;  Length 63;
  Best Local Similarity   100.0%;  Pred. No. 97;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         16 ETKFL 20
              |||||
Db         49 ETKFL 53


RESULT 15
US-09-134-001C-3074
; Sequence 3074, Application US/09134001C
; Patent No. 6380370
; GENERAL INFORMATION:
;  APPLICANT: Lynn Doucette-Stamm et al
;  TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STAPHYLOCOCCUS
;  TITLE OF INVENTION:  EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE: GTC-007
;  CURRENT APPLICATION NUMBER: US/09/134,001C
;  CURRENT FILING DATE:  1998-08-13
;  PRIOR APPLICATION NUMBER: US 60/064,964
;  PRIOR FILING DATE: 1997-11-08
;  PRIOR APPLICATION NUMBER: US 60/055,779
;  PRIOR FILING DATE: 1997-08-14
;  NUMBER OF SEQ ID NOS: 5674
; SEQ ID NO 3074
;   LENGTH: 74
;   TYPE: PRT
;   ORGANISM: Staphylococcus epidermidis
US-09-134-001C-3074

  Query Match             25.0%;  Score 5;  DB 3;  Length 74;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         58 PRGAP 62


RESULT 16
US-09-134-001C-4851
; Sequence 4851, Application US/09134001C
; Patent No. 6380370
; GENERAL INFORMATION:
;  APPLICANT: Lynn Doucette-Stamm et al
;  TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STAPHYLOCOCCUS
;  TITLE OF INVENTION:  EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE: GTC-007
;  CURRENT APPLICATION NUMBER: US/09/134,001C
;  CURRENT FILING DATE:  1998-08-13
;  PRIOR APPLICATION NUMBER: US 60/064,964
;  PRIOR FILING DATE: 1997-11-08
;  PRIOR APPLICATION NUMBER: US 60/055,779
;  PRIOR FILING DATE: 1997-08-14
;  NUMBER OF SEQ ID NOS: 5674
; SEQ ID NO 4851
;   LENGTH: 74
;   TYPE: PRT
;   ORGANISM: Staphylococcus epidermidis
US-09-134-001C-4851

  Query Match             25.0%;  Score 5;  DB 3;  Length 74;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         58 PRGAP 62


RESULT 17
US-08-436-420-15
; Sequence 15, Application US/08436420
; Patent No. 5840524
;  GENERAL INFORMATION:
;    APPLICANT:  VAN DAMME, Jo; and
;    APPLICANT:  PROOST, Paul
;    TITLE OF INVENTION:  GRANULOCYTE CHEMOTACTIC PROTEIN
;    NUMBER OF SEQUENCES:  45
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  HALE and DORR LLP
;      STREET:  1455 PENNSYLVANIA AVENUE, N.W.
```

```
;       CITY:  WASHINGTON
;       STATE:  DISTRICT OF COLUMBIA
;       COUNTRY:  USA
;       ZIP:  20004
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.25 (EPO)
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/436,420
;       FILING DATE:  24-MAY-1995
;       CLASSIFICATION:  530
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  PCT/EP93/03330
;       FILING DATE:  26-NOV-1993
;       CLASSIFICATION:  530
;     PRIOR APPLICATION DATA:
;       APPLICATION NUMBER:  US 07/982,539
;       FILING DATE:  27-NOV-1992
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  BAKER, Hollie L.
;       REGISTRATION NUMBER:  31,321
;       REFERENCE/DOCKET NUMBER:  102378.215
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (202) 942-8400
;       TELEFAX:  (202) 942-8484
;   INFORMATION FOR SEQ ID NO:  15:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  75 amino acids
;       TYPE:  amino acid
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  protein
US-08-436-420-15

  Query Match             25.0%;  Score 5;  DB 2;  Length 75;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         10 LRCVC 14


RESULT 18
US-09-270-767-36912
; Sequence 36912, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 36912
;   LENGTH: 77
;   TYPE: PRT
;   ORGANISM: Drosophila melanogaster
;   FEATURE:
;   OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-36912

  Query Match             25.0%;  Score 5;  DB 4;  Length 77;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         70 PRGAP 74


RESULT 19
US-09-270-767-52129
; Sequence 52129, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 52129
;   LENGTH: 77
;   TYPE: PRT
;   ORGANISM: Drosophila melanogaster
;   FEATURE:
;   OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-52129

  Query Match             25.0%;  Score 5;  DB 4;  Length 77;
  Best Local Similarity   100.0%;  Pred. No. 1.1e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         70 PRGAP 74


RESULT 20
US-07-778-413E-12
; Sequence 12, Application US/07778413E
; Patent No. 5401651
;  GENERAL INFORMATION:
;    APPLICANT:  Walz, Alfred
;    TITLE OF INVENTION:  No. 5401651el Neutrophil
;    TITLE OF INVENTION:  Activating Factors
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Amgen Inc.
;      STREET:  Amgen Center
;      STREET:  1840 Dehavilland Drive
;      CITY:  Thousand Oaks
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  91320-1789
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 in., DS, 2.0 MB
;      COMPUTER:  Apple Macintosh
;      OPERATING SYSTEM:  Macintosh OS 7.0
;      SOFTWARE:  Microsoft Word Version 5.1a
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/07/778,413E
;      FILING DATE:  16-OCT-1991
;      CLASSIFICATION:  536
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Cook, Robert R.
;      REGISTRATION NUMBER:  31602
;      REFERENCE/DOCKET NUMBER:  A-204
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (805) 499-5725 EXTENSION 4955
;      TELEFAX:  (805) 499-8011
;  INFORMATION FOR SEQ ID NO:  12:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  78
;      TYPE:  Amino Acid
;      TOPOLOGY:  Linear
US-07-778-413E-12

  Query Match             25.0%;  Score 5;  DB 1;  Length 78;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;
```

```
Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 21
US-08-340-102-12
; Sequence 12, Application US/08340102
; Patent No. 5591718
;  GENERAL INFORMATION:
;    APPLICANT:  Walz, Alfred
;    TITLE OF INVENTION:  No. 5591718el Neutrophil
;    TITLE OF INVENTION:  Activating Factors
;    NUMBER OF SEQUENCES:  22
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Amgen Inc.
;      STREET:  Amgen Center
;      STREET:  1840 Dehavilland Drive
;      CITY:  Thousand Oaks
;      STATE:  California
;      COUNTRY:  USA
;      ZIP:  91320-1789
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette, 3.5 in., DS, 1.4 MB
;      COMPUTER:  MS-DOS
;      OPERATING SYSTEM:  MS-DOS 6.22
;      SOFTWARE:  Microsoft Word Version 5.1a for
;      SOFTWARE:  Macintosh
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/340,102
;      FILING DATE:  15-NOV-1994
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Cook, Robert R.
;      REGISTRATION NUMBER:  31602
;      REFERENCE/DOCKET NUMBER:  A-204A
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (805) 499-5725 EXTENSION 4955
;      TELEFAX:  (805) 499-8011
;  INFORMATION FOR SEQ ID NO:  12:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  78
;      TYPE:  Amino Acid
;      TOPOLOGY:  Linear
US-08-340-102-12

  Query Match             25.0%;  Score 5;  DB 1;  Length 78;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 22
US-08-330-163-8
; Sequence 8, Application US/08330163
; Patent No. 5656724
;  GENERAL INFORMATION:
;    APPLICANT:  Daly, Thomas J.
;    APPLICANT:  LaRosa, Gregory J.
;    TITLE OF INVENTION:  Chemokine-Like Proteins and Methods of
;    TITLE OF INVENTION:  Use
;    NUMBER OF SEQUENCES:  46
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson
;      STREET:  225 Franklin Street
;      CITY:  Boston
;      STATE:  MA
;      COUNTRY:  U.S.A.
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30B
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/330,163
;      FILING DATE:  05-AUG-1994
;      CLASSIFICATION:  530
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fasse, J. Peter
;      REGISTRATION NUMBER:  32,983
;      REFERENCE/DOCKET NUMBER:  00231/080001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 542-5070
;      TELEFAX:  (617) 542-8906
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  78 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-330-163-8

  Query Match             25.0%;  Score 5;  DB 1;  Length 78;
  Best Local Similarity   100.0%;  Pred. No. 1.2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         11 LRCVC 15


RESULT 23
US-08-482-111-8
; Sequence 8, Application US/08482111
; Patent No. 5789539
;  GENERAL INFORMATION:
;    APPLICANT:  Daly, Thomas J.
;    APPLICANT:  LaRosa, Gregory J.
;    TITLE OF INVENTION:  Chemokine-Like Proteins and Methods of
;    TITLE OF INVENTION:  Use
;    NUMBER OF SEQUENCES:  70
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Fish & Richardson P.C.
;      STREET:  225 Franklin Street
;      CITY:  Boston
;      STATE:  MA
;      COUNTRY:  U.S.A.
;      ZIP:  02110-2804
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30B
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/482,111
;      FILING DATE:  07-JUN-1995
;      CLASSIFICATION:  514
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Fasse, J. Peter
;      REGISTRATION NUMBER:  32,983
;      REFERENCE/DOCKET NUMBER:  00231/083001
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  (617) 542-5070
;      TELEFAX:  (617) 542-8906
;  INFORMATION FOR SEQ ID NO:  8:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  78 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
```

US-08-482-111-8

Query Match 25.0%; Score 5; DB 1; Length 78;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVC 12
||||||
Db 11 LRCVC 15

RESULT 24
US-08-436-420-32
; Sequence 32, Application US/08436420
; Patent No. 5840524
; GENERAL INFORMATION:
; APPLICANT: VAN DAMME, Jo; and
; APPLICANT: PROOST, Paul
; TITLE OF INVENTION: GRANULOCYTE CHEMOTACTIC PROTEIN
; NUMBER OF SEQUENCES: 45
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE and DORR LLP
; STREET: 1455 PENNSYLVANIA AVENUE, N.W.
; CITY: WASHINGTON
; STATE: DISTRICT OF COLUMBIA
; COUNTRY: USA
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/436,420
; FILING DATE: 24-MAY-1995
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP93/03330
; FILING DATE: 26-NOV-1993
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/982,539
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: BAKER, Hollie L.
; REGISTRATION NUMBER: 31,321
; REFERENCE/DOCKET NUMBER: 102378.215
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 942-8400
; TELEFAX: (202) 942-8484
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 78 amino acids
; TYPE: amino acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: protein
US-08-436-420-32

Query Match 25.0%; Score 5; DB 2; Length 78;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVC 12
||||||
Db 11 LRCVC 15

RESULT 25
US-09-461-697-464
; Sequence 464, Application US/09461697
; Patent No. 6277974
; GENERAL INFORMATION:
; APPLICANT: COGENT NEUROSCIENCE, Inc.
; APPLICANT: Lo, Donald C.
; APPLICANT: Barney, Shawn
; APPLICANT: Thomas, Mary Beth
; APPLICANT: Portbury, Stuart D.
; APPLICANT: Puranam, Kasturi
; APPLICANT: Katz, Lawrence C.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING
; TITLE OF INVENTION: AND TREATING CONDITIONS, DISORDERS, OR DISEASES INVOLVING
; TITLE OF INVENTION: CELL DEATH
; FILE REFERENCE: 10001-005-999
; CURRENT APPLICATION NUMBER: US/09/461,697
; CURRENT FILING DATE: 1999-12-14
; NUMBER OF SEQ ID NOS: 466
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 464
; LENGTH: 80
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-461-697-464

Query Match 25.0%; Score 5; DB 3; Length 80;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
|||||
Db 54 PRGAP 58

RESULT 26
US-09-270-767-41916
; Sequence 41916, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 41916
; LENGTH: 85
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-41916

Query Match 25.0%; Score 5; DB 4; Length 85;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVC 12
||||||
Db 27 LRCVC 31

RESULT 27
US-09-252-991A-24182
; Sequence 24182, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190

```
;  PRIOR FILING DATE:  1998-07-27
;  NUMBER OF SEQ ID NOS:  33142
; SEQ ID NO 24182
;   LENGTH: 91
;   TYPE: PRT
;   ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-24182

  Query Match             25.0%;  Score 5;  DB 4;  Length 91;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          2 RGAPM 6
              |||||
Db         37 RGAPM 41


RESULT 28
US-09-270-767-38667
; Sequence 38667, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 38667
;   LENGTH: 91
;   TYPE: PRT
;   ORGANISM: Drosophila melanogaster
US-09-270-767-38667

  Query Match             25.0%;  Score 5;  DB 4;  Length 91;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         65 PRGAP 69


RESULT 29
US-09-270-767-53884
; Sequence 53884, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 53884
;   LENGTH: 91
;   TYPE: PRT
;   ORGANISM: Drosophila melanogaster
US-09-270-767-53884

  Query Match             25.0%;  Score 5;  DB 4;  Length 91;
  Best Local Similarity   100.0%;  Pred. No. 1.3e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         65 PRGAP 69


RESULT 30
US-09-248-796A-27372
; Sequence 27372, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
;  APPLICANT: Keith Weinstock et al
;  TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN
;  TITLE OF INVENTION:  FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE: 107196.132
;  CURRENT APPLICATION NUMBER: US/09/248,796A
;  CURRENT FILING DATE:  1999-02-12
;  PRIOR APPLICATION NUMBER: US 60/074,725
;  PRIOR FILING DATE: 1998-02-13
;  PRIOR APPLICATION NUMBER: US 60/096,409
;  PRIOR FILING DATE: 1998-08-13
;  NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 27372
;   LENGTH: 95
;   TYPE: PRT
;   ORGANISM: Candida albicans
US-09-248-796A-27372

  Query Match             25.0%;  Score 5;  DB 4;  Length 95;
  Best Local Similarity   100.0%;  Pred. No. 1.4e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         16 ETKFL 20
              |||||
Db         53 ETKFL 57


RESULT 31
US-09-489-039A-13486
; Sequence 13486, Application US/09489039A
; Patent No. 6610836
; GENERAL INFORMATION:
;  APPLICANT:  Gary Breton et. al
;  TITLE OF INVENTION:  NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA
;  TITLE OF INVENTION:  PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE:  2709.2004001
;  CURRENT APPLICATION NUMBER: US/09/489,039A
;  CURRENT FILING DATE:  2000-01-27
;  PRIOR APPLICATION NUMBER:  US 60/117,747
;  PRIOR FILING DATE:  1999-01-29
;  NUMBER OF SEQ ID NOS:  14342
; SEQ ID NO 13486
;   LENGTH: 105
;   TYPE: PRT
;   ORGANISM: Klebsiella pneumoniae
US-09-489-039A-13486

  Query Match             25.0%;  Score 5;  DB 4;  Length 105;
  Best Local Similarity   100.0%;  Pred. No. 1.5e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         11 VCQML 15
              |||||
Db         21 VCQML 25


RESULT 32
US-08-816-772-9
; Sequence 9, Application US/08816772
; Patent No. 6410268
;  GENERAL INFORMATION:
;    APPLICANT:  NI, JIAN
;    APPLICANT:  LI, HAODONG
;    APPLICANT:  SU, JEFFREY
;    TITLE OF INVENTION:  CHEMOKINE ALPHA-3
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
;      STREET:  1100 NEW YORK AVENUE, SUITE 600
;      CITY:  WASHINGTON
;      STATE:  DC
```

```
;       COUNTRY:  US
;       ZIP:  20005-3934
;     COMPUTER READABLE FORM:
;       MEDIUM TYPE:  Floppy disk
;       COMPUTER:  IBM PC compatible
;       OPERATING SYSTEM:  PC-DOS/MS-DOS
;       SOFTWARE:  PatentIn Release #1.0, Version #1.30
;     CURRENT APPLICATION DATA:
;       APPLICATION NUMBER:  US/08/816,772
;       FILING DATE:
;       CLASSIFICATION:  435
;     ATTORNEY/AGENT INFORMATION:
;       NAME:  STEFFE, ERIC K.
;       REGISTRATION NUMBER:  36,688
;       REFERENCE/DOCKET NUMBER:  1488.0980001
;     TELECOMMUNICATION INFORMATION:
;       TELEPHONE:  (202) 371-2600
;       TELEFAX:  (202) 371-2540
;   INFORMATION FOR SEQ ID NO:  9:
;     SEQUENCE CHARACTERISTICS:
;       LENGTH:  113 amino acids
;       TYPE:  amino acid
;       STRANDEDNESS:  not relevant
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  peptide
US-08-816-772-9

  Query Match             25.0%;  Score 5;  DB 4;  Length 113;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         47 LRCVC 51


RESULT 33
US-08-352-324A-3
; Sequence 3, Application US/08352324A
; Patent No. 5633149
;  GENERAL INFORMATION:
;    APPLICANT:  Guegler, Karl J.
;    APPLICANT:  Hawkins, Phillip R.
;    APPLICANT:  Wilde, Craig G.
;    APPLICANT:  Seilhamer, Jeffrey J.
;    TITLE OF INVENTION:  A NOVEL CHEMOKINE EXPRESSED IN
;    TITLE OF INVENTION:  INFLAMED ADENOID, ITS PRODUCTION AND USES
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Incyte Pharmaceuticals, Inc.
;      STREET:  3174 Porter Drive
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  US
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/352,324A
;      FILING DATE:  07-DEC-1994
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Luther, Barbara J.
;      REGISTRATION NUMBER:  33,954
;      REFERENCE/DOCKET NUMBER:  PF-0025 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-855-0555
;      TELEFAX:  415-852-0195
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  114 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-352-324A-3

  Query Match             25.0%;  Score 5;  DB 1;  Length 114;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         47 LRCVC 51


RESULT 34
US-08-862-607-3
; Sequence 3, Application US/08862607
; Patent No. 5844084
;  GENERAL INFORMATION:
;    APPLICANT:  Guegler, Karl J.
;    APPLICANT:  Hawkins, Phillip R.
;    APPLICANT:  Wilde, Craig G.
;    APPLICANT:  Seilhamer, Jeffrey J.
;    TITLE OF INVENTION:  A NOVEL CHEMOKINE EXPRESSED IN
;    TITLE OF INVENTION:  INFLAMED ADENOID, ITS PRODUCTION AND USES
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Incyte Pharmaceuticals, Inc.
;      STREET:  3174 Porter Drive
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  US
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/862,607
;      FILING DATE:  23-MAY-1997
;      CLASSIFICATION:  435
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/352,324
;      FILING DATE:  07-DEC-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Luther, Barbara J.
;      REGISTRATION NUMBER:  33,954
;      REFERENCE/DOCKET NUMBER:  PF-0025 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-855-0555
;      TELEFAX:  415-852-0195
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  114 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-862-607-3

  Query Match             25.0%;  Score 5;  DB 2;  Length 114;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         47 LRCVC 51


RESULT 35
```

```
US-08-468-819-4
; Sequence 4, Application US/08468819
; Patent No. 5871723
;  GENERAL INFORMATION:
;    APPLICANT:  Strieter, Robert M.
;    APPLICANT:  Polverini, Peter J.
;    APPLICANT:  Kunkel, Steven L.
;    TITLE OF INVENTION:  CXC Chemokines as Regulators of
;    TITLE OF INVENTION:  Angiogenesis
;    NUMBER OF SEQUENCES:  93
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Arnold, White & Durkee
;      STREET:  P.O. Box 4433
;      CITY:  Houston
;      STATE:  TX
;      COUNTRY:  US
;      ZIP:  77210
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/468,819
;      FILING DATE:  Concurrently herewith
;      CLASSIFICATION:  424
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Highlander, Steven L.
;      REGISTRATION NUMBER:  37,642
;      REFERENCE/DOCKET NUMBER:  UMIC:003/HYL
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  512/418-3000
;      TELEFAX:  512/474-7477
;      TELEX:  N/A
;  INFORMATION FOR SEQ ID NO:  4:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  114 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-08-468-819-4

  Query Match             25.0%;  Score 5;  DB 2;  Length 114;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         47 LRCVC 51


RESULT 36
US-09-203-235-3
; Sequence 3, Application US/09203235
; Patent No. 6071701
;  GENERAL INFORMATION:
;    APPLICANT:  Guegler, Karl J.
;    APPLICANT:  Hawkins, Phillip R.
;    APPLICANT:  Wilde, Craig G.
;    APPLICANT:  Seilhamer, Jeffrey J.
;    TITLE OF INVENTION:  A NOVEL CHEMOKINE EXPRESSED IN
;    TITLE OF INVENTION:  INFLAMED ADENOID, ITS PRODUCTION AND USES
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Incyte Pharmaceuticals, Inc.
;      STREET:  3174 Porter Drive
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  US
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Diskette
;      COMPUTER:  IBM Compatible
;      OPERATING SYSTEM:  DOS
;      SOFTWARE:  FastSEQ Version 1.5
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/09/203,235
;      FILING DATE:
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  08/862,607
;      FILING DATE:  23-MAY-1997
;      APPLICATION NUMBER:  08/352,324
;      FILING DATE:  07-DEC-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Luther, Barbara J.
;      REGISTRATION NUMBER:  33,954
;      REFERENCE/DOCKET NUMBER:  PF-0025 US
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-855-0555
;      TELEFAX:  415-852-0195
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  114 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  single
;      TOPOLOGY:  linear
;    MOLECULE TYPE:  peptide
US-09-203-235-3

  Query Match             25.0%;  Score 5;  DB 3;  Length 114;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         47 LRCVC 51


RESULT 37
US-08-679-493A-149
; Sequence 149, Application US/08679493A
; Patent No. 6303295
; GENERAL INFORMATION:
;  APPLICANT: Taylor, Ethan W.
;  TITLE OF INVENTION: SELENOPROTEINS, CODING SEQUENCES AND METHODS
;  FILE REFERENCE: 55-95
;  CURRENT APPLICATION NUMBER: US/08/679,493A
;  CURRENT FILING DATE:  1996-07-12
;  PRIOR APPLICATION NUMBER: 60/001203
;  PRIOR FILING DATE: 1995-07-14
;  PRIOR APPLICATION NUMBER: 60/003,112
;  PRIOR FILING DATE: 1995-09-01
;  NUMBER OF SEQ ID NOS: 216
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 149
;   LENGTH: 114
;   TYPE: PRT
;   ORGANISM: Homo sapiens
US-08-679-493A-149

  Query Match             25.0%;  Score 5;  DB 3;  Length 114;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         47 LRCVC 51


RESULT 38
US-09-213-383-4
; Sequence 4, Application US/09213383
; Patent No. 6491906
;  GENERAL INFORMATION:
```

```
;         APPLICANT: Strieter, Robert M.
;                    Polverini, Peter J.
;                    Kunkel, Steven L.
;         TITLE OF INVENTION: CXC Chemokines as Regulators of
;                             Angiogenesis
;         NUMBER OF SEQUENCES: 93
;         CORRESPONDENCE ADDRESS:
;              ADDRESSEE: Arnold, White & Durkee
;              STREET: P.O. Box 4433
;              CITY: Houston
;              STATE: TX
;              COUNTRY: US
;              ZIP: 77210
;         COMPUTER READABLE FORM:
;              MEDIUM TYPE: Floppy disk
;              COMPUTER: IBM PC compatible
;              OPERATING SYSTEM: PC-DOS/MS-DOS
;              SOFTWARE: PatentIn Release #1.0, Version #1.30
;         CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/09/213,383
;              FILING DATE: 09-Dec-1998
;              CLASSIFICATION: <Unknown>
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: 08/468,819
;              FILING DATE: <Unknown>
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Highlander, Steven L.
;              REGISTRATION NUMBER: 37,642
;              REFERENCE/DOCKET NUMBER: UMIC:003/HYL
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: 512/418-3000
;              TELEFAX: 512/474-7477
;              TELEX: N/A
;    INFORMATION FOR SEQ ID NO: 4:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 114 amino acids
;              TYPE: amino acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         MOLECULE TYPE: peptide
;         SEQUENCE DESCRIPTION: SEQ ID NO: 4:
US-09-213-383-4

  Query Match             25.0%;  Score 5;  DB 4;  Length 114;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         47 LRCVC 51


RESULT 39
US-09-588-044-3
; Sequence 3, Application US/09588044
; Patent No. 6692920
;   GENERAL INFORMATION:
;         APPLICANT: Guegler, Karl J.
;                    Hawkins, Phillip R.
;                    Wilde, Craig G.
;                    Seilhamer, Jeffrey J.
;         TITLE OF INVENTION: A NOVEL CHEMOKINE EXPRESSED IN
;                             INFLAMED ADENOID, ITS PRODUCTION AND USES
;         NUMBER OF SEQUENCES: 9
;         CORRESPONDENCE ADDRESS:
;              ADDRESSEE: Incyte Pharmaceuticals, Inc.
;              STREET: 3174 Porter Drive
;              CITY: Palo Alto
;              STATE: CA
;              COUNTRY: US
;              ZIP: 94304
;         COMPUTER READABLE FORM:
;              MEDIUM TYPE: Diskette
;              COMPUTER: IBM Compatible
;              OPERATING SYSTEM: DOS
;              SOFTWARE: FastSEQ Version 1.5
;         CURRENT APPLICATION DATA:
;              APPLICATION NUMBER: US/09/588,044
;              FILING DATE: 05-Jun-2000
;              CLASSIFICATION: <Unknown>
;         PRIOR APPLICATION DATA:
;              APPLICATION NUMBER: 08/352,324
;              FILING DATE: 07-DEC-1994
;         ATTORNEY/AGENT INFORMATION:
;              NAME: Luther, Barbara J.
;              REGISTRATION NUMBER: 33,954
;              REFERENCE/DOCKET NUMBER: PF-0025 US
;         TELECOMMUNICATION INFORMATION:
;              TELEPHONE: 415-855-0555
;              TELEFAX: 415-852-0195
;    INFORMATION FOR SEQ ID NO: 3:
;         SEQUENCE CHARACTERISTICS:
;              LENGTH: 114 amino acids
;              TYPE: amino acid
;              STRANDEDNESS: single
;              TOPOLOGY: linear
;         MOLECULE TYPE: peptide
;         SEQUENCE DESCRIPTION: SEQ ID NO: 3:
US-09-588-044-3

  Query Match             25.0%;  Score 5;  DB 4;  Length 114;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         47 LRCVC 51


RESULT 40
PCT-US95-16144-3
; Sequence 3, Application PC/TUS9516144
;  GENERAL INFORMATION:
;    APPLICANT:  INCYTE PHARMACEUTICALS, INC.
;    TITLE OF INVENTION:  A NOVEL CHEMOKINE EXPRESSED IN INFLAMED
;    TITLE OF INVENTION:  ADENOID, ITS PRODUCTION AND USES
;    NUMBER OF SEQUENCES:  9
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  INCYTE PHARMACEUTICALS, INC.
;      STREET:  3174 Porter Drive
;      CITY:  Palo Alto
;      STATE:  CA
;      COUNTRY:  USA
;      ZIP:  94304
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  WordPefect 6.1/MS-DOS 6.2
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  PCT/US95/16144
;      FILING DATE:  07-DEC-1995
;      CLASSIFICATION:
;    PRIOR APPLICATION DATA:
;      APPLICATION NUMBER:  US 08/352,324
;      FILING DATE:  07-DEC-1994
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  LUTHER, BARBARA J.
;      REGISTRATION NUMBER:  33954
;      REFERENCE/DOCKET NUMBER:  PF-0025 PCT
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  415-855-0555
;      TELEFAX:  415-852-0195
;  INFORMATION FOR SEQ ID NO:  3:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  114 amino acids
```

```
;       TYPE:  amino acid
;       STRANDEDNESS:  single
;       TOPOLOGY:  linear
;     MOLECULE TYPE:  protein
PCT-US95-16144-3

  Query Match             25.0%;  Score 5;  DB 5;  Length 114;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          8 LRCVC 12
              |||||
Db         47 LRCVC 51


RESULT 41
US-09-489-039A-11951
; Sequence 11951, Application US/09489039A
; Patent No. 6610836
; GENERAL INFORMATION:
;  APPLICANT:  Gary Breton et. al
;  TITLE OF INVENTION:  NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO KLEBSIELLA
;  TITLE OF INVENTION:  PNEUMONIAE FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE:  2709.2004001
;  CURRENT APPLICATION NUMBER: US/09/489,039A
;  CURRENT FILING DATE:  2000-01-27
;  PRIOR APPLICATION NUMBER:  US 60/117,747
;  PRIOR FILING DATE:  1999-01-29
;  NUMBER OF SEQ ID NOS:  14342
; SEQ ID NO 11951
;   LENGTH: 119
;   TYPE: PRT
;   ORGANISM: Klebsiella pneumoniae
US-09-489-039A-11951

  Query Match             25.0%;  Score 5;  DB 4;  Length 119;
  Best Local Similarity   100.0%;  Pred. No. 1.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         93 PRGAP 97


RESULT 42
US-09-270-767-34903
; Sequence 34903, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 34903
;   LENGTH: 125
;   TYPE: PRT
;   ORGANISM: Drosophila melanogaster
;   FEATURE:
;   OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-34903

  Query Match             25.0%;  Score 5;  DB 4;  Length 125;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         50 PRGAP 54


RESULT 43
US-09-270-767-50120
; Sequence 50120, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 50120
;   LENGTH: 125
;   TYPE: PRT
;   ORGANISM: Drosophila melanogaster
;   FEATURE:
;   OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-50120

  Query Match             25.0%;  Score 5;  DB 4;  Length 125;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         50 PRGAP 54


RESULT 44
US-09-270-767-36650
; Sequence 36650, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 36650
;   LENGTH: 127
;   TYPE: PRT
;   ORGANISM: Drosophila melanogaster
;   FEATURE:
;   OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-36650

  Query Match             25.0%;  Score 5;  DB 4;  Length 127;
  Best Local Similarity   100.0%;  Pred. No. 1.7e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          7 WLRCV 11
              |||||
Db         69 WLRCV 73


RESULT 45
US-09-270-767-51867
; Sequence 51867, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 51867
;   LENGTH: 127
;   TYPE: PRT
```

; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-51867

  Query Match 25.0%; Score 5; DB 4; Length 127;
  Best Local Similarity 100.0%; Pred. No. 1.7e+02;
  Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 7 WLRCV 11
      |||||
Db 69 WLRCV 73

RESULT 46
US-09-583-110-4139
; Sequence 4139, Application US/09583110
; Patent No. 6699703
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al.
; TITLE OF INVENTION: Nucleic Acid and Amino Acid Sequences Relating to Streptococcus
; TITLE OF INVENTION: Pneumoniae for Diagnostics and Therapeutics
; FILE REFERENCE: PATH00-07A
; CURRENT APPLICATION NUMBER: US/09/583,110
; CURRENT FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 09/107,433
; PRIOR FILING DATE: 1998-06-30
; PRIOR APPLICATION NUMBER: US 60/085,131
; PRIOR FILING DATE: 1998-05-12
; PRIOR APPLICATION NUMBER: US 60/051,553
; PRIOR FILING DATE: 1997-07-02
; NUMBER OF SEQ ID NOS: 5322
; SEQ ID NO 4139
; LENGTH: 132
; TYPE: PRT
; ORGANISM: Streptococcus pneumoniae
US-09-583-110-4139

  Query Match 25.0%; Score 5; DB 4; Length 132;
  Best Local Similarity 100.0%; Pred. No. 1.8e+02;
  Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 15 LETKF 19
      |||||
Db 27 LETKF 31

RESULT 47
US-09-252-991A-30594
; Sequence 30594, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 30594
; LENGTH: 133
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-30594

  Query Match 25.0%; Score 5; DB 4; Length 133;
  Best Local Similarity 100.0%; Pred. No. 1.8e+02;
  Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
      |||||
Db 47 PRGAP 51

RESULT 48
US-09-312-283C-425
; Sequence 425, Application US/09312283C
; Patent No. 6573095
; GENERAL INFORMATION:
; APPLICANT: Watson, James D.
; APPLICANT: Strachan, Lorna
; APPLICANT: Sleeman, Matthew
; APPLICANT: Onrust, Rene
; APPLICANT: Murison, James G.
; APPLICANT: Kumble, Krishanand D.
; TITLE OF INVENTION: Compositions Isolated from Skin Cells
; TITLE OF INVENTION: and Methods for Their Use
; FILE REFERENCE: 11000.1011c2
; CURRENT APPLICATION NUMBER: US/09/312,283C
; CURRENT FILING DATE: 1999-05-14
; NUMBER OF SEQ ID NOS: 425
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 425
; LENGTH: 133
; TYPE: PRT
; ORGANISM: Mouse
US-09-312-283C-425

  Query Match 25.0%; Score 5; DB 4; Length 133;
  Best Local Similarity 100.0%; Pred. No. 1.8e+02;
  Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVC 12
      |||||
Db 52 LRCVC 56

RESULT 49
US-10-101-464A-726
; Sequence 726, Application US/10101464A
; Patent No. 6768041
; GENERAL INFORMATION:
; APPLICANT: Strabala, Timothy
; APPLICANT: Nieuwenhuizen, Nicolaas
; APPLICANT: Higgins, Colleen M.
; TITLE OF INVENTION: Compositions Isolated from Plant Cells
; TITLE OF INVENTION: and Their Use in the Modification of Plant Cell Signaling
; FILE REFERENCE: 11000.1020c2
; CURRENT APPLICATION NUMBER: US/10/101,464A
; CURRENT FILING DATE: 2002-03-18
; PRIOR APPLICATION NUMBER: 09/704,302
; PRIOR FILING DATE: 2000-11-01
; PRIOR APPLICATION NUMBER: 09/228,986
; PRIOR FILING DATE: 1999-01-12
; PRIOR APPLICATION NUMBER: 60/162,866
; PRIOR FILING DATE: 1999-11-01
; PRIOR APPLICATION NUMBER: PCT/US00/00724
; PRIOR FILING DATE: 2000-01-11
; NUMBER OF SEQ ID NOS: 989
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 726
; LENGTH: 135
; TYPE: PRT
; ORGANISM: Pinus radiata
US-10-101-464A-726

  Query Match 25.0%; Score 5; DB 4; Length 135;
  Best Local Similarity 100.0%; Pred. No. 1.8e+02;
  Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 4 APMWL 8
      |||||

```
Db          76 APMWL 80


RESULT 50
US-09-270-767-39768
; Sequence 39768, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 39768
;   LENGTH: 139
;   TYPE: PRT
;   ORGANISM: Drosophila melanogaster
;   FEATURE:
;   OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-39768

  Query Match             25.0%;  Score 5;  DB 4;  Length 139;
  Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           1 PRGAP 5
                 |||||
Db          57 PRGAP 61


RESULT 51
US-09-270-767-54985
; Sequence 54985, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 54985
;   LENGTH: 139
;   TYPE: PRT
;   ORGANISM: Drosophila melanogaster
;   FEATURE:
;   OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-54985

  Query Match             25.0%;  Score 5;  DB 4;  Length 139;
  Best Local Similarity   100.0%;  Pred. No. 1.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           1 PRGAP 5
                 |||||
Db          57 PRGAP 61


RESULT 52
US-09-513-999C-6252
; Sequence 6252, Application US/09513999C
; Patent No. 6783961
; GENERAL INFORMATION:
;  APPLICANT: Dumas Milne Edwards, J.B.
;  APPLICANT:  Duclert, A.
;  APPLICANT:  Giordano, J.Y.
;  TITLE OF INVENTION: Expressed Sequence Tags and Encoded Human Proteins.
; Patent No. 6783961
;  FILE REFERENCE: 59.US2.REG
;  CURRENT APPLICATION NUMBER: US/09/513,999C
;  CURRENT FILING DATE:  2000-02-24
;  PRIOR APPLICATION NUMBER: US 60/122,487
;  PRIOR FILING DATE: 1999-02-26
;  NUMBER OF SEQ ID NOS: 36681
;  SOFTWARE: Patent.pm
; SEQ ID NO 6252
;   LENGTH: 141
;   TYPE: PRT
;   ORGANISM: Homo sapiens
;   FEATURE:
;   NAME/KEY: UNSURE
;   LOCATION: 109
;   OTHER INFORMATION: Xaa=Ala or Val
US-09-513-999C-6252

  Query Match             25.0%;  Score 5;  DB 4;  Length 141;
  Best Local Similarity   100.0%;  Pred. No. 1.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          14 MLETK 18
                 |||||
Db         118 MLETK 122


RESULT 53
US-09-248-796A-18178
; Sequence 18178, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
;  APPLICANT: Keith Weinstock et al
;  TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN
;  TITLE OF INVENTION:  FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE: 107196.132
;  CURRENT APPLICATION NUMBER: US/09/248,796A
;  CURRENT FILING DATE:  1999-02-12
;  PRIOR APPLICATION NUMBER: US 60/074,725
;  PRIOR FILING DATE: 1998-02-13
;  PRIOR APPLICATION NUMBER: US 60/096,409
;  PRIOR FILING DATE: 1998-08-13
;  NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 18178
;   LENGTH: 158
;   TYPE: PRT
;   ORGANISM: Candida albicans
US-09-248-796A-18178

  Query Match             25.0%;  Score 5;  DB 4;  Length 158;
  Best Local Similarity   100.0%;  Pred. No. 2e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy           8 LRCVC 12
                 |||||
Db         126 LRCVC 130


RESULT 54
US-09-248-796A-23447
; Sequence 23447, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
;  APPLICANT: Keith Weinstock et al
;  TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN
;  TITLE OF INVENTION:  FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE: 107196.132
;  CURRENT APPLICATION NUMBER: US/09/248,796A
;  CURRENT FILING DATE:  1999-02-12
;  PRIOR APPLICATION NUMBER: US 60/074,725
;  PRIOR FILING DATE: 1998-02-13
;  PRIOR APPLICATION NUMBER: US 60/096,409
;  PRIOR FILING DATE: 1998-08-13
;  NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 23447
;   LENGTH: 158
```

; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-23447

  Query Match 25.0%; Score 5; DB 4; Length 158;
  Best Local Similarity 100.0%; Pred. No. 2e+02;
  Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 14 MLETK 18
      |||||
Db 36 MLETK 40

RESULT 55
US-09-252-991A-23275
; Sequence 23275, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 23275
; LENGTH: 160
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-23275

  Query Match 25.0%; Score 5; DB 4; Length 160;
  Best Local Similarity 100.0%; Pred. No. 2.1e+02;
  Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
      |||||
Db 23 PRGAP 27

RESULT 56
US-09-134-000C-3710
; Sequence 3710, Application US/09134000C
; Patent No. 6617156
; GENERAL INFORMATION:
; APPLICANT: Lynn Doucette-Stamm et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO
; TITLE OF INVENTION: ENTEROCOCCUS FAECALIS FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 032796-032
; CURRENT APPLICATION NUMBER: US/09/134,000C
; CURRENT FILING DATE: 1998-08-13
; PRIOR APPLICATION NUMBER: US 60/055,778
; PRIOR FILING DATE: 1997-08-15
; NUMBER OF SEQ ID NOS: 6812
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3710
; LENGTH: 163
; TYPE: PRT
; ORGANISM: Enterococcus faecalis
US-09-134-000C-3710

  Query Match 25.0%; Score 5; DB 4; Length 163;
  Best Local Similarity 100.0%; Pred. No. 2.1e+02;
  Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 RGAPM 6
      |||||
Db 12 RGAPM 16

RESULT 57
US-09-270-767-36562
; Sequence 36562, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 36562
; LENGTH: 180
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-36562

  Query Match 25.0%; Score 5; DB 4; Length 180;
  Best Local Similarity 100.0%; Pred. No. 2.3e+02;
  Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVC 12
      |||||
Db 3 LRCVC 7

RESULT 58
US-09-270-767-51779
; Sequence 51779, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
; APPLICANT: Homburger et al.
; TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
; FILE REFERENCE: File Reference: 7326-094
; CURRENT APPLICATION NUMBER: US/09/270,767
; CURRENT FILING DATE: 1999-03-17
; NUMBER OF SEQ ID NOS: 62517
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 51779
; LENGTH: 180
; TYPE: PRT
; ORGANISM: Drosophila melanogaster
; FEATURE:
; OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-51779

  Query Match 25.0%; Score 5; DB 4; Length 180;
  Best Local Similarity 100.0%; Pred. No. 2.3e+02;
  Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 8 LRCVC 12
      |||||
Db 3 LRCVC 7

RESULT 59
US-09-252-991A-21850
; Sequence 21850, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190

```
;  PRIOR FILING DATE:  1998-07-27
;  NUMBER OF SEQ ID NOS:  33142
; SEQ ID NO 21850
;   LENGTH: 183
;   TYPE: PRT
;   ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-21850

  Query Match             25.0%;  Score 5;  DB 4;  Length 183;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db        107 PRGAP 111


RESULT 60
US-09-252-991A-32100
; Sequence 32100, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
;  APPLICANT:  Marc J. Rubenfield et al.
;  TITLE OF INVENTION:  NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
;  TITLE OF INVENTION:  AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE:  107196.136
;  CURRENT APPLICATION NUMBER: US/09/252,991A
;  CURRENT FILING DATE:  1999-02-18
;  PRIOR APPLICATION NUMBER:  US 60/074,788
;  PRIOR FILING DATE:  1998-02-18
;  PRIOR APPLICATION NUMBER:  US 60/094,190
;  PRIOR FILING DATE:  1998-07-27
;  NUMBER OF SEQ ID NOS:  33142
; SEQ ID NO 32100
;   LENGTH: 185
;   TYPE: PRT
;   ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-32100

  Query Match             25.0%;  Score 5;  DB 4;  Length 185;
  Best Local Similarity   100.0%;  Pred. No. 2.3e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db        170 PRGAP 174


RESULT 61
US-09-270-767-61094
; Sequence 61094, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 61094
;   LENGTH: 195
;   TYPE: PRT
;   ORGANISM: Drosophila melanogaster
;   FEATURE:
;   OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-61094

  Query Match             25.0%;  Score 5;  DB 4;  Length 195;
  Best Local Similarity   100.0%;  Pred. No. 2.4e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         16 ETKFL 20
              |||||
Db        138 ETKFL 142


RESULT 62
US-09-270-767-47191
; Sequence 47191, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 47191
;   LENGTH: 199
;   TYPE: PRT
;   ORGANISM: Drosophila melanogaster
US-09-270-767-47191

  Query Match             25.0%;  Score 5;  DB 4;  Length 199;
  Best Local Similarity   100.0%;  Pred. No. 2.5e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         13 QMLET 17
              |||||
Db        109 QMLET 113


RESULT 63
US-09-615-192A-385
; Sequence 385, Application US/09615192A
; Patent No. 6410718
; GENERAL INFORMATION:
;  APPLICANT:  Bloksberg, Leonard N.
;  APPLICANT:  Havukkala, Ilkka
;  TITLE OF INVENTION:  Materials and Methods for the
;  TITLE OF INVENTION:  Modification of Plant Lignin Content
;  FILE REFERENCE:  11000.1003c4U
;  CURRENT APPLICATION NUMBER: US/09/615,192A
;  CURRENT FILING DATE:  2000-07-12
;  PRIOR APPLICATION NUMBER:  US 08/975,316
;  PRIOR FILING DATE:  1997-11-21
;  PRIOR APPLICATION NUMBER:  US 08/713,000
;  PRIOR FILING DATE:  1996-09-11
;  PRIOR APPLICATION NUMBER:  US 09/169,789
;  PRIOR FILING DATE:  1998-10-09
;  NUMBER OF SEQ ID NOS:  405
;  SOFTWARE:  FastSEQ for Windows Version 3.0
; SEQ ID NO 385
;   LENGTH: 208
;   TYPE: PRT
;   ORGANISM: Pinus radiata
US-09-615-192A-385

  Query Match             25.0%;  Score 5;  DB 4;  Length 208;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         15 LETKF 19
              |||||
Db        182 LETKF 186


RESULT 64
US-09-134-000C-3778
; Sequence 3778, Application US/09134000C
; Patent No. 6617156
; GENERAL INFORMATION:
;  APPLICANT: Lynn Doucette-Stamm et al
;  TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO
```

```
;  TITLE OF INVENTION:  ENTEROCOCCUS FAECALIS FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE: 032796-032
;  CURRENT APPLICATION NUMBER: US/09/134,000C
;  CURRENT FILING DATE:  1998-08-13
;  PRIOR APPLICATION NUMBER: US 60/055,778
;  PRIOR FILING DATE: 1997-08-15
;  NUMBER OF SEQ ID NOS: 6812
;  SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3778
;   LENGTH: 215
;   TYPE: PRT
;   ORGANISM: Enterococcus faecalis
US-09-134-000C-3778

  Query Match             25.0%;  Score 5;  DB 4;  Length 215;
  Best Local Similarity   100.0%;  Pred. No. 2.6e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         15 LETKF 19
              |||||
Db         40 LETKF 44


RESULT 65
US-09-270-767-60336
; Sequence 60336, Application US/09270767
; Patent No. 6703491
; GENERAL INFORMATION:
;  APPLICANT: Homburger et al.
;  TITLE OF INVENTION: Nucleic acids and proteins of Drosophila melanogaster
;  FILE REFERENCE: File Reference: 7326-094
;  CURRENT APPLICATION NUMBER: US/09/270,767
;  CURRENT FILING DATE: 1999-03-17
;  NUMBER OF SEQ ID NOS: 62517
;  SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 60336
;   LENGTH: 220
;   TYPE: PRT
;   ORGANISM: Drosophila melanogaster
;   FEATURE:
;   OTHER INFORMATION: Xaa means any amino acid
US-09-270-767-60336

  Query Match             25.0%;  Score 5;  DB 4;  Length 220;
  Best Local Similarity   100.0%;  Pred. No. 2.7e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         90 PRGAP 94


RESULT 66
US-09-627-376-12
; Sequence 12, Application US/09627376
; Patent No. 6342385
; GENERAL INFORMATION:
;  APPLICANT: Qi, Fengxia       Caufield, Page       Chen, Ping
;  TITLE OF INVENTION: MUTACIN I BIOSYNTHESIS GENES AND PROTEINS
;  FILE REFERENCE: UAB-17402/22
;  CURRENT APPLICATION NUMBER: US/09/627,376
;  CURRENT FILING DATE:  2001-05-30
;  NUMBER OF SEQ ID NOS: 17
;  SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12
;   LENGTH: 233
;   TYPE: PRT
;   ORGANISM: Streptococcus mutans
US-09-627-376-12

  Query Match             25.0%;  Score 5;  DB 3;  Length 233;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         14 MLETK 18
              |||||
Db          4 MLETK 8


RESULT 67
US-10-047-676B-12
; Sequence 12, Application US/10047676B
; Patent No. 6699970
; GENERAL INFORMATION:
;  APPLICANT: Qi, Fengxia
;  APPLICANT:  Caufield, Page W.
;  APPLICANT:  Chen, Ping
;  TITLE OF INVENTION: MUTACIN I BIOSYNTHESIS GENES AND PROTEINS
;  FILE REFERENCE: UAB-17403/22
;  CURRENT APPLICATION NUMBER: US/10/047,676B
;  CURRENT FILING DATE:  2002-01-14
;  PRIOR APPLICATION NUMBER: US 09/627,376
;  PRIOR FILING DATE: 2000-07-28
;  NUMBER OF SEQ ID NOS: 19
;  SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
;   LENGTH: 233
;   TYPE: PRT
;   ORGANISM: Streptococcus mutans
US-10-047-676B-12

  Query Match             25.0%;  Score 5;  DB 4;  Length 233;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         14 MLETK 18
              |||||
Db          4 MLETK 8


RESULT 68
US-09-198-452A-818
; Sequence 818, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
;  APPLICANT: Griffais, R.
;  TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
;  TITLE OF INVENTION:  thereof and uses thereof, in particular for the diagnosis, prever
;  TITLE OF INVENTION:  and treatment of infection
;  FILE REFERENCE: 9710-003-999
;  CURRENT APPLICATION NUMBER: US/09/198,452A
;  CURRENT FILING DATE:  1998-11-24
;  NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 818
;   LENGTH: 235
;   TYPE: PRT
;   ORGANISM: Chlamydia pneumoniae
US-09-198-452A-818

  Query Match             25.0%;  Score 5;  DB 4;  Length 235;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         16 ETKFL 20
              |||||
Db        177 ETKFL 181


RESULT 69
US-09-252-991A-23304
; Sequence 23304, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
;  APPLICANT:  Marc J. Rubenfield et al.
;  TITLE OF INVENTION:  NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
;  TITLE OF INVENTION:  AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
```

```
;  FILE REFERENCE:  107196.136
;  CURRENT APPLICATION NUMBER: US/09/252,991A
;  CURRENT FILING DATE:  1999-02-18
;  PRIOR APPLICATION NUMBER:  US 60/074,788
;  PRIOR FILING DATE:  1998-02-18
;  PRIOR APPLICATION NUMBER:  US 60/094,190
;  PRIOR FILING DATE:  1998-07-27
;  NUMBER OF SEQ ID NOS:  33142
; SEQ ID NO 23304
;   LENGTH: 237
;   TYPE: PRT
;   ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-23304

  Query Match             25.0%;  Score 5;  DB 4;  Length 237;
  Best Local Similarity   100.0%;  Pred. No. 2.8e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         40 PRGAP 44


RESULT 70
US-09-134-001C-4165
; Sequence 4165, Application US/09134001C
; Patent No. 6380370
; GENERAL INFORMATION:
;  APPLICANT: Lynn Doucette-Stamm et al
;  TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO STAPHYLOCOCCUS
;  TITLE OF INVENTION:  EPIDERMIDIS FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE: GTC-007
;  CURRENT APPLICATION NUMBER: US/09/134,001C
;  CURRENT FILING DATE:  1998-08-13
;  PRIOR APPLICATION NUMBER: US 60/064,964
;  PRIOR FILING DATE: 1997-11-08
;  PRIOR APPLICATION NUMBER: US 60/055,779
;  PRIOR FILING DATE: 1997-08-14
;  NUMBER OF SEQ ID NOS: 5674
; SEQ ID NO 4165
;   LENGTH: 239
;   TYPE: PRT
;   ORGANISM: Staphylococcus epidermidis
US-09-134-001C-4165

  Query Match             25.0%;  Score 5;  DB 3;  Length 239;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy         11 VCQML 15
              |||||
Db         52 VCQML 56


RESULT 71
US-09-252-991A-28343
; Sequence 28343, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
;  APPLICANT:  Marc J. Rubenfield et al.
;  TITLE OF INVENTION:  NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
;  TITLE OF INVENTION:  AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
;  FILE REFERENCE:  107196.136
;  CURRENT APPLICATION NUMBER: US/09/252,991A
;  CURRENT FILING DATE:  1999-02-18
;  PRIOR APPLICATION NUMBER:  US 60/074,788
;  PRIOR FILING DATE:  1998-02-18
;  PRIOR APPLICATION NUMBER:  US 60/094,190
;  PRIOR FILING DATE:  1998-07-27
;  NUMBER OF SEQ ID NOS:  33142
; SEQ ID NO 28343
;   LENGTH: 242
;   TYPE: PRT
;   ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-28343

  Query Match             25.0%;  Score 5;  DB 4;  Length 242;
  Best Local Similarity   100.0%;  Pred. No. 2.9e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db         23 PRGAP 27


RESULT 72
US-08-426-819A-37
; Sequence 37, Application US/08426819A
; Patent No. 5723318
;  GENERAL INFORMATION:
;    APPLICANT:  Yamaguchi, No. 5723318omi
;    APPLICANT:  Kojima, Tetsuo
;    APPLICANT:  Oh-Eda, Masayoshi
;    APPLICANT:  Hattori, Kunihiro
;    TITLE OF INVENTION:  Genes Coding for Megakaryocyte
;    TITLE OF INVENTION:  Potentiator
;    NUMBER OF SEQUENCES:  37
;    CORRESPONDENCE ADDRESS:
;      ADDRESSEE:  Birch, Stewart, Kolasch & Birch
;      STREET:  P.O. Box 747
;      CITY:  Falls Church
;      STATE:  Virginia
;      COUNTRY:  USA
;      ZIP:  22040-0747
;    COMPUTER READABLE FORM:
;      MEDIUM TYPE:  Floppy disk
;      COMPUTER:  IBM PC compatible
;      OPERATING SYSTEM:  PC-DOS/MS-DOS
;      SOFTWARE:  PatentIn Release #1.0, Version #1.30
;    CURRENT APPLICATION DATA:
;      APPLICATION NUMBER:  US/08/426,819A
;      FILING DATE:  21-APR-1995
;      CLASSIFICATION:  435
;    ATTORNEY/AGENT INFORMATION:
;      NAME:  Murphy Jr., Gerald M.
;      REGISTRATION NUMBER:  28,977
;      REFERENCE/DOCKET NUMBER:  230-107P
;    TELECOMMUNICATION INFORMATION:
;      TELEPHONE:  703-205-8000
;      TELEFAX:  703-205-8050
;  INFORMATION FOR SEQ ID NO:  37:
;    SEQUENCE CHARACTERISTICS:
;      LENGTH:  248 amino acids
;      TYPE:  amino acid
;      STRANDEDNESS:  not relevant
;      TOPOLOGY:  not relevant
;    MOLECULE TYPE:  protein
;    HYPOTHETICAL:  NO
;    FRAGMENT TYPE:  internal
US-08-426-819A-37

  Query Match             25.0%;  Score 5;  DB 1;  Length 248;
  Best Local Similarity   100.0%;  Pred. No. 3e+02;
  Matches    5;  Conservative    0;  Mismatches    0;  Indels    0;  Gaps    0;

Qy          1 PRGAP 5
              |||||
Db        115 PRGAP 119


RESULT 73
US-09-248-796A-27518
; Sequence 27518, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
;  APPLICANT: Keith Weinstock et al
```

; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDIDA ALBICAN
; TITLE OF INVENTION: FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.132
; CURRENT APPLICATION NUMBER: US/09/248,796A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,725
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/096,409
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 27518
; LENGTH: 257
; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-27518

Query Match 25.0%; Score 5; DB 4; Length 257;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 QMLET 17
|||||
Db 180 QMLET 184

RESULT 74
US-09-252-991A-21547
; Sequence 21547, Application US/09252991A
; Patent No. 6551795
; GENERAL INFORMATION:
; APPLICANT: Marc J. Rubenfield et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO PSEUDOMONAS
; TITLE OF INVENTION: AERUGINOSA FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.136
; CURRENT APPLICATION NUMBER: US/09/252,991A
; CURRENT FILING DATE: 1999-02-18
; PRIOR APPLICATION NUMBER: US 60/074,788
; PRIOR FILING DATE: 1998-02-18
; PRIOR APPLICATION NUMBER: US 60/094,190
; PRIOR FILING DATE: 1998-07-27
; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 21547
; LENGTH: 259
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-21547

Query Match 25.0%; Score 5; DB 4; Length 259;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 PRGAP 5
|||||
Db 56 PRGAP 60

RESULT 75
US-09-328-352-6699
; Sequence 6699, Application US/09328352
; Patent No. 6562958
; GENERAL INFORMATION:
; APPLICANT: Gary L. Breton et al.
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO ACINETOBACTER
; TITLE OF INVENTION: BAUMANNII FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: GTC99-03PA
; CURRENT APPLICATION NUMBER: US/09/328,352
; CURRENT FILING DATE: 1999-06-04
; NUMBER OF SEQ ID NOS: 8252
; SEQ ID NO 6699
; LENGTH: 264
; TYPE: PRT
; ORGANISM: Acinetobacter baumannii
US-09-328-352-6699

Query Match 25.0%; Score 5; DB 4; Length 264;
Best Local Similarity 100.0%; Pred. No. 3.1e+02;
Matches 5; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 14 MLETK 18
|||||
Db 133 MLETK 137

Search completed: October 26, 2004, 07:25:08
Job time : 24.25 secs